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ABSTRACT OF THE DISSERTATION 
COMPARISON OF MEDICAL AND FORENSIC PROFILING POTENTIAL OF 
VOLATILE BIOMARKERS FROM DIFFERENT BIOLOGICAL SPECIMENS FROM 
INDIVIDUALS AND ACROSS POPULATIONS 
by 
Maiko Kusano 
Florida International University, 2010 
Miami, Florida 
Professor Kenneth Furton, Major Professor 
There is limited scientific knowledge on the composition of human odor from different 
biological specimens and the effect that physiological and psychological health 
conditions could have on them. There is currently no direct comparison of the volatile 
organic compounds (VOCs) emanating from different biological specimens collected 
from healthy individuals as well as individuals with certain diagnosed medical 
conditions. Therefore the question of matching VOCs present in human odor across 
various biological samples and across health statuses remains unanswered. 
The main purpose of this study was to use analytical instrumental methods to compare 
the VOCs from different biological specimens from the same individual and to compare 
the populations evaluated in this project. The goals of this study were to utilize headspace 
solid-phase microextraction gas chromatography mass spectrometry (HS-SPME-GC/MS) 
to evaluate its potential for profiling VOCs from specimens collected using standard 
forensic and medical methods over three different populations: healthy group with no 
viii 
 
diagnosed medical or psychological condition, one group with diagnosed type 2 diabetes, 
and one group with diagnosed major depressive disorder.  
The pre-treatment methods of collection materials developed for the study allowed for the 
removal of targeted VOCs from the sampling kits prior to sampling, extraction and 
analysis. Optimized SPME-GC/MS conditions has been demonstrated to be capable of 
sampling, identifying and differentiating the VOCs present in the five biological 
specimens collected from different subjects and yielded excellent detection limits for the 
VOCs from buccal swab, breath, blood, and urine with average limits of detection of 8.3 
ng.  
Visual, Spearman rank correlation, and PCA comparisons of the most abundant and 
frequent VOCs from each specimen demonstrated that each specimen has characteristic 
VOCs that allow them to be differentiated for both healthy and diseased individuals. 
Preliminary comparisons of VOC profiles of healthy individuals, patients with type 2 
diabetes, and patients with major depressive disorder revealed compounds that could be 
used as potential biomarkers to differentiate between healthy and diseased individuals. 
Finally, a human biological specimen compound database has been created compiling the 
volatile compounds present in the emanations of human hand odor, oral fluids, breath, 
blood, and urine.  
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1. RESEARCH INTRODUCTION 
1.1. Basis for research 
Cases have been reported where pet dogs have detected cancers on their owners1,2. In 
each case, the patient’s dog paid excessive attention to a particular part of the owner’s 
body and, upon seeking medical advice, the owners were diagnosed with cancer. Cases 
like these have triggered interest in the scientific community to investigate the odors 
emitted by the human body. In the forensic science field, this is especially true in terms of 
understanding how canines differentiate people by their scents.  
Volatile organic compounds (VOCs) are naturally occurring chemical compounds that 
are characterized by having low boiling points. The human body produces odors made up 
of a variety of VOCs. The individual odor hypothesis theorizes that each individual 
possesses a unique scent, referred to as “human scent”, which allows for scent 
identification using canines in law enforcement and forensic fields. However, if persons 
with certain diseases are known to emit disease-specific odors, it is possible that 
problems may arise in scent identification line-ups as a result of diseases or disorders 
which could result in false matching of persons of interest. Therefore, the analysis of the 
scent biomarkers among different populations can provide valuable information as to 
what impact it could have on law enforcement in terms of matching people. Identification 
of such biomarkers is also useful for the medical field for diagnostic purposes. To date, 
no studies have been published that compare the volatile organic compounds obtained 
from different biological specimens collected from healthy volunteers, those with type 2 
diabetes, and clinically depressed patients to establish a profile that can be used to 
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differentiate between healthy and diseased persons. Results obtained from this research 
will provide valuable information not only for the medical perspectives but also for the 
law enforcement/person detection perspectives helping to determine the uniqueness of 
odor profiles from different individuals for diagnostic and/or identification purposes. 
1.2. Research Objectives 
This research was conducted to test two main hypotheses: 
Hypothesis I: Individuals can be differentiated using any biological fluids.  
Hypothesis II: Subjects can be grouped based on being healthy or having a medical or 
psychiatric condition.  
The main objectives of this research were to employ analytical instrumental methods to 
compare the VOCs from different samples taken from the same individual and to 
compare among the populations evaluated in this project. The content of this report 
focuses on data obtained via instrumental evaluation of human scent samples from 
different biological specimens, as well as samples taken from different populations. The 
different tasks that were addressed are listed below. 
a. Optimization of collection and analysis methods for human scent samples from 
different biological specimens using SPME to extract the volatile compounds and 
GC/MS as separation and identification technique 
b. Evaluation of odor profiles of different specimens of individuals over time 
c. Evaluation of the similarities/differences in sampling from different biological 
specimens using SPME-GC/MS 
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d. Population analyses of the VOCs present above collected odor samples using 
SPME-GC/MS 
i. Healthy individuals 
ii. Patients with type 2 diabetes 
iii. Patients with Major Depressive Disorder (MDD) 
e. Creation of human biological specimen compound database 
1.3. Forensic Science and Human Scent 
1.3.1. Admissibility of Scientific Evidence 
For scientific evidence to be admissible in a United States court of law, it must satisfy the 
requirements of either the Frye standard, the Daubert standard, or the Federal Rules of 
Evidence. The appropriate standard is dependent on the case and in which jurisdiction the 
case is being handled. The Federal Rules of Evidence govern the admission of evidence 
in civil and criminal proceedings in federal courts. These rules are applied through the 
cases of Frye v. United States (1923) and Daubert v. Merrell Dow Pharmaceuticals 
(1993)3. 
The Frye standard, or the general acceptance test, is applied to determine the 
admissibility of scientific evidence. Under the Frye standard, scientific evidence is 
admissible if the technology is “generally accepted” in that field. Frye defines general 
acceptance as follows: 
Just when a scientific principle or discovery crosses the line between the 
experimental and demonstrable stages is difficult to define. Somewhere in this 
twilight zone the evidential force of the principle must be recognized, and while 
courts will go a long way in admitting expert testimony deduced from a well 
recognized scientific principle or discovery, the thing from which the deduction is 
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made must be sufficiently established to have gained general acceptance in the 
particular field in which it belongs3. 
 
The issue with the Frye standard is that it does not specify in which field the technology 
is accepted. It also does not distinguish between science and pseudo-science. In 1975, the 
Frye test was superseded by the Federal Rules of Evidence (Rule 702) governing expert 
testimony: 
If scientific, technical, or other specialized knowledge will assist the trier of fact 
to understand the evidence or to determine a fact in issue, a witness qualified as 
an expert by knowledge, skill, experience, training, or education, may testify 
thereto in the form of an opinion or otherwise, if (1) the testimony is based upon 
sufficient facts or data, (2) the testimony is the product of reliable principles and 
methods, and (3) the witness has applied the principles and methods reliably to 
the facts of the case4. 
 
While many states (including Florida, New York, Alaska, California, and Washington) 
still follow the Frye standard, the U.S. federal court and half of the states now use the 
Daubert standard in their proceedings governing the admissibility of expert testimony. 
With the Daubert standard, scientific expert testimony’s admissibility is regulated by 
several guidelines. The judge is given the task of “gatekeeping” in which s/he must 
ensure the relevance and reliability of the expert’s testimony to the case. Beyond “general 
acceptance” as is the case with Frye, Daubert requires that the scientific knowledge is a 
product of a scientific methodology which has been tested for its validity and reliability, 
subjected to peer review and publication, tested for its error rate, have standards and 
controls of operation, and has gained widespread acceptance in the relevant scientific 
community3. 
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1.3.2. Human Scent as Scientific Evidence 
Human scent as scientific evidence is still very controversial and often challenged in 
court5. While research on human scent has been a growing interest in the scientific and 
law enforcement communities, there are still many unanswered questions concerning the 
use of human scent and there is not a common method of evidence collection, storage, 
and analysis that is implemented across different law enforcement agencies and research 
groups. For this reason, introduction of human scent evidence in a United States court is 
not an easy task; however, there are instances wherein human scent evidence has been 
accepted as scientific evidence in court cases.  
The most recent U.S. court ruling pertaining to human scent evidence was a court case in 
2009 of U.S. v. Wade where the defendant requested a Daubert hearing regarding the 
reliability of human scent trailing canines6. The prosecution introduced evidence that the 
scent of the victim was trailed to the defendant’s residence by a trained trailing dog. 
Scent trailing was performed using scent collected with the scent transfer unit from the 
victim’s clothing. The introduction of this human scent (dog trailing) evidence was 
challenged by the defendant on the durability of human scent, the reliability of the scent 
transfer unit, and the dog trailing methods in general. The court ruled that there was no 
prejudice from the admission of the scent evidence because of other sufficient 
corroborating pieces of evidence that justified the issuance of the search warrant. In this 
case, the dog trail evidence met the threshold for reliability under Evidence Rule 702 and 
Daubert and was ruled admissible.  Table 1 lists several court rulings pertaining to the 
use of human scent evidence. 
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Table 1. U.S. Court Cases with Human Scent Evidence 
Court Case Year Standard  
People v. Gonzalez 
218 Cal.App.3d 403 1990 Frye 
Corroborating evidence is required when 
using canine human scent evidence. 
People of the State of 
California v. Jeffrey 
Dewyane Mitchell7 
2003 Frye 
Evidence was scent collected from scent 
transfer unit. Issues on the novelty of the 
device as well as the degradation of 
human scent after collection were 
challenged.  
People v. Ryan Willis8 2004 Frye 
Dog scent identification was challenged 
on the persistence and uniqueness of 
human scent, as well as the adequacy of 
the certification procedures for scent 
identification. 
People of the State of 
California v. Benigo 
Salcido9 
2005 Frye 
Scent identification line-up by canines 
was challenged on the basis of the 
uniqueness and survivability of human 
scent. Court ruled that human scent 
evidence can be admissible if “the person 
performing the technique used the correct 
scientific procedures, the training and 
experience of the dog and dog handler 
prove them to be proficient, and the 
methods used by the dog handler in the 
case are reliable.9” 
U.S. v. Wade 2008 Daubert 
Dog trailing evidence was accepted as 
meeting the standard for admissibility 
under Rule 702 and Daubert because dog 
trail evidence is “based on scientifically 
valid principles6”.  
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1.3.3. Canines and Human Scent 
Specialized use of human scent in criminal investigations is well-established by detector 
canines. Scent-discriminating canines have been used in criminal investigations for over 
100 years. Many European countries have been using trained dogs for scent identification 
line-ups, where the dogs match the scent sample from a crime scene to scent collected 
from the hands of a suspect. Human scent identification line-ups have gained widespread 
acceptance in Europe, and have been admitted as evidence in the court. However, it is 
still very controversial and debated upon in the United States. Studies have indicated that 
with sufficient training, detector canines are capable of matching scents emanating from 
different areas of the body10,11. In addition to criminal investigations, canines are being 
trained on human scent for search and rescue to search for missing persons, disaster site 
survivors, and decomposing human remains12.  
1.4. Alternative Biological Specimens as Scent Sources 
There is currently no direct comparison made between different biological specimens as 
scent sources. In the forensic field, skin odor and sweat (on clothing articles) are the main 
sources used for human scent identification. Forensic research on human scent have 
utilized scent collected on gauze, stainless steel bars, and glass beads from skin 
contact10,12-14. In the medical field, blood and urine are the specimens of choice for 
testing, diagnostics, and metabolic profiling. The advantages and disadvantages of the 
collection and testing for the five biological specimens of interest to this study are 
outlined in Table 2. 
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Table 2. Advantages and disadvantages of hand odor, buccal swabs, breath, blood, 
and urine testing 
 Hand Odor Buccal Swab Breath Blood Urine 
Sample Collection Noninvasive Noninvasive Noninvasive Invasive Privacy 
concerns 
Sample 
Availability 
Microliters of 
insensible 
sweat 
1 – 5 mL > 50  mL > 5 mL > 50 mL 
Speed of 
Collection 
20 minutes 
with hand-
washing 
procedure 
< 1 minute < 1 minute Minutes Minutes 
Currently Routine 
Method? 
No For DNA For breath-
alcohol only 
Yes Yes 
 
Published research on VOC detection and identification on different specimens generally 
focuses on only one specimen. The VOC research on the biological specimens of interest 
to this study will be discussed in detail in subsequent sections. Research on VOC 
detection across multiple specimens is usually only limited to two, at most three 
specimens15-17. Statheropoulos et al. reported the use of VOCs from human expired air, 
blood, and urine for locating entrapped people in earthquakes to determine whether a 
relatively small target group of VOCs common to all three matrices can be determined18. 
The VOCs from blood and urine were analyzed by headspace SPME-GC/MS and breath 
samples were analyzed by thermal desorption GC/MS. Acetone was found in all three 
matrices, and isoprene was found in both breath and blood samples. 
Identification of target odor compounds can provide valuable information to both the 
medical and forensic communities. From the medical perspective, analysis of VOCs in 
biological fluids can reveal interesting diagnostic properties of different biomarkers. In 
addition to the disease diagnostic potential, analysis of VOCs in biological samples may 
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be useful in differentiating populations (i.e. healthy vs. illness). The differences found 
among the different populations can lead to potential for early diagnosis of certain 
medical diseases. 
From the forensic perspective, biological evidence collected may be useful for human 
identification in terms of matching individuals to odor from a crime scene. Canines have 
the ability to discriminate human scent because people vary in their odors. However, if 
persons with certain diseases are known to emit disease-specific VOCs, it is possible that 
problems may arise in scent identification line-ups which could result in false matching 
between two people with the same disease. Therefore, the analysis of the volatile 
biomarkers among different populations can provide valuable information as to the 
impact of matching people for law enforcement purposes. 
1.5. Theory of Instrumental Techniques 
1.5.1. Solid Phase Microextraction (SPME) 
Solid phase microextraction was invented in 1989 by Pawliszyn as a new 
preconcentration technology19. Since then, SPME methods have been developed and 
widely adopted for various applications. Solid phase microextraction gained its 
popularity over the recent years for numerous advantageous characteristics. The 
extraction process does not require a solvent, making SPME economically and 
environmentally friendly. Minimal sample volume is required. SPME is known for its 
high sensitivity when coupled to analytical instruments. It is also field portable, providing 
a simple and convenient mean for sampling on-site. SPME can be used for the extraction 
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of volatile and semi-volatile components in a sample matrix from both liquid and gaseous 
phases. 
A SPME device has a very simple yet sophisticated configuration similar to a syringe 
(Figure 1). The SPME fiber, a fused silica fiber coated with an absorbent polymer about 
1.0cm in length, is attached to a stainless steel needle and encased by a metal sheath for 
the purpose of fiber protection in between extractions. The body of the SPME holder 
consists of a spring loaded plunger, barrel, and an adjustable depth gauge. By pushing the 
plunger down the fiber is exposed out of the needle and can perform extraction of the 
sample. Extraction can be done by immersing the SPME fiber directly into a sample, by 
exposing the fiber to the headspace of a sample, or by membrane protection where the 
fiber is separated from the sample with a selective membrane20. In this study, extraction 
mode of interest was headspace sampling. 
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Figure 1. Schematic of a SPME fiber 
 
Fiber coating varies in terms of polarity and thickness. Choosing the appropriate fiber 
type depends on the properties of the analytes of interest. Commercially available fibers 
come in various polymeric phases, some of which are shown in Table 3. Polar 
compounds have a higher affinity to polar coatings than non-polar coatings, where non-
polar compounds will be retained more effectively with non-polar coatings. Therefore, 
fiber optimization and choosing the correct fiber type is essential in analysis using the 
SPME sampling method.  
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Table 3. SPME Fiber Characteristics 
Fiber Coating Polarity Extraction Applications 
Polydimethylsiloxane (PDMS) Non-polar Absorbent 
Volatiles, mid- to 
non-polar semi-
volatiles 
Polydimethylsiloxane/divinylbenzene 
(PDMS/DVB) Bi-polar Adsorbent Polar volatiles 
Polyacrylate (PA) Polar Absorbent Polar semi-volatiles 
Carbowax/Polyethylene Glycol  (PEG) Polar Adsorbent Polar analytes 
Polydimethylsiloxane/carboxen  
(PDMS/CAR) Bi-polar Adsorbent 
Gases and 
volatiles 
Divinylbenzene/carboxen/polydimethyl
siloxane (DVB/CAR/PDMS) Bi-polar Adsorbent Odors and flavors 
 
SPME is a multiphase equilibration process involving two main steps. The first step 
involves the partitioning of the analytes between the fiber coating and the sample matrix 
via adsorption or absorption. Extraction is considered complete when equilibrium is 
reached between the coating and the matrix. The second step is desorption of the 
extracted analytes from the fiber into an analytical instrument. In headspace sampling, the 
phases in the SPME equilibrium system are the solid or liquid sample, the headspace 
above the sample, and the fiber coating. The equilibrium condition can be described with 
the following equation:  
 Equation 1 
where nf is the amount of analyte extracted by the fiber coating, Kfs is the fiber coating-
sample matrix distribution constant, Vf is the fiber-coating volume, KhsVh is the analyte 
capacity of the headspace, Vs is the sample volume, and C0 is the initial concentration of a 
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given analyte in the sample matrix21. When equilibrium is reached, the sample 
concentration is directly proportional to the amount of analyte extracted.     
1.5.2. Gas-Chromatography/Mass Spectrometry (GC/MS) 
Gas chromatography/mass spectrometry is the synergistic combination of two well-
established and powerful analytical instruments. Separation of analytes in complex 
mixture samples is performed by the gas chromatograph; structural identification of these 
analytes is then provided by the mass spectrometer through the measurement of mass and 
abundance of ions. The complimentary characteristics of GC and MS allow for the 
separation, quantification, and identification of substances at low concentrations and have 
led to the general acceptance of GC/MS as the “gold standard” in forensic and clinical 
laboratories.  
Gas chromatography was first introduced in 1952 by James and Martin22. The basic 
operation sequence of the gas chromatograph is as follows: the volatilization of the 
sample introduced at the heated injection port, the separation of the analytes in the 
sample through selective distribution between the mobile phase (inert carrier gas, 
typically helium or hydrogen) and the stationary phase (coating of the column), and the 
detection of the separated analytes by the detector. The amount of time the analyte 
resides in the column, the retention time, is based on the interaction of the analyte with 
the stationary phase. Because the samples require volatilization at the time of sample 
introduction, separation by GC requires that the sample be volatile and thermally stable. 
Optimization of the column parameters such as polarity, phase thickness, internal 
diameter, and column length determine the selectivity and efficiency of the separation of 
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the analytes of interest22-24. Separated analytes are then introduced into the mass 
spectrometer downstream for further identification. 
The first mass spectrometer was constructed by J.J. Thomson in 191225. In the mass 
spectrometer, neutral sample molecules are ionized to generate a charged molecule or 
fragments of a molecule and the mass-to-charge (m/z) ratio of gaseous ions is measured. 
The sample is introduced into the ion source where the vaporized analyte is converted 
into ions via electron, chemical, or field ionization. The ions are then accelerated into and 
sorted by the mass analyzer according to their m/z ratio in either time or space. The sorted 
ions are detected by the detector in proportion to their abundance. The resulting mass 
spectrum of a molecule is thus a plot of m/z ratio against ion abundance. 
Figure 2. Block diagram of a gas chromatograph coupled to a mass spectrometer 
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2. BIOLOGICAL SPECIMENS 
2.1. Human Scent 
2.1.1. Production of Human Scent 
Human odor production is a complex process that is yet to be fully understood. The most 
common interpretation of the human odor production rests on the idea that glandular 
secretions, volatile organic compounds synthesized by metabolism, and bacterial action 
on dead skin cells play key roles in the generation of human scent.  There is a current of 
warm air that surrounds the human body carrying germs that come from the bacteria that 
are shed with dead skin cells (called “rafts”)26. This warm current of air, or the human 
thermal plume, allows for the deposition of human scent to the environment.  
2.1.2. Distinctiveness of Human Scent 
The concept that individuals have their own distinctive scent that is retained by a variety 
of factors such as diet, exercise, circadian and seasonal changes, menstrual cycle, 
emotional and physical health status has been around for over a century27. This individual 
odor hypothesis has triggered many researchers to investigate the fingerprint 
characteristics in and discriminatory power of compounds found in human scent.  A 
large-scale study involving 197 subjects whose scent samples were collected five times 
each over a ten-week period revealed strong evidence of individual fingerprints, 
particularly from axillary sweat samples28. Statistical evaluations of data demonstrated 
repeat samples of individuals clustering closely. In another study, subjects were sampled 
during different seasons and the results showed that although emission behavior of the 
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scents were different between seasons, the ratios of the significant fingerprint peaks did 
not fluctuate as much29. 
A very recently published study by a research group at Florida International University 
also demonstrated that distinguishable human scent profiles can be produced by utilizing 
the relative ratio patterns of a combination of compounds in hand scent profiles which 
vary in degree of frequency of detection13. This research group has categorized human 
scent components into three distinguishing categories: primary, secondary, and tertiary5. 
The primary odor of a person contains constituents that are stable over time regardless of 
diet or environmental factors. Secondary odor constituents are present as a result of diet 
and environmental factors. Tertiary odor constituents are those which are present because 
of outside source influences (i.e., lotions, shampoos, and perfumes). Individual scent is 
likely to be a combination of various primary odor compounds differing in ratio from 
person to person as well as other compounds that vary among individuals. To date, no 
specific marker has been found that is unique or exclusive to one gender. There is still 
much work to be done to classify what specific compounds are exclusively “human 
scent”, or to determine how and from where these human scent compounds originate. 
While fingerprint characteristics of human scent are being researched extensively, current 
knowledge on human scent indicates that human odor may be analogous to facial features 
in that there is no single measurement on the face that characterizes an individual, and 
characterization requires the combination of features and inclusion of other traits. The 
same can be said for human odor. Hence, human odor can be considered an “extended 
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phenotype” where the variations may be genetically or environmentally induced, or by 
combination of both28. 
2.1.3. Persistence and Stability of Human Scent 
The persistence of human scent has also been investigated by examining the effects of 
aging on scent samples. In a scent-weight dissipation study, results revealed that 
measurable amounts of human scent compounds were still present in a controlled 
environment three months after the scent compounds were deposited onto sterile gauze 
and sealed in a glass vial30. However, aging of samples seems to affect the scent profiles 
to some extent, especially depending on the storage conditions under which they were 
kept. In an aging study on crime scene objects performed by the Netherlands National 
Police, trials were conducted where canine performance was tested to determine how 
well dogs could match fresh and stored (aged) scent samples31. Dogs were able to 
faultlessly match fresh scent samples to the originating subject, but when tested with 
stored scent samples, their performances decreased. A storage and scent stability study 
conducted in a laboratory setting demonstrated that scent profiles changed over time, 
with the greatest profile variations seen between week 0 and week 312. Excessive 
exposure of samples to UVA/UVB also altered the human scent profile, indicating that 
choosing the appropriate storage conditions is vital in human scent sample storage12. 
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2.1.4. Hand odor sampling 
Scent collected from hand odor sampling using the method previously established served 
as a base human scent sample to which odor profiles of the remaining biological 
specimens were compared. 
2.1.4.1. Materials & Methods 
DUKAL brand, 100% cotton, sterile, 2 X 2, 8 ply, gauze pads used to collect hand odor 
were purchased from DUKAL Corporation (Syosset, NY, USA). The soap used for hand 
washing was Natural, Clear Olive Oil Soap from Life of the Party (North Brunswick, NJ, 
USA). Ten ml glass, clear, screw top headspace vials with PTFE/Silicone septa were used 
to hold the samples (SUPELCO, Bellefonte, PA, USA). The methanol used for the pre-
treatment of gauze pads was HPLC grade (Fisher Scientific, Pittsburgh, PA, USA). 
Divinylbenzene/Carboxen/Polydimethylsiloxane (DVB/CAR/PDMS) (50/30 μm film 
thickness) SPME fibers and SPME fiber holders were obtained from SUPELCO 
(Bellefonte, PA, USA).  
Prior to sample collection, DUKAL gauze pads were pretreated by spiking 1000 µL of 
HPLC-grade methanol and baking in a 105°C oven for 45 minutes in an Isotemp Oven, 
Model 655G (Fisher Scientific, Pittsburgh, PA, USA). Pretreated gauze pads were 
analyzed to ensure analytical cleanliness by SPME-GC/MS.  
The hand odor sampling protocol is as follows: 30 seconds washing of the hands and 
forearms with olive oil based soap, two minutes rinsing of the washed areas with water, 
two minutes air drying, and five minutes of rubbing the palms of the hands over the 
forearms. Subjects were given a pre-treated sterile gauze pad to hold between the palms 
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of their hands for ten minutes. Samples were collected in triplicates with ten minute-
breaks in between each sampling. The gauze pad was re-sealed back into the 10 ml glass 
headspace vial. All samples were stored at room temperature and were allowed to sit for 
approximately 24 hours prior to extraction. No attempt was made to control microbial 
interactions with the samples as that may make contributions to the overall odor profile.  
The GC/MS analysis was carried out using an Agilent Technologies 6890N gas 
chromatograph coupled to an Agilent Technologies 5973N mass selective detector (Palo 
Alto, CA, USA). The column used to separate the analytes was a HP5-MS, 30 m, 0.25 
um, 0.25 mm with helium as the carrier gas with a flow rate of 1.0mL/min. The extracted 
VOCs were desorbed in the injection port of the GC with a temperature of 250°C for five 
minutes in splitless mode. The GC oven temperature program was as follows: an initial 
oven temperature of 40°C for five minutes, 10°C/min ramp to a final temperature of 
250°C, followed by a final hold for two minutes for a total run time of 28 minutes. The 
mass spectrometer used was an HP 5973 MSD with a quadrupole analyzer operated in 
electron ionization mode. The mass spectrometer transfer line was maintained at 280°C 
and the source temperature was 230°C. The analytes were acquired in full-scan mode in 
41-550 m/z range. 
2.2. Oral Fluids (Saliva) 
Saliva is an exocrine secretion composed of water, salts, mucus and the digestive enzyme 
α-amylase32-35. Human saliva has several functions pertaining to oral health and 
homeostasis. Protective functions of saliva include lubrication, antimicrobial, mucosal 
integrity, cleansing, buffering, and remineralization of the teeth. Digestive functions 
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include food preparation, digestion, and tasting. When food is introduced into the mouth, 
as chewing starts the process of digestion, saliva moistens the food and provides 
lubrication so that the food can be swallowed. Preliminary digestion of food starts by the 
polysaccharide-digesting enzyme α-amylase.  
Saliva is secreted by three main salivary glands, the parotid, sublingual, and 
submandibular glands which are located in the mouth (Figure 336). The parotid gland is 
found wrapped around the ramus of the mandible, and the sublingual and submandibular 
glands are found below the tongue. There are also numerous minor salivary glands 
including Von Ebner glands and Blandin-Nühm mucous glands. Submandibular glands 
contribute the greatest to the unstimulated saliva secretion at 65%-70%, followed by 20% 
by the parotid glands, 7%-8% by the sublingual glands, and less than 10% by the minor 
salivary glands32,33,37. The contributions of these salivary glands change with stimulated 
saliva secretion, where the parotid glands contribute the greatest at over 50% of the total 
saliva secretion. Saliva production from a healthy adult ranges from 500 mL to 1500 mL 
per day. Salivary pH is close to neutral (about six or seven), and changes with the 
salivary flow where the pH becomes more acidic (pH 5.3) at low salivary flow and more 
basic (pH 7.8) at high salivary flow33. Quantitative and qualitative saliva production can 
be affected by different conditions, pathological and physiological, including chewing, 
health status, stimulation by smell or taste, age, and oral hygiene32.  
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Figure 3. Schematic of human salivary glands (source: Causes of Dry Mouth by 
Morefocus Group, Inc.) 
 
In addition to the fluids secreted from the salivary glands, components of whole saliva 
also include serum and blood derivatives, oral bacterial and viral products, fluids from 
bronchial and nasal secretions, epithelial lining cells, and exogenous substances like food 
debris. There are both inorganic and organic components in saliva. Inorganic components 
of saliva are ions and electrolytes (Na+, K+, Cl-, Ca2+, H+, HCO3-) that help with the 
buffering capacity (bicarbonate and phosphate ions), remineralization of teeth enamels 
(calcium and phosphate ions), and maintenance of mucosal integrity. Organic 
components of saliva include a wide range of proteins and glycoproteins that contribute 
to the protective and food- and speech-related functions of saliva. Proline-rich proteins 
(PRPs) are the proteins that contain high levels of proline that account for about 70% of 
the parotid saliva protein content38. Acidic PRPs contribute to the protection of oral 
tissues and surfaces by forming pellicle, and by maintaining saliva calcium in equilibrium 
with the enamel. Other acidic and basic PRPs also play roles in food processing as well 
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as microbial management in the mouth. Statherin, histatins, and mucins are other proteins 
that are major contributors to the protective, food processing, and microbial management 
functions of saliva. Some of the other proteins that are present in lower concentrations 
but also play anti-microbial roles include lysozyme, lactoferrins, cystatins, peroxidases, 
and secretory immunoglobulin A33. Most of the aforementioned proteins are 
multifunctional.  
There are some constituents of saliva that are not normally a part of salivary secretion. 
Drugs and hormones are examples of such non-ordinary saliva constituents. These 
constituents are serum constituents that are transported from the blood to saliva via 
different transport mechanisms. The transport mechanisms can either be intracellular or 
extracellular34. Intracellular transport mechanisms include passive diffusion across a 
concentration gradient and active transport through protein channels, of which passive 
diffusion is the more common of the two. The most common route of extracellular 
transport is ultrafiltration through tight gap junctions between the cells. Constituents 
transported to saliva must have some water solubility to be retained in saliva, since saliva 
is 99% water. The saliva/plasma concentrations of the non-salivary constituents depend 
on the pH of the saliva37. 
Analysis of odiferous volatile saliva compounds have generally been in relation to 
disease of the mouth, such as periodontitis39-41. Volatile sulfur compounds and aromatic 
nitrogen containing compounds have been found at elevated levels in the mouth air and 
saliva samples of patients with moderate to severe preriodontitis40,42. More recently, 
saliva analysis has gained interest for its diagnostic tool potential for cancer, infections 
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from virus and bacteria, hormonal abnormality, and drug testing32,37,43. Saliva sampling is 
noninvasive and simple. In the clinical and forensic fields, buccal swab sampling is a 
routine sampling method for the collection of DNA. Analysis of VOCs from such swab 
samples has not yet been investigated.  
2.2.1. Materials & Methods 
Sterile cotton-tipped applicators to collect cheek cells and saliva were purchased from 
Solon Manufacturing Co (Skowhegan, ME, USA). Reagent quality (200 proof) ethyl 
alcohol used for the pre-treatment of cotton swabs was purchased from Florida Distillers 
Co (Lake Alfred, FL, USA).  Ten ml glass, clear, screw top headspace vials with 
PTFE/Silicone septa were used to hold the samples (SUPELCO, Bellefonte, PA, USA). 
Divinylbenzene/Carboxen/Polydimethylsiloxane (DVB/CAR/PDMS) (50/30 μm film 
thickness) SPME fibers and SPME fiber holders were obtained from SUPELCO 
(Bellefonte, PA, USA). 
The GC/MS analysis was carried out using an Agilent Technologies 6890N gas 
chromatograph coupled to an Agilent Technologies 5973N mass selective detector (Palo 
Alto, CA, USA). The column used to separate the analytes was a HP5-MS, 30 m, 0.25 
um, 0.25 mm with helium as the carrier gas with a flow rate of 1.0mL/min. The extracted 
VOCs were desorbed in the injection port of the GC with a temperature of 250°C for five 
minutes in splitless mode. The GC method begins with an initial oven temperature of 
40°C for five minutes, then ramped at 10°C/min to a final temperature of 270°C, and held 
at 270°C for two minutes for a total run time of 30 minutes. The mass spectrometer used 
was an HP 5973 MSD with a quadrupole analyzer operated in electron ionization mode. 
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The mass spectrometer transfer line was maintained at 280°C and the source temperature 
was 230°C. The analytes were acquired in full-scan mode in 41-550 m/z range. 
2.2.2. Pre-treatment of buccal swab collection material 
2.2.2.1. Methods 
Sterile cotton-tipped swabs were pre-treated prior to sample collection to eliminate any 
background compounds. Swabs were spiked with 200 µL of ethanol, then baked in a 
105°C oven for one hour, and the procedure was repeated again. Pre-treated swabs were 
analyzed using SPME-GC/MS with a 21-hour extraction time to ensure they were free of 
undesired compounds and analytically clean. 
2.2.2.2. Results 
Pretreated cotton swabs were analyzed using SPME-GC/MS to ensure they were free of 
undesired human scent compounds. Example of a chromatogram of pre-and post-cleaning 
treatment of the sterile cotton swabs prior to sample collection are shown in Figure 4. As 
seen in Figure 5, the pre-treatment procedure effectively removes the numerous 
compounds that were originally present in the scent collection materials.  
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Figure 4. Comparison of untreated and pre-treated cotton swab 
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Figure 5 Comparison of cotton swab pretreatment for the removal of undesired 
VOCs 
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2.2.3. Buccal swab sampling procedure 
Each subject was asked not to eat or drink anything other than water at least two hours 
prior to buccal swab and breath samplings. Subjects sampled themselves with a pre-
treated cotton-tipped sterile swab. Subjects followed a set sampling procedure of rinsing 
their mouths with water for 30 seconds followed by rubbing the swabs on the inside of 
both cheek sides (rubbing 20 times up and down per side of cheek). Samples were 
collected in triplicates with ten minute breaks in between each sampling. Swabs were re-
sealed back into the ten ml glass headspace vial. All samples were stored at room 
temperature and were allowed to sit for approximately 24 hours prior to extraction. No 
attempt was made to control microbial interactions with the samples as that may make 
contributions to the overall odor profile.  
2.2.4. Determination of optimal extraction conditions for buccal swab 
2.2.4.1. Methods 
Buccal swab samples were collected from subjects Male 1, Male 5, and Female 4 
following a set sampling procedure as described in section 2.2.3.  Each subject sampled 
themselves using a pre-treated sterile cotton-tipped swab. Samples were taken in 
triplicates with 10 minutes break in between each sampling. Swabs were re-sealed back 
into the 10 ml glass vial. All samples were stored in the ten ml glass vials at room 
temperature, and were allowed to equilibrate for approximately 24 hours prior to 
extraction. During optimization, the odor exposures were done at room temperature on 
multiple samples for 3, 6, 12, 15, 21, and 24 hours. The 50/30 μm DVB/CAR/PDMS 
SPME fibers (SUPELCO, Bellefonte, PA, USA) were used to extract the VOCs from the 
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headspace of the buccal swab samples in the vials. All samples were run using the 
GC/MS method for buccal swab samples previously mentioned in section 2.2.1.  
2.2.4.2. Results 
Figure 6 shows the number of compounds that have been previously reported as “human 
scent compounds” extracted from buccal swab samples against extraction times. 
“Common compounds” denote the number of VOCs present in all triplicate samples. The 
optimal extraction time for buccal swab samples was evaluated on a combination of the 
number of human scent compounds extracted as well as the abundances of six selected 
common buccal swab compounds (1-octen-3-ol, acetophenone, benzaldehyde, nonanal, 
decanal, and nonanoic acid methyl ester) present in the collected samples. Twenty-one 
(21) hours was determined to be the optimal extraction time for collected buccal swab 
odor compounds. 
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Figure 6. Number of human scent compounds extracted from buccal swab samples 
vs. extraction time 
 
 
2.3. Breath  
Human breath is “a bulk matrix consisting of nitrogen, oxygen, carbon dioxide, water 
vapor, inert gases and some trace components; volatile organic compounds” that is 
produced in the concentrations of nmol/l to pmol/l range44,45. For humans, breathing is 
the process that exchanges oxygen and carbon dioxide between the body and the external 
environment and is governed by the respiratory system. Some of the major functions of 
the respiratory system are to provide oxygen, eliminate carbon dioxide, regulate the blood 
pH, and to defend the body against microbes46.  The anatomical features of the human 
respiratory system include the lungs, the airways, and the respiratory muscles.  
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The trachea branches into two bronchi, one entering the right lung and the other entering 
the left lung. The bronchi branch further into smaller, narrower bronchioles. At the end of 
the bronchioles are the round air sacs called alveoli where the gas exchange occurs 
between the capillaries and alveoli. The mechanics of breathing follows Boyle’s law, 
which states that at in a closed system at constant temperature, pressure and volume of a 
gas are inversely proportional to each other46. The closed system in the respiratory system 
is the thoracic cavity, and the mechanics of breathing depends on the changes in volume 
and pressure of the thoracic cavity. Breathing occurs in two phases, inspiration (inhaling) 
and expiration (exhaling). The diaphragm contracts during inspiration, increasing the 
thoracic cavity volume and thereby decreasing the pressure within. The lungs expand; the 
air pressure inside the alveoli becomes subatmospheric resulting in the air rushing in to 
fill the lungs until equilibrium is reached. Conversely, during expiration, the diaphragm 
relaxes, decreasing the thoracic volume and increasing the pressure within (alveolar 
pressure becomes larger than atmospheric pressure), and, as a result, the lungs contract 
and air is expelled out into the atmosphere. The VOCs are also transported in the 
bloodstream and expired through the lungs along with the other gases that compose the 
“bulk matrix” of the human breath.  
The VOCs in breath may be of endogenous or exogenous origins. Volatile substances of 
exogenous origins are contaminants from the environment that are breathed in and 
absorbed by the body. Inorganic gases such as nitric oxide and carbon monoxide are 
endogenous compounds that are generated in the airways. Other endogenous VOCs that 
are exhaled can be produced virtually anywhere in the body as a result of metabolic and 
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biochemical processes. These VOCs are transported through the bloodstream and 
eventually exhaled through the lungs. The VOCs can diffuse across the pulmonary 
alveolar membrane which separates the alveolar air from the blood in the capillaries, 
thereby crossing from blood to air and air to blood44. The exhalation rates and route of 
transport of individual blood-borne VOCs depends on whether the VOC has a high or 
low Henry’s constant, as having a low Henry’s constant means that the VOC is not 
readily soluble in water44. In other words, the exhalation rates of the VOCs in human 
breath depend on their molecular weight and hydrophobicity.  
Modern breath analysis started in 1971 when Pauling et al. determined more than 200 
components in human breath using gas chromatography15. Since then, variations in the 
VOCs as well as the effect of age and gender on the profile of volatile components in 
normal human breath have been studied widely resulting in the detection of over 3000 
compounds47,48. Some known endogenous VOCs present in human breath include ethane, 
pentane, isoprene, and acetone48-53. Acetone and isoprene are two of the most common 
VOCs in human breath, and the biochemical pathways of these compounds are well 
known. Acetone production is a result of decarboxylation of excess acetyl-CoA which 
generates ketone bodies45,49. Isoprene generation is a result of mevalonate metabolism of 
cholesterol synthesis49.  However, the source and the biochemical pathways of most 
VOCs that have been detected in human expired breath are still not known. 
There has been an increasing interest in human breath analysis for its investigation 
potential for biomarkers for diseases such as certain types of cancer (lung and breast), 
oxidative stress, pulmonary tuberculosis, diabetes mellitus, and kidney impairment52,54-57. 
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The interest in human exhaled breath is based on the non-invasiveness and safeness in the 
sampling process as compared to blood testing. Breath VOC measurements can be used 
to estimate the body burden and different processes in the body because there exists a 
dynamic equilibrium between the blood VOCs and the expired breath VOC 
concentrations. However, a standard breath sampling and analysis protocol for clinical 
settings has yet to be settled. Studies on the analysis of endogenous compounds found in 
humane exhaled breath are still challenged because of the low concentrations of the 
VOCs. Currently, breath-alcohol testing is the only typical routine breath analysis 
application implemented in the medical and forensic fields. 
2.3.1. Materials & Methods 
Breath samples were collected using a Teflon Bio-VOC® breath sampler (Markes 
International Ltd., Rhondda Cynon Taff, UK). Disposable cardboard pediatric 
mouthpieces attached to the Bio-VOC® apparatus were purchased from Alliance Tech 
Medical, Inc.TM (Grandbury, TX, USA). To seal the apparatus, 11mm crimp seals with 
PTFE/Silicone septa (Sun Sri, Rockwood, TN, USA) were used. The acetone used for the 
pre-treatment of Bio-VOC® breath sampler apparatus was ACS grade acetone purchased 
from Fisher Scientific, Pittsburgh, PA, USA). 
The GC/MS analysis was carried out using an Agilent Technologies 6890N gas 
chromatograph coupled to an Agilent Technologies 5973N mass selective detector (Palo 
Alto, CA, USA). The column used to separate the analytes was a HP5-MS, 30 m, 0.25 
um, 0.25 mm with helium as the carrier gas with a flow rate of 1.0mL/min. The extracted 
VOCs were desorbed in the injection port of the GC for five minutes in splitless mode. 
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The injection port temperature was set at 280°C for breath samples. The GC method 
begins with an initial oven temperature of 40°C for five minutes, then ramped at 
10°C/min to a final temperature of 270°C, and held at 270°C for two minutes for a total 
run time of 30 minutes. The mass spectrometer used was an HP 5973 MSD with a 
quadrupole analyzer operated in electron ionization mode. The mass spectrometer 
transfer line was maintained at 280°C and the source temperature was 230°C. The 
analytes were acquired in full-scan mode in 41-550 m/z range.   
2.3.2. Pre-treatment of Bio-VOC® Breath Sampler 
2.3.2.1. Methods 
Sample collection materials were pre-treated prior to sample collection to eliminate any 
background compounds. The Bio-VOC® apparatus was rinsed with acetone and placed 
in an oven of 40°C for at least one hour followed by 30 minutes in a 105°C oven, then 
pure nitrogen gas was passed through the bulb for two minutes. The breath sampler was 
crimp sealed until time of breath sampling. 
2.3.2.2. Results 
Pretreated Bio-VOC® breath samplers were analyzed using SPME-GC/MS to ensure 
they were free of undesired human scent compounds. Example of a chromatogram of pre-
and post-cleaning treatment of the breath samplers prior to sample collection are shown 
in Figure 7. As seen in Figure 8, the pre-treatment procedure effectively removes the 
numerous compounds that were originally present in the scent collection materials.  
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Figure 7. Comparison of untreated and pre-treated Bio-VOC® breath sampler 
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Figure 8. Comparison of breath sampler pretreatment for the removal of undesired 
VOCs 
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2.3.3. Breath sampling procedure 
Breath samples were collected following a set sampling procedure. Subjects were asked 
to perform a single slow vital capacity breath into a disposable cardboard mouthpiece 
connected to a 150 ml Teflon®-bulb, which traps the end-expired air. The Teflon®-bulb 
was immediately sealed after sampling. 
2.3.4. Determination of optimal extraction conditions for breath 
2.3.4.1. Methods 
Breath samples were collected from subjects Male 1 and Female 4 following a set 
sampling procedure as described in section 2.3.3. Each subject sampled themselves by 
performing a single slow vital capacity breath into a disposable cardboard mouthpiece 
connected to a 150 ml Teflon® Bio-VOC® breath sampler (Markes International Ltd., 
Rhondda Cynon Taff, UK), which traps the end-expired air. The Teflon®-bulb was 
immediately sealed using an 11 mm crimp seal with PTFE/Silicone septa (Sun Sri, 
Rockwood, TN, USA) after sampling. The exhaled breath VOCs were extracted by 50/30 
μm DVB/CAR/PDMS SPME fibers (SUPELCO, Bellefonte, PA, USA) directly inserted 
into the Teflon®-bulb. During extraction optimization, the breath exposures were done at 
room temperature on multiple samples for 10 min, 15 min, 30 min, 45 min, 1 hr, 3 hrs, 6 
hrs, 12 hrs, 15 hrs, 18 hrs, 21 hrs, and 24 hrs. Optimization of sample equilibration time 
was also performed at 15 min, 1 hr, and 24 hrs. All samples were run using the GC/MS 
method for breath samples previously mentioned in section 2.3.1.  
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2.3.4.2. Results 
2.3.4.2.1. Optimal Extraction Time 
The exhaled breath VOCs from four subjects (Male 1, Male 5, Female 2, and Female 4) 
were extracted by SPME fibers inserted directly into the Teflon®-bulb portion of the 
BioVOC® Breath Sampler. During optimization, the breath exposures were done at room 
temperature on duplicate samples taken from subjects Male 1 and Female 4 for 10 min, 
15 min, 30 min, 45 min, 1 hr, 3 hrs, 6 hrs, 12 hrs, 15 hrs, 18 hrs, 21 hrs, and 24 hrs 
(Figure 9). Extraction time optimization was only investigated for the 15, 18, 21, and 24 
hours exposures for subjects Male 5 and Female 2, since fewer compounds were 
extracted at extraction times below 12 hours (Figure 10). The optimal extraction time for 
breath samples was evaluated on a combination of the number of human scent 
compounds extracted as well as the abundances of selected common breath VOCs present 
in the subject breath samples: phenol, styrene, nonanal, decanal, and acetophenone. 
Figure 11 shows an example of the abundances of common breath VOCs extracted for 
the 15, 18, 21, and 24-hour extraction times for subject M5. Similar results were seen for 
the other three subjects. Twenty-one (21) hours was determined to be the optimal 
extraction time for collected breath odor compounds using the Bio-VOC® breath sampler 
through the evaluation parameters stated. 
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Figure 9. Number of common human scent compounds extracted vs. extraction time 
for breath samples for subjects M1 and F4 
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Figure 10. Number of common human scent compounds extracted vs. extraction 
time for breath samples for subjects M5 and F2 
 
Figure 11 Abundances of selected common breath VOCs extracted vs. extraction 
time for Male 5 
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2.3.4.2.2. Optimal Equilibration Time 
Equilibration time is the time which the collected sample is allowed to sit for in order for 
the VOCs in the sample to reach a steady state between the headspace and the sample 
collection matrix/material. The optimal equilibration time for breath samples collected in 
Bio-VOC® breath sampler was evaluated with the previously-determined 21-hr 
extraction time. Optimal equilibration time was evaluated on a combination of the 
number of human scent compounds extracted and the abundances of selected common 
human scent compounds, phenol, styrene, nonanal, decanal, and acetophenone, present in 
the breath samples. Fifteen (15) minutes was determined to be the most optimal 
equilibration time as shown in Figure 12 and Figure 13. At longer equilibration times, 
fewer compounds were extracted. There is a potential loss of compounds at longer 
equilibration times; with longer equilibration times it is possible that some of the 
compounds dissipate through the breath sampler and, therefore, the compounds are no 
longer present in the breath sampler at the time of extraction by SPME. 
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Figure 12. Number of compounds extracted vs. equilibration time for breath 
 
Figure 13. Abundances of selected common breath VOCs extracted vs. equilibration 
time 
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2.4. Blood 
Blood is the essential body fluid which transports oxygen and nutrients to the body cells 
and carries carbon dioxide and waste materials away from the cells. Blood accounts for 
about 7% to 9% of a person’s total body weight, and the volume is about 4-6 L of blood 
for an average adult58. Blood is composed of cells and plasma; plasma constitutes about 
55% of blood volume and is the liquid portion of the blood in which the cells are 
suspended. The blood cells, called formed elements, are erythrocytes (red blood cells), 
leukocytes (white blood cells), and platelets (fragment cells). Erythrocytes carry oxygen 
and carbon dioxide and account for majority of the blood cells (>99%). Erythrocytes 
contain the protein hemoglobin which binds the oxygen  and carbon dioxide molecules, 
resulting in the characteristic red color of blood. The functions of leucocytes and platelets 
are infection/cancer protection and blood clotting, respectively. Plasma is mostly water 
(91% of plasma by weight), and a variety of inorganic electrolytes, proteins, gases, 
nutrients, hormones, and waste products46 (Figure 14). The other functions of blood 
include immunological functions, self-repair mechanism (blood clotting and coagulation), 
messenger functions, homeostatic functions such as pH and body temperature 
regulations. Blood pH is maintained via homeostasis between 7.35 and 7.4559.  
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Figure 14. Components of blood 
 
Blood, nutrients, gases, ions, and hormones are transported among the cells in the body 
via the circulatory system. The circulatory system is made up of the cardiovascular 
system and the lymphatic system; blood flow is through the former. The cardiovascular 
system is further composed of two pumping systems: pulmonary circulation and systemic 
circulation58,60. The pulmonary circuit involves the right side of the heart where oxygen-
depleted blood is pumped to the lungs. Carbon dioxide and waste products are eliminated 
from the blood via the pulmonary circuit. Deoxygenated blood is carried from the right 
heart chamber to the lungs via the pulmonary arteries; oxygenated blood is transported 
from the lungs back to the heart via the pulmonary veins. Returned oxygenated blood is 
then pumped from the left side of the heart and is circulated to the rest of the body by the 
Blood (8%)
Other fluids & 
tissues (92%)
Plasma 
(55%)
Proteins
(7%)
Albumins
Globulins 
Fibrinogen 
Water
(91%)
Other solutes
(2%)
Ions
Nutrients
Waste products
Gases
Hormones
Formed 
elements
(45%)
Erythrocytes
Leukocytes
Platelets
42 
 
systemic circuit. The blood moves from the heart into aorta which feeds into the arteries, 
to arterioles, and finally to capillaries where the two-way exchange of gases, nutrients, 
and waste materials between blood and cells occurs. The blood-cell exchange of water 
(via osmosis) and dissolved solutes mainly occurs by process of diffusion, and to a lesser 
extent, by the blood pressure exerted against the capillary walls as blood flows through 
the capillaries.  
Blood VOCs have been studied for the health effects of occupational and environmental 
exposures61-63. When increased levels of volatile aromatic compounds such as benzene, 
toluene, and xylene isomers are present in most human blood, they are indicative of 
occupational or environmental VOC exposures and/or smoking16,61-64. Benzene and 
toluene concentrations in the blood of smokers (median concentration of 493 ng/l and 
2001 ng/l for benzene and toluene, respectively) have been reported to be significantly 
different (p<0.0001 for benzene, p<0.05 for toluene)from those of non-smokers (median 
concentrations of 190 ng/l and 1141 ng/l for benzene and toluene, respectively)61. Blood 
sampling is the most invasive technique compared to collection of other biological 
specimens, as it requires needles to withdraw blood or breaking of the skin with a lancet, 
causing physical pain and psychological discomfort to the subject. Despite the sampling 
method being more invasive compared to breath or urine, blood VOC analysis is more 
representative of the internal environment of human biological activities. For this reason, 
analyses of volatile biomarkers for diseases have been gaining interest in the recent 
years65-68. Hexanal and heptanal were found in higher levels (greater than 1.8μM) in lung 
cancer blood compared to normal control blood (lower than 0.20 μM)66,67. In a study 
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comparing blood VOCs of healthy participants and liver cancer patients, hexanal, 1-
octen-3-ol, and octane were found with positive rates greater than 84% in lung cancer 
patient blood (p≤0.0001)68.    
Blood testing is still the most definitive testing method for DNA testing and disease 
diagnostics and therefore is widely performed in medical, toxicological, and forensic 
fields. Blood testing normally involves venipuncture to obtain venous blood, and requires 
several milliliters of blood in quantity. FTA cards have been used as a blood DNA 
storage method, and only require several drops of blood. To date, blood VOC detection 
using FTA cards as the collection medium has not been performed. 
2.4.1. Materials & Methods 
Blood samples were collected on Whatman FTA® MiniCard (Whatman International 
Ltd, Maidstone, UK). Unistik2 Super (21G, 0.81mm) single-use capillary sampling 
devices used for obtaining blood were purchased from Fisher HealthCare (Houston, TX, 
USA). Human whole blood containing anticoagulant sodium EDTA was obtained from 
Bioreclamation Inc. (Hicksville, NY, USA). 
Divinylbenzene/Carboxen/Polydimethylsiloxane (DVB/CAR/PDMS) (50/30 μm film 
thickness) SPME fibers and SPME fiber holders were obtained from SUPELCO 
(Bellefonte, PA, USA). 
The GC/MS analysis was carried out using an Agilent Technologies 6890N gas 
chromatograph coupled to an Agilent Technologies 5973N mass selective detector (Palo 
Alto, CA, USA). The column used to separate the analytes was a HP5-MS, 30 m, 0.25 
um, 0.25 mm with helium as the carrier gas with a flow rate of 1.0mL/min. The extracted 
44 
 
VOCs were desorbed in the injection port of the GC with a temperature of 250°C for five 
minutes in splitless mode. For blood, the GC method begins with an initial oven 
temperature of 30°C ramped at 10°C/min to a final temperature of 200°C where it is held 
for two minutes, for a total run time of 19 minutes. The mass spectrometer used was an 
HP 5973 MSD with a quadrupole analyzer operated in electron ionization mode. The 
mass spectrometer transfer line was maintained at 280°C and the source temperature was 
230°C. The analytes were acquired in full-scan mode in 41-550 m/z range.   
2.4.2. Pre-treatment of FTA card 
2.4.2.1. Methods 
Sample collection materials were pre-treated prior to sample collection to eliminate any 
background compounds. One half of the Whatman FTA® MiniCard (one circle) was 
inserted in a sterile ten ml glass headspace vial and baked in a 105°C oven for 45 
minutes. Pre-treated materials were analyzed using SPME-GC/MS to make sure they 
were free of undesired compounds and analytically clean. 
2.4.2.2. Results 
Pretreated FTA cards were analyzed using SPME-GC/MS to ensure they were free of 
undesired human scent compounds. An example of a chromatogram of pre-and post-
cleaning treatment of the FTA cards prior to sample collection is shown in Figure 15. As 
seen in Figure 16, the pre-treatment procedure effectively removes the numerous 
compounds that were originally present in the scent collection materials.  
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Figure 15. Comparison of untreated and pre-treated FTA card 
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Figure 16. Comparison of FTA card pretreatment for the removal of undesired 
VOCs 
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2.4.3. Blood sampling procedure 
Blood samples were collected from two fingers (right and left ring fingers) using a 
fingerstick apparatus. Subjects sampled themselves by filling the circle of the FTA card 
with their blood. All samples were stored in the ten ml vials at room temperature.  
2.4.4. Determination of optimal extraction conditions for blood 
2.4.4.1. Methods 
Human whole blood containing the anticoagulant sodium EDTA (Bioreclamation Inc., 
Hicksville, NY, USA) was used for the optimization study for blood. Whole blood 
samples were collected on pre-treated Whatman FTA® MiniCard (Whatman 
International Ltd, Maidstone, UK). To each individual FTA card, 200 μL of whole blood 
was added, where blood was evenly distributed within the FTA circle. FTA cards were 
then resealed in their respective vials. During optimization, the blood exposures were 
done in a 37°C sand bath in triplicate samples for 1 min, 5 min, 10 min, 30 min, 1 hr, 3 
hrs, 12 hrs, 18 hrs, 21 hrs, and 24 hrs. Optimization studies were also performed for 
sample equilibration time at 5 min, 1 hr, 8 hrs, 18 hrs, and 24 hrs as well as the effect of 
sample heating. The 50/30 μm DVB/CAR/PDMS SPME fibers (SUPELCO, Bellefonte, 
PA, USA) were used to extract the VOCs from the headspace of the blood samples in the 
vials. All samples were run using the GC/MS method for blood samples previously 
mentioned in section 2.4.1.  
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2.4.4.2. Results 
2.4.4.2.1. Optimal Extraction Time 
During optimization, the blood sample exposures were done in a 37°C sand bath in 
triplicate for one min, 5 min, 10 min, 30 min, 1 hr, 3 hrs, 12 hrs, 18 hrs, 21 hrs, and 24 
hrs. The optimal extraction time for blood samples was evaluated on a combination of the 
number of human scent compounds extracted as well as the abundance of selected human 
scent compounds of various functional groups (decane, toluene, heptanal, and 1-octen-3-
ol). Eighteen (18) hours was determined to be the optimal extraction time for collected 
blood VOCs as shown in Figure 17 and Figure 18. No compounds were detected below 
the one hour extraction time. Beyond 18 hours, the abundance of majority of the 
extracted compounds decreased. The 24-hour extraction resulted in half the abundance of 
what was extracted under the 18-hour extraction time. 
Figure 17. Number of compounds extracted vs. extraction time for whole blood 
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Figure 18. Abundance of selected common compounds extracted vs. extraction time 
for whole blood 
 
2.4.4.2.2. Optimal Equilibration Time 
Once the optimal extraction time was determined, the optimal equilibration time was 
investigated. Various equilibration times (5 min, 1 hr, 8 hrs, 18 hrs, and 24 hrs) were 
investigated with the optimized 18 hour extraction time in a 37°C sand bath. One hour 
equilibration resulted in the greatest number of compounds extracted with SPME (Figure 
19). The optimal equilibration time for blood samples were evaluated on a combination 
of the number of human scent compounds extracted as well as the abundance of selected 
human scent compounds of various functional groups (decane, undecane, toluene, 
heptanal, and 1-octen-3-ol). The abundance of the compounds detected was not greatly 
affected by the different equilibration times (Figure 20). No single obvious trend was 
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seen in the abundances of compounds with varying equilibration times; however, with the 
exception of 1-octen-3-ol, a general decrease in the abundance was seen with increasing 
equilibration times. While abundances of extracted compounds were slightly higher for 
the 5-minute equilibration time than for the 1-hour equilibration time, the number of 
compounds extracted was greater for the latter. Therefore, the combination of a 1-hour 
equilibration time and 18-hour extraction time was chosen for the blood samples.  
Figure 19. Number of compounds extracted vs. equilibration time for whole blood 
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Figure 20. Abundance of selected common blood VOCs extracted vs. equilibration 
time 
 
2.4.4.2.3. Effect of Sample Heating 
The extraction efficiency of heating the blood samples was investigated. High 
temperatures degrade the blood samples so a comparison was made between unheated 
samples (room temperature equilibration and extraction) and samples heated to 37°C 
(human body temperature). More VOCs were extracted from the samples heated in the 
37°C sand bath regardless of the extraction time, although the difference decreased as 
extraction time increased (Figure 21). Abundance of compounds significantly increased 
for the heated samples also. An example is shown for a common VOC extracted from 
blood samples, undecane, in Figure 22.  
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
500000
5min 1hr 8hr 18hr 24hr
A
bu
nd
an
ce
Equilibration Time
Toluene
Heptanal
1-Octen-3-ol
Decane
Undecane
Toluene
Heptanal
1-Octen-3-ol
Decane
Undecane
51 
 
Figure 21. Number of compounds extracted at room temperature and 37°C for 
whole blood 
 
Figure 22. Abundance vs. extraction time for undecane at room temperature and 
37°C 
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2.4.4.2.4. Blood Sample Stability 
The stability of blood stored over time below 3°C was investigated. Blood collection 
tubes used to collect and store the blood only contained the anticoagulant K2EDTA, and 
no preservatives. The VOC profiles of subject Male 5 were shown to be relatively stable 
even after one month of storage below 3°C as shown in Figure 23. Decanal, hexadecane, 
heptadecane, and octadecane were not present after one month of storage.  
Figure 23. VOC profiles of M5 blood fresh, 1 day, and 1 month after storage 
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2.5. Urine 
Urine is a transparent, aqueous liquid of mostly metabolic waste products that is secreted 
by the kidneys. Urine is composed of mostly water (95%), and the rest are dissolved 
organic waste products, inorganic salts, and gases60. Organic waste materials include 
urea, creatinine, ammonia, and uric acid46,69. Inorganic constituents of urine include 
sodium, potassium, calcium, magnesium, phosphates, and sulfates. It is usually pale-
yellow in color; however, the color may range from yellow to amber, depending on the 
solute concentration in the urine and ingestion of certain foods.  Urine secreted by the 
kidneys flows to the bladder through the ureters and is stored there until it is eliminated 
by the urethra during micturition.  
Figure 24. Schematic of urine production 
 
The urinary excretion mechanism begins by filtration by the nephrons of the kidneys 
(Figure 24). Initially, urine is an ultrafiltrate of the plasma from the glomerular capillaries 
into the glomerular  capsule58,59. The glomerular filtration process is a bulk flow 
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movement of the solvent (water) and the solutes within. Molecular weight determines 
what molecules are allowed to pass through the filter. The ultrafiltrate that results from 
the process is essentially all of the plasma constituents in almost exactly the same 
concentration, with the exception of proteins. The ultrafiltrate does not contain any cells. 
Following filtration, kidney tubular transport mechanisms of reabsorption and secretion 
occur. Reabsorption of tubular fluid, either by active transport or passive diffusion, 
moves water and solutes and transports back into the bloodstream59. There are two 
potential routes of reabsorption, the paracellular pathway where solutes are reabsorbed 
between tight junctions, and the transcellular pathway where solutes are reabsorbed 
through epithelial cells. Passive reabsorption via diffusion depends on the polarity and 
therefore the lipid solubility of the solute. Secretion is the opposite of reabsorption, where 
substances are moved from the blood into the tubular fluid to be excreted. The few mLs 
of urine containing water and solutes that were not reabsorbed are excreted. Table 4 
shows the solute concentrations in plasma, ultrafiltrate in the glomerular capsule, and 
final urine. On average, humans produce approximately one to two liters per day. The 
average pH of freshly collected urine is 6.0, but it can range between 4.5 and 8.060. 
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Table 4. Plasma, initial ultrafiltrate and final urine concentrations of major solutes54 
 Plasma  
(mmol/L) 
Bowman’s capsule 
(mmol/L) 
Urine  
(mmol/L) 
Sodium 142 142 50-150 
Potassium 4.0 4.0 20-100 
Chloride 103 113 50-150 
Bicarbonate 24-27 27-30 0-25 
Glucose 5.5 5.9 0 
Protein 6g/100mL 0.020g/100mL < 0.010g/100mL 
 
Urine as collected in the bladder is sterile until it reaches the urethra59. However, 
bacterial colonies reside in the epithelial cells of the urethra, and when urine passes 
through the urethra and comes in contact with the bacteria, the interaction between the 
urine and the bacterial community can result in strong odor. Urinary odor depends on the 
volume and concentration of the solutes excreted by the kidneys. Dilute urine is nearly 
odorless; concentrated urine may result in strong odor of ammonia, resulting from the 
breakdown of urea. Diet and physiological conditions may also affect the odor of urine. 
Unusual urinary odor may be related to pathological conditions, infections, or renal 
failure.  
Volatile organic compounds in urine result from food, drinks, air pollutants, drugs, 
bacterial interaction within the body, and metabolic processes70,71. Studies on the profiles 
of volatile metabolites in urine have demonstrated the presence of compounds of wide 
range of functional groups including alcohols, aldehydes, ketones, oxygen- and nitrogen-
containing compounds, sulfur-containing compounds, and other heterocyclic 
compounds70-73. The VOCs in the headspace of urine have been studied in a variety of 
fields including toxicology (drug detection and recovery)74-76, occupational and 
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environmental exposures77-80, and metabolic investigations70,71,81. Early studies on the 
urinary VOC profiles showed that there was a significant variance between different 
individuals, but intra-person urinary VOC profiles remained constant over time even with 
variation factors such as diet, exercise, circadian and seasonal changes73. Disturbances of 
volatile compounds found in urine have been associated with physiological disorders 
including diabetes mellitus, liver and kidney disease, and trimethylaminuria71,82,83. 
2.5.1. Materials & Methods 
Sterile, disposable specimen collection cups were purchased from Dynarex Corporation 
(Orangeburg, NY, USA). Laboratory grade artificial urine was obtained from WARD’S 
Natural Science (Rochester, NY, USA). NaCl, KCl, MgSO4, K2CO3, and Na2CO3 used 
for the urine optimization studies were purchased from Fisher Scientific (Fair Lawn, NJ, 
USA). Ten ml glass, clear, screw top headspace vials with PTFE/Silicone septa were used 
to hold the samples (SUPELCO, Bellefonte, PA, USA). 
Divinylbenzene/Carboxen/Polydimethylsiloxane (DVB/CAR/PDMS) (50/30 μm film 
thickness) SPME fibers and SPME fiber holders were obtained from SUPELCO 
(Bellefonte, PA, USA). 
The GC/MS analysis was carried out using an Agilent Technologies 6890N gas 
chromatograph coupled to an Agilent Technologies 5973N mass selective detector (Palo 
Alto, CA, USA). The column used to separate the analytes was a HP5-MS, 30 m, 0.25 
um, 0.25 mm with helium as the carrier gas with a flow rate of 1.0mL/min. The extracted 
VOCs were desorbed in the injection port of the GC with a temperature of 250°C for five 
minutes in splitless mode. The GC oven temperature programming was as follows: the 
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initial oven temperature of 40°C held for five minutes, and then ramped at 15°C/min to a 
final temperature of 280°C where it was held for two minutes, for a total run time of 23 
minutes. The mass spectrometer used was an HP 5973 MSD with a quadrupole analyzer 
operated in electron ionization mode. The mass spectrometer transfer line was maintained 
at 280°C and the source temperature was 230°C. The analytes were acquired in full-scan 
mode in 41-550 m/z range.   
2.5.2. Urine sampling procedure 
Subjects sampled themselves by collecting urine in a disposable sterile specimen 
collection cup. Urine samples were stored in a 4°C refrigerator until ready for use.  
2.5.3. Determination of optimal extraction conditions for urine 
2.5.3.1. Methods 
Laboratory grade artificial urine (WARD’S Natural Science, Rochester, NY, USA) was 
spiked with acetone, 2-pentanone, dimethyl disulfide, 1H-pyrrole, toluene, hexanal, 4-
heptanone, 3-heptanone, 2-heptanone, benzaldehyde, phenol, 1-octanol, octanoic acid, 
and nonanoic acid for the optimization study. Urine samples were prepared in sterile 10 
ml glass headspace vials with 2 ml urine, 0.5 ml deionized water, 1.5 g NaCl (except 
during salting-out study), and spiked with 25 μL of 200 ppm standard mix comprised of 
the 14 volatile compounds mentioned above. Samples were made in triplicates and 
vortexed at 2800 rpm using lab dancer vortex (IKA® Works, Inc., Wilmington, NC, 
USA) for 30 seconds. Optimization studies were performed for SPME fiber exposure 
time (1, 5, 15, 30 min, and 1hr), sample equilibration time (5, 15, and 30 min), extraction 
temperature (room temperature, 40°C, 50°C, 60°C, and 70°C), and salting-out effects of 
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5 different inorganic salts (NaCl, KCl, MgSO4, K2CO3, and Na2CO3).  The 50/30 μm 
DVB/CAR/PDMS SPME fibers (SUPELCO, Bellefonte, PA, USA) were used to extract 
the VOCs from the headspace of the urine samples in the vials. All samples were run 
using the GC/MS method for urine samples previously mentioned in section 2.5.1.  
2.5.3.2. Results 
2.5.3.2.1. Optimal Extraction Time 
Laboratory grade artificial urine was spiked with 25 µl of 200 ppm standard mix 
comprised of 14 volatile compounds listed in section 2.5.3.1.  Urine samples were 
exposed for 1 min, 5 min, 15 min, 30 min, and 1 hour to determine the optimal extraction 
time in a 50°C water bath with a 30 minute equilibration time. Signal increased with 
increasing extraction time until 30 minutes. The signal remained the same for the 30 
minute- and one hour-extraction times. As shown in Table 5, 13 out of the 14 spiked 
compounds were recovered for both 30 minute- and one hour-extraction times. No 
acetone was detected in any of the samples, as it was masked by the acetonitrile solvent 
peak. From the results, 30 minutes was determined to be the optimal extraction time.  
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Table 5. Compounds detected under different extraction times for urine SPME 
optimization 
RT Compound Extraction Time 
  1 min 5 min 15 min 30 min 1 hr 
1.89 Acetone      
3.28 2-Pentanone x x x x x 
4.44 Dimethyl Disulfide x x x x x 
4.76 Pyrrole  x x x x 
5.07 Toluene x x x x x 
6.02 Hexanal x x x x x 
7.73 4-Heptanone x x x x x 
8.05 3-Heptanone x x x x x 
8.13 2-Heptanone x x x x x 
9.25 Benzaldehyde x x x x x 
9.58 Phenol x x x x x 
10.86 1-Octanol  x x x x 
12.15 Octanoic acid    x x 
12.94 Nonanoic acid   x x x 
 
2.5.3.2.2. Optimal Equilibration Time 
Equilibration times were varied (5, 15, and 30 minutes) with a 30 minute extraction time 
at 50°C. Results demonstrated that peak areas for the three equilibration times were 
comparable with one another (Figure 25 through Figure 29). Longer equilibration time 
did not affect the signal strength or peak area; therefore, the shortest equilibration time of 
five minutes was chosen.  
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Figure 25. Abundance vs. equilibration times of aldehydes for urine optimization 
 
Figure 26. Abundance vs. equilibration times for acids for urine optimization 
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Figure 27. Abundance vs. equilibration times for alcohols for urine optimization 
 
Figure 28. Abundance vs. equilibration times for ketones for urine optimization 
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Figure 29. Abundance vs. equilibration time for other functional group compounds 
for urine optimization 
 
2.5.3.2.3. Optimal Extraction Temperature 
Temperature of the hot water bath was varied (room temperature (~25°C, 40°C, 50°C, 
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when it is withdrawn back into the needle. Therefore, 60°C was chosen as the optimal 
extraction temperature. 
Figure 30. Abundance vs. extraction temperatures of aldehydes for urine 
optimization 
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Figure 31. Abundance vs. extraction temperatures of acids for urine optimization 
 
Figure 32. Abundance vs. extraction temperatures of alcohols for urine optimization 
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Figure 33. Abundance vs. extraction temperatures of ketones for urine optimization 
 
Figure 34. Abundance vs. extraction temperatures of other functional group 
compounds for urine optimization 
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2.5.3.2.4. Effect of Salting Out 
Five inorganic salts (NaCl, KCl, MgSO4, K2CO3, and Na2CO3) were tested for their 
salting-out abilities. Adding an inorganic salt to a sample solution improves extraction 
efficiency for volatile compounds in biological fluids. Salting out can be used not only to 
lower the detection limits, but also to buffer random salt concentration in body fluids. 
Salt (1.5g) was added to completely saturate the sample solution. Samples were 
equilibrated for five minutes and SPME fibers were exposed for 30 minutes in a 60°C hot 
water bath. As shown in Figure 35 through Figure 39, NaCl improved the extraction 
efficiency of the VOCs best out of the five inorganic salts investigated. No acids were 
detected with the addition of K2CO3 or Na2CO3 (Figure 36).  
Figure 35. Effect of salt addition for urine optimization for aldehydes 
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Figure 36. Effect of salt addition for urine optimization for acids 
 
Figure 37. Effect of salt addition for urine optimization for alcohols 
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Figure 38. Effect of salt addition for urine optimization for ketones 
 
Figure 39. Effect of salt addition for urine optimization for other functional group 
compounds 
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2.6. Comparison of Five Specimens from Individuals 
2.6.1. Methods 
Five biological specimen samples were collected from four subjects: two females (F2 and 
F4) and two males (M1 and M5) ranging in age from 27 to 31 years old. Each specimen 
sample was collected in duplicate (hand odor and breath) or triplicate (buccal swab, 
blood, and urine) and analyzed by the SPME-GC/MS methods mentioned in the 
preceding sections of this chapter and subjected to chromatographic and statistical 
analyses as described below to determine the similarities and differences in the VOCs 
extracted from the five samples. Hand odor, buccal swab, breath, and urine samples were 
collected using the specimen sampling procedures as described previously. Blood was 
obtained using venipuncture method from subjects F4, M1, and M5 in a BD Vacutainer 
® blood collection tube containing K2EDTA (BD, Franklin Lakes, NJ, USA) for this 
portion of study. Subject F2 was not able to give the blood sample, therefore human 
whole blood containing anticoagulant sodium EDTA (Bioreclamation Inc., Hicksville, 
NY, USA) was used in place of F2 blood sample for the VOC profile comparison of 
blood. Hand odor, buccal swab, and breath samples were stored at room temperature. 
Blood and urine samples were stored at 4°C until ready for use. The optimized conditions 
are summarized in Table 6. Extraction conditions for hand odor were determined 
previously by Curran84.  All subsequent studies involving human subject samplings 
utilized the optimized SPME conditions established here. Methods for GC/MS analyses 
of samples from each specimen are described in the previous sections also.  
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Table 6. Summary of optimized SPME conditions for biological specimens 
 Hand 
Odor 
Buccal 
Swab 
Breath Blood Urine 
Equilibration Time 24 hours 24 hours 15 minutes 1 hour 5 minutes 
Extraction Time 21 hours 21 hours 21 hours 18 hours 30 minutes 
Extraction Temperature RT RT RT 37°C 60°C 
Other -- -- -- -- NaCl 
 
2.6.2. Results 
Using the optimized sample collection and SMPE conditions, preliminary human subject 
odor profiles were compared for the five biological specimens prior to larger population 
sampling. Examples of a typical chromatogram for each specimen are shown in Figure 
40. Specimen samples were compared among four subjects (two female subjects F2 and 
F4, two male subjects M1 and M5). Figure 41 through Figure 44 show the chromatogram 
expanded and siloxane peaks removed to compare the odor profiles produced from the 
four subjects (F4, F2, M1, and M5) for the four specimens (buccal swab, breath, blood, 
and urine). As seen from these figures, qualitatively there are commonalities in the 
compounds present in the headspace of the collected samples from different individuals. 
Figure 45 shows the comparison of the relative peak area ratios for the common VOCs 
present in triplicate samples of buccal swabs collected from the four subjects. Figure 45 
also demonstrates the reproducibility between samples collected from the same 
individual. For buccal swab samples, hexanoic acid and decanal were common to all 
subjects; however, the ratios of all compounds demonstrate unique overall VOC profiles 
per individual.  
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Figure 40. Typical odor profile chromatogram for a) hand odor, b) buccal swab, c) 
breath, d) blood, and e) urine 
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Figure 41. Comparison of buccal swab odor profiles from subjects F4, F2, M1, and 
M5 
 
 
Figure 42. Comparison of breath odor profiles from subjects F4, F2, M1, and M5 
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Figure 43. Comparison of blood odor profiles from subjects F4, F2, M1, and M5 
 
 
Figure 44. Comparison of urine odor profiles from subjects F4, F2, M1, and M5 
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Figure 45. Buccal swab VOC profile comparison between 4 subjects 
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Compounds common to all blood samples were undecane, nonanal, dodecane, tridecane, 
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collected from the same individual. Compounds that were present in all four subjects 
varied in the ratios of the compounds present in the profile, demonstrating the 
individuality of the overall VOC profiles per individual.   
Figure 46. Subject comparison of breath VOC profiles from subjects F4, F2, M1, 
and M5 
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Figure 47. Subject comparison of blood VOC profiles from subjects F4, WB, M1, 
and M5 
 
Figure 48. Subject comparison of urine VOC profiles from subjects F4, F2, M1, and 
M5 
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2.6.3. Spearman Correlation Ranking 
Spearman’s rank correlation is a statistical technique that is used to test the statistical 
dependence, in terms of direction and strength of the relationships, between two 
variables85. The Spearman rank correlation coefficient method is a nonparametric, or 
distribution-free technique, that allows for ranked data to be compared to determine the 
correlation between the variables. The null hypothesis is that there is no relationship 
between the variables being compared. The Spearman correlation coefficient ranges from 
-1 to +1.  The Spearman rank correlation coefficient is defined by the following equation:  
 Equation 2 
The correlation coefficient, rs, is determined in terms of the difference between the 
ranked compounds, d, and the number of compounds being compared, n. The Spearman 
rank correlation determined the possible correlation between the chemical odor profile 
(set of VOCs) of a single individual or a single specimen with a population or other 
specimens13. 
Spearman correlation coefficient comparisons were conducted utilizing the VOCs 
detected in the headspace of the four specimens investigated in this study. Using a 
Spearman correlation macro developed in-house13, analysis of specimen profiles from 
subjects demonstrated that intra-subject samples have a high correlation (correlation 
coefficient > 0.9) while inter-subject samples comparison shows a low correlation 
(correlation coefficient < 0.6), reiterating the individuality of odor profiles characteristic 
for each subject (Figure 49). Similarly, Spearman rank correlation comparisons for breath 
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(Figure 50), blood (Figure 51), and urine (Figure 52) were performed and showed similar 
results as that for buccal swab samples shown above. High correlation (correlation 
coefficient > 0.9) was seen between the samples from the same subject, while low 
correlation (correlation coefficient ≤ 0.6) was seen between different sub jects, reiterating 
the individuality of odor profiles for each subject. 
Figure 49. Spearman rank correlation with respect to Female 4, sample 1 for buccal 
swab 
 
Figure 50. Spearman rank correlation with respect to Female 2, sample 1 for breath 
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Figure 51. Spearman rank correlation with respect to Male 1, sample 1 for blood 
 
 
Figure 52. Spearman rank correlation with respect to Male 5, sample 1 for urine 
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2.7. Quantitation of VOCs Collected from Specimens 
It is important to determine the level of the signal of the analyte where it could be 
distinguished from the background noise of the instrument. With human scent where the 
amounts of volatile organic compounds emitted from the specimens are very low.  The 
limit of detection (LOD) and limit of quantitation (LOQ) must be determined for each 
analyte using the instrument of analyses. In analytical chemistry, the limit of detection is 
defined as the concentration of the analyte which gives an instrument a signal three times 
greater than the background noise. The limit of quantitation is defined as the lower limit 
of the analyte concentration for precise quantitative measurements. LOD and LOQ can be 
determined by Equation 3 and Equation 4, respectively:  
 Equation 3 
 Equation 4 
where ylod is the y-coordinate of the limit of detection for the calibration curve, a is the y-
intercept, and 3sx/y is the standard error for the predicted y value for all x values in the 
regression.  
Limits of detection and quantitation were investigated for selected compounds most 
commonly found in the five biological specimens. To determine the LODs and LOQs of 
the analytes found in each specimen, a calibration graph was prepared for each analyte 
using 5, 10, 20, 40, 60, and 80 ng/uL concentrations of standard solutions prepared in 
dichloromethane and analyzed by GC/MS. The LODs and LOQs were calculated using 
the slopes from the calibration curves of each analyte in conjunction with a regression 
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equation as shown in Equation 3. The LODs and LOQs for all analytes tested are 
presented in Table 7 through Table 11. The average LOD values of the VOCs commonly 
found in hand odor, buccal swab, breath, blood, and urine were 3.65ng, 7.98ng, 6.88ng, 
5.07ng, and 8.46ng, respectively. The average LOQ values were 12.15ng (hand odor), 
29.60ng (buccal swab), 22.92ng (breath), 16.90ng (blood), and 28.20ng (urine). Sample 
calibration curves of selected compounds of various functional groups for each specimen 
can be found in the Appendices section.  
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Table 7. Limits of detection and quantitation of VOCs found in the headspace of 
hand odor 
 
 
RT (min) Compound Name LOD (ng) LOQ (ng)
6.25 Furfural 4.86 16.19
6.93 2-Furanmethanol 4.08 13.60
8.10 Heptanal 4.57 15.23
8.85 Propanedioicacid,dimethylester 3.78 12.59
9.44 Benzaldehyde 2.24 7.48
10.01 Phenol 1.58 5.27
10.06 5-Hepten-2-one,6-methyl- 2.44 8.13
10.25 Hexanoicacid ND ND
10.36 Octanal 6.88 22.92
10.97 BenzylAlcohol 2.32 7.74
11.56 Acetophenone 1.82 6.06
12.13 Undecane 3.83 12.78
12.16 1,6-Octadien-3-ol,3,7-dimethyl- 5.77 19.22
12.22 Nonanal 3.97 13.24
12.56 Octanoicacid,methylester 1.68 5.60
13.14 2-Nonenal,(E)- 2.99 9.95
13.31 Nonanol 3.05 10.17
13.65 2-Decanone 1.59 5.30
13.75 Dodecane 2.20 7.32
13.85 Decanal 1.85 6.16
15.21 Tridecane 2.15 7.18
15.33 Undecanal 2.25 7.51
16.57 Tetradecane 2.40 8.01
16.70 Dodecanal 2.22 7.41
17.04 5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 2.18 7.27
17.74 1-Pentadecene 2.61 8.69
17.83 Pentadecane 3.11 10.35
18.65 Dodecanoic acid 4.33 14.42
19.02 Hexadecane 3.11 10.36
20.16 Heptadecane 5.38 17.92
23.23 Eicosane 3.22 10.73
24.17 Heneicosane 4.11 13.71
25.06 Docosane 18.09 60.30
Average 3.65 12.15
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Table 8. Limits of detection and quantitation of VOCs found in the headspace of 
buccal swab 
 
RT (min) Compound Name LOD (ng) LOQ (ng)
5.24 Hexanal 10.20 34.00
6.25 Furfural 6.60 22.01
7.28 1-Hexanol 7.54 25.14
8.16 Pentanoicacid 12.42 41.41
9.44 Benzaldehyde 5.78 19.27
9.95 Phenol 9.13 30.44
10.12 Furan,2-pentyl- 9.23 30.77
10.13 1-Decene ND ND
10.40 Hexanoicacid 5.19 17.29
11.41 2-Octenal,(E)- 5.61 18.69
11.56 Acetophenone 9.96 33.21
11.64 1-Octanol 6.78 22.60
11.83 Heptanoicacid 4.88 16.27
12.12 Heptanoicacid,ethylester 8.47 28.23
13.14 2-Nonenal,(E)- 5.06 16.87
13.37 Menthol 6.51 21.69
13.48 OctanoicAcid 4.79 15.98
13.63 1-Dodecene 6.89 22.96
13.71 Octanoicacid,ethylester 16.98 56.60
13.85 Decanal 5.84 19.47
13.99 2,4-Nonadienal,(E,E)- 5.43 18.10
15.16 Nonanoicacid,ethylester 12.11 40.36
15.21 Tridecane 5.73 19.10
15.46 Naphthalene,1-methyl- 7.19 23.98
16.46 1-Tetradecene 7.55 25.17
16.51 Decanoicacid,ethylester 10.54 35.14
16.57 Tetradecane 6.49 21.62
16.70 Dodecanal 5.82 19.41
16.97 Caryophyllene 7.56 25.20
17.03 5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 9.92 33.05
17.74 1-Pentadecene 6.82 22.72
18.13 Dodecanoicacid,methylester 9.36 31.19
18.59 Dodecanoicacid 9.47 31.58
19.02 Hexadecane 7.05 23.51
19.48 Benzophenone 10.09 33.65
20.16 Heptadecane 5.87 19.56
23.23 Eicosane 6.99 23.29
24.17 Heneicosane 7.20 24.02
25.06 Docosane 14.16 47.19
Average 7.98 26.60
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Table 9. Limits of detection and quantitation of VOCs found in the headspace of 
breath 
 
RT (min) Compound Name LOD (ng) LOQ (ng)
4.16 Octane 6.93 23.09
4.28 Hexanal ND ND
5.28 Ethylbenzene 5.73 19.11
5.42 Xylenes 11.00 36.67
5.75 3-Heptanone 5.72 19.06
5.79 Styrene 6.14 20.46
6.52 1R-.alpha.-Pinene 6.18 20.60
6.89 Benzene,propyl- 5.27 17.55
7.03 Benzaldehyde 6.03 20.09
7.37 Phenol 4.38 14.61
7.47 5-Hepten-2-one,6-methyl- 4.89 16.29
8.16 Limonene 6.12 20.40
8.26 Benzene,1,2-dichloro- 5.26 17.54
8.80 Acetophenone 4.96 16.53
9.29 Undecane 6.14 20.46
9.37 Nonanal 4.47 14.90
9.58 Benzene,1,2,4,5-tetramethyl- 5.10 16.99
10.46 Menthol 6.54 21.79
10.65 Naphthalene 22.41 74.70
10.69 1-Dodecene 3.73 12.42
10.81 Methyl Salicylate 5.16 17.19
10.81 Dodecane 4.69 15.62
10.91 Decanal 5.30 17.67
12.23 Tridecane 5.65 18.83
12.35 Undecanal 4.90 16.34
12.49 Naphthalene,1-methyl- 5.79 19.29
13.12 n-Decanoicacid 9.04 30.13
13.57 Tetradecane 6.00 20.00
13.71 Dodecanal 5.11 17.02
13.98 Caryophyllene 6.22 20.74
14.04 5,9-Undecadien-2-one,6,10-dimethyl- 5.54 18.45
14.28 5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 11.39 37.98
15.07 ButylatedHydroxytoluene 5.63 18.76
15.57 Dodecanoicacid 11.07 36.89
16.02 Hexadecane 6.59 21.95
16.48 Benzophenone 6.16 20.55
17.16 Heptadecane 6.71 22.37
17.57 2,6-Diisopropylnaphthalene 6.17 20.57
19.70 n-Hexadecanoicacid 17.13 57.11
20.02 Eicosane 6.98 23.26
Average 6.88 22.92
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Table 10. Limits of detection and quantitation of VOCs found in the headspace of 
blood 
 
RT (min)Compound Name LOD (ng) LOQ (ng)
4.80 1-Hexanol 2.73 9.11
4.88 4-Heptanone 3.69 12.29
5.08 3-Heptanone 2.81 9.38
5.14 2-Heptanone 4.19 13.95
5.20 Cyclohexanone 4.34 14.47
5.23 Nonane 5.88 19.61
5.30 Heptanal 3.21 10.68
6.23 Benzaldehyde 3.74 12.45
6.33 1-Heptanol 3.31 11.02
6.49 1-Octen-3-ol 18.66 62.18
6.53 Phenol 17.14 57.14
6.62 5-Hepten-2-one,6-methyl- 5.04 16.81
6.67 1-Decene 10.84 36.14
6.68 Furan,2-pentyl- 16.89 56.31
7.28 Limonene 2.81 9.38
7.38 Benzene,1,2-dichloro- 1.58 5.28
7.39 Benzyl Alcohol 4.63 15.42
7.89 Acetophenone 4.66 15.52
7.92 1-Octanol 3.34 11.15
8.35 Undecane 2.68 8.95
8.43 Nonanal 2.57 8.58
8.64 Benzene,1,2,4,5-tetramethyl- 4.39 14.64
9.49 Menthol 4.68 15.61
9.69 Naphthalene 10.50 35.01
9.71 1-Dodecene 5.71 19.03
9.74 2-Decanone 5.39 17.97
9.84 Dodecane 2.76 9.21
9.94 Decanal 3.22 10.73
11.25 Tridecane 2.47 8.22
11.51 Naphthalene,1-methyl- 3.71 12.37
12.48 1-Tetradecene 2.36 7.85
12.58 Tetradecane 2.41 8.04
12.71 Dodecanal 2.49 8.31
13.05 5,9-Undecadien-2-one,6,10-dimethyl-,(E)- 5.01 16.69
13.52 1-Dodecanol 4.78 15.92
15.02 Hexadecane 2.45 8.16
16.16 Heptadecane 1.63 5.42
16.57 2,6-Diisopropylnaphthalene 3.92 13.08
Average 5.07 16.90
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Table 11. Limits of detection and quantitation of VOCs found in the headspace of 
urine 
 
 
 
 
RT (min) Compound Name LOD (ng) LOQ (ng)
Toluene ND ND
2-Pentanone ND ND
Pyrrole ND ND
4-Nonylphenol ND ND
7.08 4-Heptanone 7.91 26.36
7.38 3-Heptanone 9.52 31.73
7.46 2-Heptanone 7.54 25.15
8.69 Benzaldehyde 10.07 33.56
8.80 Dimethyltrisulfide 7.15 23.83
9.15 1-Decene 7.59 25.30
9.77 Benzene,1,2-dichloro- 8.23 27.42
10.24 1-Octanol 7.89 26.28
10.30 Phenol,4-methyl- 9.39 31.30
10.60 1,6-Octadien-3-ol,3,7-dimethyl- 7.98 26.59
10.65 Nonanal 5.21 17.36
11.29 2-Nonenal,(E)- 8.25 27.51
11.46 Menthol 7.41 24.71
11.71 MethylSalicylate 8.65 28.85
11.77 Decanal 6.50 21.66
12.67 1,3-Benzodioxole,5-(2-propenyl)- 8.06 26.85
14.10 5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 7.44 24.79
14.64 ButylatedHydroxytoluene 7.00 23.34
14.95 Dodecanoicacid 16.52 55.08
15.26 Hexadecane 8.09 26.98
15.38 Phenol,4-(1,1,3,3-tetramethylbutyl)- 7.92 26.40
15.55 Diphenylamine 9.78 32.58
15.63 Benzophenone 10.34 34.47
16.02 Heptadecane 8.59 28.62
Average 8.46 28.20
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2.8. Summary of Biological Specimen Optimization 
Thus far, SPME-GC/MS conditions of VOCs above the headspace of collected buccal 
swab, breath, blood, and urine specimens have been optimized. Data obtained using these 
optimized conditions yielded promising results as VOC profiles of different subjects are 
distinct from one another and reproducible within themselves. The specimen sampling 
methods described through the present chapter were utilized for the simultaneous 
collection of hand odor, buccal swab, breath, blood, and urine for the subsequent 
population studies on healthy, diabetic, and depressed individuals. The optimized SPME-
GC/MS conditions were used for the extraction, separation, and analysis of the VOCs 
extracted above the headspace of the collected specimen samples.  
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3. POPULATION STUDIES 
3.1. Scent Biomarkers for Diseases 
“By the sense of smell we can recognize the peculiar perspiration of many diseases, 
which has an important bearing on their identification.86” – Susruta Samhita 
The above quote was taken from an ancient ayurvedic medicine transcript over 2000 
years ago. Thus it is clear that people have long used the smell of individuals to diagnose 
diseases, and the above statement holds true today. The difference is that today, instead 
of physicians simply using the sense of smell or taste, there are analytical methods and 
instruments available to detect and identify such potential biomarkers. The VOC analysis 
in biological specimens is of research interest because of its potential to identify 
diagnostic biomarkers for various diseases. The appearance of specific biomarkers can 
indicate physiological malfunction. Odor can be a diagnostic marker that can lead to early 
diagnosis of diseases. Identification of target VOCs for a particular disease would be a 
useful screening tool. Over the last couple decades, research describing the detection and 
identification of VOCs that are specific to certain diseases has been growing in published 
literature (Table 12).  
Since the initial demonstration of a peculiar odor emanating from schizophrenic patients, 
there have been several studies attempting to identify the odoriferous substance which 
could perhaps provide an approach to an etiologic diagnosis of schizophrenia87,88. It has 
been reported that the mean alveolar gradients of carbon disulfide and pentane were 
significantly higher in schizophrenic patients compared to patients with other psychiatric 
disorders and subjects with no psychiatric disorder.  
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There are numerous studies on the investigation of volatile biomarkers for cancer. Deng 
et al. have developed a procedure for headspace SPME-GC/MS with on-fiber 
derivatization to determine the levels of hexanal and heptanal in the blood of cancer 
patients, as aldehydes with low molecular weight have been proposed to be cancer 
biomarkers66. It was found that high levels of hexanal and heptanal were found only in 
blood taken from patients with lung cancer. Their results corresponded with other studies 
that also found that aldehyde compounds were only present in breath and urine of cancer 
patients67. These findings suggest that early screening of lung cancer may be carried out 
by analysis of these aldehydes in biological fluids. Other studies on volatile biomarkers in 
breath samples of lung cancer patients have also identified potential VOCs that could 
discriminate between individuals with and without lung cancer, although there is no 
single compound that marks the disease54,57,89,90.  
There are many published studies on the profiling potential of VOCs in biological 
specimens in attempt to associate disturbances of volatile compounds with many other 
metabolic illnesses (Table 12). While many of the reported VOCs are also present in 
healthy individuals, studies have reported an elevation in the levels of these compounds 
in patients with asthma91-93, diabetes56,94, liver and kidney disease/impairment70,71,83, 
gastrointestinal diseases95, and oxidative stress56,96. 
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Table 12. Published studies on VOCs in biological specimens identified as potential 
diagnostic markers of various diseases 
Diseases VOCs Detected Specimen References 
Lung or breast 
cancer 
Alkanes, monomethylated alkanes, 
benzene and benzene derivatives 
Breath, blood 54,57,66-
68,89,90,97 
Oxidative stress Ethane, pentane, other alkanes and 
methylated alkanes 
Breath 56,87,96 
Asthma NO, pentane, ethane, 8-isoprostane Breath 91-93 
Diabetes mellitus Acetone, ethanol, methyl nitrate, 4-
heptanone 
Breath, urine 55,94 
Schizophrenia Carbon disulfide, pentane, ethane Breath 87,88 
Cystic fibrosis Carbonyl sulfide, alkanes Breath 98 
Kidney impairment Nitrogen-containing compounds 
(ammonia, dimethylamine, 
trimethylamine) 
Urine 71 
Liver 
impairment/failure  
Benzaldehyde and phenolics 
(phenylketonuria),  
dimethyl disulfide and sulfur-
containing compounds (hepatitis),  
Urine 70,71,83 
Gastrointestinal 
disease 
Sulfur-containing compounds,  
p-menth-1-en-8-ol 
Feces 95 
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3.1.1. Medicine and Human Scent 
3.1.1.1. Disease-Specific Scent 
Certain medical conditions are known to cause odor symptoms. Patients of acidosis have 
acetone smelling breath86. Maple syrup urine disease is an inherited disease of amino acid 
metabolism, which causes urine to have a characteristic sweet smell like maple syrup99. 
This disease is an autosomal recessively inherited disorder in which branched-chain 
amino acids and their α-keto and α-hydroxy acids accumulate in the body fluids, leading 
to mental retardation and neurological damage. The odor of this disease is a result of the 
presence of a ketone called sotolone, which is a component of maple syrup. Sotolone is 
only present in the urine of patients with maple syrup urine disease, and not in urine of 
healthy individuals. Trimethylaminuria, or fish odor syndrome (or fish malodor 
syndrome), is a genetically inherited enzyme deficiency where the patient fails to 
metabolize trimethylaminuria, causing the body to emit a persistent fish odor100. Unusual 
amounts of unoxidized trimethylamine are excreted in the sweat, urine, breath, and other 
bodily secretions. Patients with diabetes mellitus may have a breath odor resembling the 
smell of fruity acetone. The smell of fresh baked brown bread is associated with typhoid 
fever86. Other diseases known to exhibit characteristic (mostly unpleasant, putrid) odors 
include foetor hepaticus of the liver, smallpox, scurvy, scrofula (tuberculosis of the neck), 
yellow fever, gout, and diseases of the respiratory tract such as bronchiectasis, 
lubabscessea and ozaena86.  Examples of metabolic disorders characterized by unusual 
odors are shown in Table 13. 
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Table 13. Metabolic disorders with characteristic odors 
Disease Characteristic Odor 
Phenylketonuria Musty or mousey odor 
Maple syrup urine disease Maple syrup 
Isovaleric academia Sweaty feet 
Trimethylaminuria Fish odor 
Diabetes Mellitus Sweet fruity acetone 
Acidosis Acetone smelling breath 
 
3.1.1.2. Canines and Cancer 
In 1989, Williams and Pembroke described a case of malignant melanoma detected by 
the patient’s pet dog2. The dog constantly sniffed and even tried to bite a specific mole on 
her leg. Upon seeking medical advice, the patient was diagnosed with basal cell 
carcinoma. More instances of this kind have been reported in the recent years. In 2001, a 
case was reported by Church where a pet Labrador constantly pushing and sniffing at his 
owner’s lesion on his left thigh led to the owner to have the lesion examined101. The 
lesion was found to be a basal cell carcinoma. After the lesion was surgically removed, 
the dog showed no more interest in the area. In 2005, Welsh et al. reported yet another 
similar case where a patient’s dog sniffed and poked at her left axilla which was later 
found to be infiltrating ductal carcinoma: breast cancer1. Following these reports, 
researchers at Cambridge Universality Veterinary School in England in collaboration 
with the Cambridge Institute of Dog Behavior & Training are testing the viability of dogs 
to be trained to detect cancer – what is now referred to as “dognoseis”. 
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3.1.1.3. Rats and Schizophrenia 
Patients with schizophrenia have been reported to emit a characteristic unpleasant odor 
that is unrelated to hygiene. In 1959, Smith and Sines’ study of the peculiar odor in the 
sweat of schizophrenic patients demonstrated the differences to that of non-schizophrenic 
individuals’ sweat through the use of trained rats102. A human panel testing the odor was 
also able to discriminate between the sweat of the patients and controls.  
3.2. Diabetes Mellitus 
Diabetes mellitus (commonly just called diabetes) is a metabolic disorder characterized 
by an insulin deficiency or to a hyporesponsiveness to insulin46,103. These conditions 
result in high blood glucose levels to the point where glucose spills over into the urine – 
hence the name diabetes (“syphon” or “running through”) and mellitus (“sweet”) in 
Greek. Despite the high blood glucose levels, the body cells do not absorb the glucose 
and therefore “starve” while the glucose accumulates in the blood, a condition known as 
hyperglycemia. High blood glucose results in the acceleration of other metabolic 
pathways like triacylglycerol hydrolysis, gluconeogenesis, fatty acid oxidation, and 
ketone body formation. When plasma ketone body level becomes abnormally high, blood 
pH-buffering capacity and renal functions are impaired. Ketosis leads to increased plasma 
H+ concentration, where excess H+ together with other important ions (Na+, K+) is 
excreted into the urine. Severe dehydration may occur from loss of these ions and water 
excretion. In addition, H+ accumulation causes brain dysfunction. Complications of 
diabetes include heart disease, high blood pressure, blindness, kidney disease, nervous 
system disease, circulatory problems, dental disease, and complication of pregnancy104. 
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Uncontrolled diabetes often results in acute life-threatening emergencies such as diabetic 
ketoacidosis, hypotention, coma, and death105. Diabetes is the third leading cause of death 
in the U.S., following heart disease and cancer. The 2007 National Diabetes Fact Sheet 
estimated 23.6 million children and adults in the U.S. (7.8% of the population) having 
diabetes, of which 17.9 million are diagnosed diabetes patients and the remaining 5.7 
million are undiagnosed106.  
3.2.1. Type 1 Diabetes 
Type 1 diabetes or insulin-dependent diabetes mellitus (IDDM) is caused by a deficiency 
of pancreatic β cells resulting in insulin deficiency46. Type 1 diabetes was previously also 
known as juvenile-onset diabetes mellitus, for its onset is most often during childhood. 
Pancreatic β cells are selectively destroyed as an autoimmune response, and individuals 
with type 1 diabetes require insulin therapy with daily injections and a specific diet. The 
cause of this autoimmune destruction is not yet fully understood. Type 1 diabetes is the 
less common type of diabetes, affecting about 5-10 percent of the diagnosed diabetic 
patients107. Diabetic ketoacidosis occurs predominantly in type 1 diabetes patients, 
because it results from a total inability of insulin secretion. The body responds to this 
insulin shortage by converting to burning fatty acids and producing acidic ketone bodies. 
As noted before, management of type 1 diabetes involves daily insulin replacement 
therapy. Pancreas transplantation and a lesser invasive islet cell transplantation are 
treatments of extreme cases, although these still do not fully cure the disease. The 
lifespan of type 1 diabetic are generally reduced by up to one-third as a result of 
degenerative complications mentioned before. 
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Figure 53. Diagram of cell glucose regulation for normal, type 1 and type 2 diabetes 
glucose insulin cell
TYPE 1 DIABETES TYPE 2 DIABETESNORMAL
Insulin lets cells take up
glucose from the blood.
Glucose in the cell is
transformed into energy
for the body.
In Type 1 diabetes the
pancreas is not producing
insulin; therefore the
glucose cannot enter the
cell.
In Type 2 diabetes the
pancreas still produces
insulin, but not enough to
help adequate amounts of
glucose into the cells.
 
3.2.2. Type 2 Diabetes 
Type 2 diabetes or non-insulin-dependent diabetes mellitus accounts for over 90% of the 
diagnosed diabetes cases106. Unlike type 1 diabetes, type 2 diabetics have normal or even 
elevated insulin levels. The issue with type 2 diabetes lies in that there is a lack of insulin 
receptors on normally insulin-responsive cells (Figure 53). The cells do not respond 
appropriately to insulin, hence these cells are said to be insulin-resistant. Consequently, 
the blood glucose level becomes elevated, particularly after a meal. Table 14 shows the 
criteria for diagnosing diabetes. 
Type 2 diabetes is also commonly known as adult-onset diabetes and usually occurs in 
obese individuals with a predisposition for this condition. High-cholesterol, hypertension, 
high-fat diet, and low exercise lifestyle are all factors that increase the risk of type 2 
diabetes. In addition to insulin resistance, type 2 diabetes is characterized by impaired 
regulation of hepatic glucose production and declining β-cell function. In extreme cases, 
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the conditions could lead up to β-cell failure where the patient will require insulin therapy 
for survival. Major complications from improperly managed type 2 diabetes include 
retinopathy leading to blindness, nephropathy, neuropathy, and cardiovascular diseases 
such as coronary artery disease46. Treatment (and prevention for onset) for type 2 
diabetes mainly involves diet therapy for weight reduction, and exercise. There are also 
oral therapeutic agents that are used in the management of type 2 diabetes (Table 
15)105,108. Since type 2 diabetes accounts for the majority of diabetic patients in the U.S., 
the type 2 will be the diabetic population of interest in this study. 
Table 14. Diabetes diagnosis criteria 
Stage 
Test 
Fasting Plasma 
Glucose 
Random Plasma 
Glucose 
Oral Glucose 
Tolerance Test (75-g) 
Normal < 100 mg/dL  2hPGa < 140 mg/dL 
Diabetes ≥ 126 mg/dL 
≥ 200 mg/dL plus 
typical diabetes 
symptoms 
2hPG ≥ 200 mg/dL 
a 2-hour plasma glucose 
 
Table 15. Current oral therapeutic agents for type 2 diabetes 
Drug Class Mechanism of Action Indication(s) 
Sulphonylureas and 
repaglinide 
Increase insulin secretion Deficient pancreatic 
secretion of insulin 
resulting in hyperglycemia 
Biguanides 
(Metformin) 
Decrease peripheral insulin 
resistance 
Decrease hepatic gluconeogenesis 
Obesity 
Insulin resistance 
Thiazolidenediones Decrease peripheral insulin 
resistance 
Reduce fatty acids 
Insulin resistance 
α-glucosidase 
inhibitors 
Slow absorption of carbohydrates Hyperglycemia after meal 
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3.3. Mood Disorders 
Mood disorders are mental disorders in which the predominant feature is having a 
disturbance in mood. The National Institute of Mental Health estimates 26.2 percent of 
Americans ages 18 and older suffer from some form of diagnosable mental disorder in a 
given year109. Of these mental disorders, the prevalence of mood disorders (major 
depressive disorder (MDD), dysthymic disorder, and bipolar disorder) is approximately 
9.5 percent of the U.S. population age 18 and older, or about 20.9 million American 
adults. In particular, in a given year, approximately 14.8 million American adults or 
about 6.7 percent of the U.S. population (age 18 or older) suffer from MDD. Worldwide, 
MDD affects about 121 million people and is among the leading causes of disability110.  
3.3.1. Major Depressive Disorder 
Depression is common. It is an episodic medical disorder in which patients are 
overwhelmed by feeling sad, hopeless, helpless, and worthless111-113. Depression 
commonly affects sleep, appetite, and general interest in life. The latest edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) defines MDD to be 
characterized by one or more Major Depressive Episodes where the depressed mood must 
be present for most of the day, almost every day, for at least a 2-week period111. Major 
Depressive Disorder can be a single episode where there is only a single presence of a 
Major Depressive Episode, or recurrent if two or more Major Depressive Episodes are 
present. To be classified as having MDD, there could not have been a Manic Episode, a 
Mixed Episode, or a Hypomanic Episode, as the diagnosis would be changed to Bipolar 
Disorder if this were the case. It is also different from a depressive mood disorder as a 
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result of a medical condition, side effect of medications or drugs of abuse. Lastly, 
Dysthymic Disorder is very similar to MDD in terms of symptoms and, therefore, is often 
difficult to distinguish from MDD. The difference between the two mood disorders lies in 
severity, chronicity, and persistence. Usually Dysthymic Disorder consists of chronic 
(depressed mood present for most days over at least two years), less severe depressive 
symptoms compared to MDD.  
Other mental disorders not under the Mood Disorders category may have depressive 
symptoms also; however, they are different from MDD. Such disorders include 
Schizophrenia, Delusional Disorder, and Psychotic Disorder Not Otherwise Specified. 
Schizoaffective Disorder is also similar to MDD with Psychotic Features, but the 
difference is that to be diagnosed with Schizoaffective Disorder, “there must be at least 2 
weeks of delusions or hallucinations occurring in the absence of prominent mood 
symptoms.111” 
The average onset age of MDD is in the early 30s and the peak age of risk is between 25 
and 44, although it can develop at any age, even prepubescent113. Major Depressive 
Disorder is approximately twice as common in women as men, with prevalence of 
lifetime risk for MDD varying around 10-25% for women and 5-12% for men 
(adolescent and adult)111 . There is a high suicide risk and high mortality rate associated 
with MDD, as completed suicide occurs in up to 15% of individuals with severe MDD114. 
Death rates increase even more for elder individuals suffering MDD115.  
While depression is so common and treatment of the disorder has been very successful, 
the exact cause of depression is yet to be understood. Many hypotheses have been 
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presented to suggest the cause of depression to be the result of genetic, biological, 
psychological, and environmental factors; however, depression most likely results from a 
combination of these factors and not from one single cause112,113. Family, twin, and 
adoption studies support the idea that there are genetic influences that affect development 
of depression. Prevalence of depression is greatly increased among blood relatives of 
individuals with diagnosed MDD when compared to the general population112. 
Biochemically, unusual levels of monoamine neurotransmitters, especially 
norepinephrine, serotonin, and dopamine, have been accounted as causal factors of 
depression. In the brain, chemical messages and information are communicated between 
neurons. Information from one neuron is transmitted to another neuron at the synaptic 
cleft by neurotransmitters that are released by the presynaptic neuron. Altered 
neurotransmitter activities such as depletion or complete absence of one or all of these 
monoamine transmitters, or increases in them are thought to result in depression (Figure 
54). 
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Figure 54. Difference in the chemical message transduction in the brain cells of 
normal individual and individual with MDD (adapted from Pfizer Japan Inc.) 
 
 
Treatment of MDD usually involves psychotherapy and/or pharmacotherapy 
(antidepressant medications). Psychological treatments include cognitive-behavioral 
therapy, interpersonal psychotherapy, and behavioral activation which all focus on the 
relationship between thoughts, perceptions, and behaviors and depressed mood. Other 
forms of treatment include electroconvulsive therapy (ECT) and light therapy. 
Antidepressant drugs have proven to be very effective in the treatment of depression. 
There are over 20 antidepressant drugs available today, and most of them work by 
normalizing the chemical imbalance in the brain. Major classes of antidepressant drugs 
are: 
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• Tricyclic antidepressants (TCAs)  
• Monoamine oxidase inhibitors (MAOIs) 
• Selective serotonin reuptake inhibitors (SSRIs) 
• Serotonin-norepinephrine reuptake inhibitors (SNRIs) 
• Others 
 Lithium 
 Dopamine-norepinephrine reuptake inhibitors 
 Serotonin modulators 
 Norepinephrine-serotonin modulator 
Tricyclic antidepressants and MAOIs are first generation antidepressants. Tricyclic 
antidepressants work by slowing down the reabsorption of norepinephrine and serotonin 
by brain cells. Monoamine oxidase inhibitors are one of the oldest classes of 
antidepressant drugs and are recommended to be restricted to patients who have not 
responded well to other antidepressant medications due to their potential adverse side 
effects and requirement for strict dietary restrictions116. Monoamine oxidase inhibitors 
work by inhibiting the enzyme monoamine oxidase from breaking down the monoamine 
neurotransmitters, thereby increasing the level of active neurotransmitters in the brain. 
Selective serotonin reuptake inhibitors, as the name suggests, selectively inhibits the 
reabsorption of serotonin by the nerve cells, thereby providing higher levels of serotonin 
at the brain receptor site.  
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3.4. Comorbidity between Diabetes and Depression 
Since 1684, it has been recognized that there is an association between diabetes and 
depression117. Since then, the persistence and prevalence of MDD in diabetic adults have 
been studied through a number of epidemiological surveys, longitudinal, follow-up, and 
prospective studies118-122. The exact factors that link the two illnesses still remain 
uncertain; however, there are hypotheses on the interrelationship between MDD and 
diabetes. One hypothesis suggests that MDD in diabetics results from biochemical factors 
related to the illness and the treatments. Another hypothesis suggests that the 
psychosocial or psychological burden from having the chronic illness (diabetes) 
accountable for MDD in diabetes. Intensive review of the current literature published on 
the covariance of MDD and diabetes found that the latter hypothesis is not supported122. 
Studies have reported that MDD doubles the risk for onset of type 2 diabetes in otherwise 
healthy individuals and over the general population117,122. 
3.5. Methods 
For all subjects sampled in the population studies, hand odor, buccal swabs, breath, 
blood, and urine were collected using the specimen sampling methods as described in the 
previous chapter. All collected specimens except for urine were stored at room 
temperature under normal laboratory conditions until ready for SPME analysis. Urine 
samples were stored at 4°C until ready for SPME analysis.  The volatile organic 
compounds from the headspace of collected specimen samples were extracted using 
50/30 µm DVB/CAR/PDMS SPME fibers. Single headspace extractions were performed 
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for each sample. VOC extraction conditions using SPME are described in Table 6 under 
section 2.6.1.  
3.5.1. Evaluation of Odor Profiles of Individuals over Time 
Unrelated subjects Male 5 and Female 4 were sampled over six months. No attempt was 
made to control the diet of the subjects during the course of sampling. Samples were 
collected on a monthly interval (month 0 to month 6). The average temperature and the 
average humidity of the sampling environment during the samplings in the laboratory 
were 22.5°C and 75%, respectively.  
3.5.2. Evaluation of the Effect of Fasting Prior to Sampling 
Four subjects were evaluated: two females (F4 and F15) and two males (M2 and M5) 
ranging in age from 24 to 29. Each subject was sampled twice during the course of a day. 
The first sample was collected at least two hours after the subject had consumed any food 
or beverage (except water) and the second sample was collected immediately after 
consuming a meal. No attempt was made to control the meal consumed by the subjects. 
The average temperature and the average humidity of the sampling environment during 
the samplings in the laboratory were 23.6°C and 56%, respectively. 
3.5.3. Population Analysis of the Volatile Organic Compounds Present Above Collected 
Odor Samples 
3.5.3.1. Healthy Individuals 
All sampling protocols were approved by the Florida International University 
Institutional Review Board (IRB) for research involving human subjects. Subjects were 
asked to read and sign an IRB-approved informed consent form prior to starting the 
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sampling protocol. Thirty-one healthy subjects (15 males, 16 females), ages 19 to 36, 
were sampled. Subjects were also asked to answer a confidential medical questionnaire 
form prior to sampling to ensure that they were not diagnosed with any major 
physiological or psychological illnesses (particularly diabetes and depression) and to be 
aware of any over-the-counter or prescription medication they may be taking at the time 
of sampling that could account for any unusual metabolites in the extracted VOCs. No 
attempt was made to control the diet of the subjects being sampled.   
3.5.3.2. Patients with Type 2 Diabetes 
All sampling protocols were approved by the Florida International University 
Institutional Review Board (IRB) for research involving human subjects as well by the 
Jackson Health System Clinical Trials Office. Subjects were asked to read and sign an 
IRB-approved informed consent form prior to starting the sampling protocol. Nineteen 
diabetic subjects (11 males, 8 females), ages 25 to 60 were sampled. Nine of these 
subjects were inpatients at Jackson North Medical Center (North Miami Beach, FL) and 
were sampled at the hospital. Subjects were also asked to answer a confidential medical 
questionnaire form. No attempt was made to control the diet of the subjects being 
sampled. Blood glucose level was tested and noted at the time of sampling for all 
subjects. 
3.5.3.3. Patients with Major Depressive Disorder 
All sampling protocols were approved by the Florida International University 
Institutional Review Board for research involving human subjects as well by the Jackson 
Health System Clinical Trials Office. Subjects were asked to read and sign an IRB-
105 
 
approved informed consent form prior to starting the sampling protocol. Twenty healthy 
subjects (10 males, 10 females), ages 18 to 49 were sampled. Nine of these subjects were 
inpatients at Jackson North Medical Center (North Miami Beach, FL) and were sampled 
at the hospital. Subjects were also asked to answer a confidential medical questionnaire 
form. No attempt was made to control the diet of the subjects being sampled. 
3.6. Results 
3.6.1. Evaluation of Odor Profiles of Individuals over Time 
The VOC profiles of subjects Female 4 and Male 5 were followed over a six-month 
period (month 0 to month 6). Fifty-five (55) compounds were extracted across the five 
biological specimens over six monthly samplings. Compounds that did not appear at least 
five times over the monthly samplings were disregarded. Table 16 and Table 17 show the 
common compounds that were extracted over the six-month period for Female 4 and 
Male 5, respectively. The VOCs from the five biological specimens included a variety of 
compounds including aldehydes, alcohols, alkanes, acids, esters, ketones, and aromatics. 
Specimen-specific compounds were detected, such as 4-heptanone and 4-nonylphenol for 
urine, which did not appear in the other four specimens. No single compound was found 
to be present across all five specimens in all six months. The variability of compounds 
present between subjects Female 4 and Male 5 for each specimen can be seen in Table 18 
through Table 22, which lists the common compounds that were extracted among the 
monthly samplings of these subjects. Ten human compounds were extracted from hand 
odor samples, of which seven were common to both subjects Female 4 and Male 5. These 
common compounds were: nonanal, decanal, undecanal, tetradecane, hexadecane, 
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heptadecane, and octadecane. Twenty-five compounds were extracted from buccal swab 
samples, of which fourteen were common to both subjects Female 4 and Male 5. These 
common compounds were: 2-pentylfuran, hexanoicacid, (E)-2-nonenal, (E,E)-2,4-
nonadienal, decanal, nonanoic acid, nonanoic acid ethyl ester, 6-dodecanone, 1-
tetradecene, (E)-6,10-dimethyl-5,9-undecadien-2-one, dodecanoic acid ethyl ester, 2,2’-
diethyl-1,1’-biphenyl, tetradecanoic acid ethyl ester, and hexadecanoic acid ethyl ester. 
Ten compounds were extracted from breath samples, of which eight were common to 
both subjects: styrene, phenol, 1,2-dichlorobenzene, 2-ethyl-1-hexanol, nonanal, decanal, 
butylated hydroxytoluene, and benzophenone. Sixteen compounds were extracted from 
blood samples, of which ten were common to both subjects. The ten common compounds 
were: hexanal, 2-pentylfuran, 1,2-dichlorobenzene, undecane, nonanal, decanal, 
tridecane, 2,4,6-trimethylbenzaldehyde, hexadecane, and 2,6-diisopropylnaphthalene. 
Finally, nine compounds were extracted from urine samples, of which two were common 
to both subjects: 4-heptanone and 4-nonylphenol. Figure 55 through Figure 59 show the 
variability of the relative peak area ratio patterns for the common compounds present in 
the monthly samplings of subjects Female 4 and Male 5. 
Curran determined that multiple sampling of one individual’s odor profile over time does 
not contain as much variation as that seen amongst members of a population using hand 
odor84. Similar results have been obtained with different biological specimens, showing 
that peak area arrays for the common human compounds extracted among six monthly 
samples for an individual have greater correlation than when compared between subjects. 
Table 23 through Table 27 show the correlation coefficients calculated between six 
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monthly samplings for subjects Female 4 and Male 5. Correlation coefficients are much 
higher when comparing samples of the same subject over the six-month period, as 
compared to the low coefficients when comparing samples between the subjects. 
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Table 16. VOCs extracted over 6 months for Female 4 
 
 
 
 
Compound Name
0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6
1,1'-Biphenyl,2,2'-diethyl- x x x x x
1-Hexanol,2-ethyl- x x x x x
1-Pentanol x x x x x
1-Tetradecene x x x x x
2,4-Nonadienal,(E,E)- x x x x x x
2,6-Diisopropylnaphthalene x x x x x x x
2-Nonenal,(E)- x x x x x x
4-Heptanone x x x x x x x
4-Nonylphenol x x x x x x
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- x x x x x x x x x x x x
6-Dodecanone x x x x x x
Benzaldehyde,2,4,6-trimethyl- x x x x x x x
Benzene,1,2-dichloro- x x x x x x x x x x x x
Benzene,1,4-dichloro- x x x x x x
Benzophenone x x x x x x
BenzylAlcohol x x x x x x x x x x x x
ButylatedHydroxytoluene x x x x x x
Decanal x x x x x x x x x x x x x x x x x x x x x x x x x x x
Decanoicacid,ethylester x x x x x x
Dodecanoicacid,ethylester x x x x x x x
Furan,2-pentyl- x x x x x x x x x x x
Heptadecane x x x x x x
Heptanoicacid,ethylester x x x x x x
Hexadecane x x x x x x x x x x x x x x
Hexadecanoicacid,ethylester x x x x x x x
Hexanal x x x x x x x x x x x
Hexanoicacid x x x x x x x
Hexanoicacid,ethylester x x x x x x x
Nonanal x x x x x x x x x x x x x x x x x x x x x
Nonanoicacid x x x x x x
Nonanoicacid,ethylester x x x x x x x
Octadecane x x x x x x
Octanoicacid,ethylester x x x x x x x
Phenol x x x x x x x
Styrene x x x x x x
Tetradecane x x x x x x x x x x x x x x
Tetradecanoicacid,ethylester x x x x x x x
Tridecane x x x x x
Undecanal x x x x x
Undecane x x x x x
Xylenes x x x x x x
HD CH BR BL UR
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Table 17. VOCs extracted over 6 months for Male 5 
 
 
Compound Name
0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6
1,1'-Biphenyl,2,2'-diethyl- x x x x x x
1-Dodecene x x x x x x
1-Hexanol,2-ethyl- x x x x x x
1-Tetradecene x x x x x x x
2,4-Nonadienal,(E,E)- x x x x x x x
2,6-Diisopropylnaphthalene x x x x x
2-Heptanone x x x x x
2-Nonenal,(E)- x x x x x x
2-Undecanone x x x x x
4-Heptanone x x x x x x x
4-Nonylphenol x x x x x x x
4-Terpineol x x x x x
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- x x x x x x x x x x x x x
6-Dodecanone x x x x x
6-Methyl-3,5-heptadiene-2-one x x x x x
Benzaldehyde,2,4,6-trimethyl- x x x x x x
Benzene,1,2-dichloro- x x x x x x x x x x x
Benzophenone x x x x x
ButylatedHydroxytoluene x x x x x x x
Carvone x x x x x x x
Caryophyllene x x x x x
Decanal x x x x x x x x x x x x x x x x x x x x x x x x x x
Dodecane x x x x x
Dodecanoicacid x x x x x
Dodecanoicacid,ethylester x x x x x x x
Furan,2-pentyl- x x x x x x x x x x x x x x
Heptadecane x x x x x x x
Hexadecane x x x x x x x x x x x x x x
Hexadecanoicacid,ethylester x x x x x x
Hexanal x x x x x x
Hexanoicacid x x x x x x x
Linalool Oxide x x x x x x
Menthol x x x x x x
Naphthalene,2-methyl- x x x x x x x
Nonanal x x x x x x x x x x x x x x x x x x x x x
Nonanoicacid x x x x x x x
Nonanoicacid,ethylester x x x x x x x
Octadecane x x x x x x x x x x x x
Phenol x x x x x x
Phenol,4-(1,1,3,3-tetramethylbutyl)- x x x x x
Pyrrole x x x x x x
Styrene x x x x x x x
Tetradecane x x x x x x x
Tetradecanoicacid,ethylester x x x x x
Tridecane x x x x x x x x x x
Undecanal x x x x x x x
Undecane x x x x x
HD CH BR BL UR
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Table 18. VOCs extracted from hand odor from F4 and M5 over 6 months 
 
Figure 55. Common compounds extracted among monthly samplings of hand odor 
from subjects F4 and M5 
 
 
RT Compound Name
(min) 0 1 2 3 4 5 6 0 1 2 3 4 5 6
11.39 BenzylAlcohol x x x x x x x
12.64 Nonanal x x x x x x x x x x x x x x
14.27 Decanal x x x x x x x x x x x x x x
15.62 Tridecane x x x x x
15.74 Undecanal x x x x x x x x x x x x
16.49 Hexadecane x x x x x x x x x x x x x x
17.63 Heptadecane x x x x x x x x x x x x x
17.69 5,9-Undecadien-2-one,6,10-dimethyl-, (E)- x x x x x x
20.17 Tetradecane x x x x x x x x x x x x x x
21.65 Octadecane x x x x x x x x x x x x x
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Table 19. VOCs extracted from buccal swabs from F4 and M5 over 6 months 
 
Figure 56. Common compounds extracted among monthly samplings of buccal 
swabs from subjects F4 and M5 
 
RT Compound Name
(min) 0 1 2 3 4 5 6 0 1 2 3 4 5 6
4.63 Hexanal x x x x x
7.98 Furan,2-pentyl- x x x x x x x x x x x x x
8.12 Hexanoicacid,ethylester x x x x x x x
9.25 Hexanoicacid x x x x x x x x x x x x x x
9.37 Linalool Oxide x x x x x x
9.73 Heptanoicacid,ethylester x x x x x x
9.87 6-Methyl-3,5-heptadiene-2-one x x x x x
10.70 2-Nonenal,(E)- x x x x x x x x x x x x
11.25 Octanoicacid,ethylester x x x x x x x
11.36 2,4-Nonadienal,(E,E)- x x x x x x x x x x x x x
11.39 Decanal x x x x x x x x x x x x x x
12.48 Nonanoicacid x x x x x x x x x x x x x
12.67 Nonanoicacid,ethylester x x x x x x x x x x x x x x
12.76 Naphthalene,2-methyl- x x x x x x x
13.71 6-Dodecanone x x x x x x x x x x x
13.91 Decanoicacid,ethylester x x x x x x
13.95 1-Tetradecene x x x x x x x x x x x x
14.49 Caryophyllene x x x x x
14.76 5,9-Undecadien-2-one,6,10-dimethyl-, (E)- x x x x x x x x x x x x x x
15.00 1-Dodecene x x x x x x
16.44 Dodecanoicacid,ethylester x x x x x x x x x x x x x x
17.70 1,1'-Biphenyl,2,2'-diethyl- x x x x x x x x x x x
18.57 Tetradecanoicacid,ethylester x x x x x x x x x x x x
18.70 Octadecane x x x x x
20.66 Hexadecanoicacid,ethylester x x x x x x x x x x x x x
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Table 20. VOCs extracted from breath from F4 and M5 over 6 months 
 
Figure 57. Common compounds extracted among monthly samplings of breath from 
subjects F4 and M5 
 
 
 
RT Compound Name
(min) 0 1 2 3 4 5 6 0 1 2 3 4 5 6
5.85 Xylenes x x x x x x
6.23 Styrene x x x x x x x x x x x x x
7.79 Phenol x x x x x x x x x x x x x
8.35 Benzene,1,2-dichloro- x x x x x x x x x x x x
8.60 1-Hexanol,2-ethyl- x x x x x x x x x x x
9.83 Nonanal x x x x x x x x x x x x x x
11.38 Decanal x x x x x x x x x x x x x x
14.75 5,9-Undecadien-2-one,6,10-dimethyl-, (E)- x x x x x
15.56 ButylatedHydroxytoluene x x x x x x x x x x x x x
16.99 Benzophenone x x x x x x x x x x x
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Table 21. VOCs extracted from blood from F4 and M5 over 6 months 
 
Figure 58. Common compounds extracted among monthly samplings of blood from 
subjects F4 and M5 
 
RT Compound Name
(min) 0 1 2 3 4 5 6 0 1 2 3 4 5 6
3.72 1-Pentanol x x x x x
4.14 Hexanal x x x x x x x x x x x x
5.50 2-Heptanone x x x x x
7.1 Furan,2-pentyl- x x x x x x x x x x x x
7.47 Benzene,1,2-dichloro- x x x x x x x x x x x
7.79 BenzylAlcohol x x x x x
8.77 Undecane x x x x x x x x x x
8.8 Nonanal x x x x x x x x x x x x x x
10.29 Dodecane x x x x x
10.39 Decanal x x x x x x x x x x x
11.63 2-Undecanone x x x x x
11.63 Tridecane x x x x x x x x x x
11.84 Benzaldehyde,2,4,6-trimethyl- x x x x x x x x x x x x x
13.04 Tetradecane x x x x x x x
15.49 Hexadecane x x x x x x x x x x x x x x
16.99 2,6-Diisopropylnaphthalene x x x x x x x x x x x x
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Table 22. VOCs extracted from urine from F4 and M5 over 6 months 
 
Figure 59. Common compounds extracted among monthly samplings of urine from 
subjects F4 and M5 
 
RT Compound Name
(min) 0 1 2 3 4 5 6 0 1 2 3 4 5 6
4.50 Pyrrole x x x x x x
7.51 4-Heptanone x x x x x x x x x x x x x x
9.85 Benzene,1,4-dichloro- x x x x x x
11.82 Menthol x x x x x x
11.88 4-Terpineol x x x x x
12.58 Carvone x x x x x x x
15.30 Dodecanoicacid x x x x x
16.51 Phenol,4-(1,1,3,3-tetramethylbutyl)- x x x x x
16.62 4-Nonylphenol x x x x x x x x x x x x x
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Table 23. Spearman rank correlation coefficients for the peak areas of hand odor 
VOCs across 6 monthly samplings of F4 and M5 
 
Table 24. Spearman rank correlation coefficients for the peak areas of buccal swab 
VOCs across 6 monthly samplings of F4 and M5 
 
Table 25. Spearman rank correlation coefficients for the peak areas of breath VOCs 
across 6 monthly samplings of F4 and M5 
 
F4 (m0) F4 (m1) F4 (m2) F4 (m3) F4 (m4) F4 (m5) F4 (m6) M5 (m0) M5 (m1) M5 (m2) M5 (m3) M5 (m4) M5 (m5) M5 (m6)
F4 (m0) 1 0.740 0.721 0.000 0.572 -0.139 0.572 0.214 0.401 0.000 0.313 0.324 -0.077 0.686
F4 (m1) 0.740 1 0.910 0.271 0.265 -0.364 0.265 0.407 0.557 0.233 0.459 0.175 0.100 0.592
F4 (m2) 0.721 0.910 1 0.323 0.560 0.000 0.560 0.280 0.436 0.126 0.341 0.132 0.000 0.560
F4 (m3) 0.000 0.271 0.323 1 0.407 0.447 0.407 0.103 0.188 -0.077 0.113 -0.211 -0.201 0.172
F4 (m4) 0.572 0.265 0.560 0.407 1 0.728 1 0.000 0.173 -0.166 0.099 0.175 -0.233 0.518
F4 (m5) -0.139 -0.364 0.000 0.447 0.728 1 0.728 -0.232 -0.129 -0.342 -0.181 -0.141 -0.402 0.165
F4 (m6) 0.572 0.265 0.560 0.407 1 0.728 1 0.000 0.173 -0.166 0.099 0.175 -0.233 0.518
M5 (m0) 0.214 0.407 0.280 0.103 0.000 -0.232 0.000 1 0.925 0.815 0.963 0.000 0.815 0.410
M5 (m1) 0.401 0.557 0.436 0.188 0.173 -0.129 0.173 0.925 1 0.815 0.983 0.278 0.772 0.552
M5 (m2) 0.000 0.233 0.126 -0.077 -0.166 -0.342 -0.166 0.815 0.815 1 0.830 0.154 0.964 0.078
M5 (m3) 0.313 0.459 0.341 0.113 0.099 -0.181 0.099 0.963 0.983 0.830 1 0.256 0.830 0.534
M5 (m4) 0.324 0.175 0.132 -0.211 0.175 -0.141 0.175 0.000 0.278 0.154 0.256 1 0.231 0.503
M5 (m5) -0.077 0.100 0.000 -0.201 -0.233 -0.402 -0.233 0.815 0.772 0.964 0.830 0.231 1 0.116
M5 (m6) 0.686 0.592 0.560 0.172 0.518 0.165 0.518 0.410 0.552 0.078 0.534 0.503 0.116 1
Spearman Rank Correlation Coeffient Matrix (Hand Odor)
F4 (m0) F4 (m1) F4 (m2) F4 (m3) F4 (m4) F4 (m5) F4 (m6) M5 (m0) M5 (m1) M5 (m2) M5 (m3) M5 (m4) M5 (m5) M5 (m6)
F4 (m0) 1 0.933 0.917 0.783 0.967 0.967 0.933 -0.184 -0.128 -0.145 -0.145 -0.145 -0.139 -0.100
F4 (m1) 0.933 1 0.983 0.867 0.933 0.933 1.000 -0.161 -0.100 -0.156 -0.117 -0.156 -0.128 -0.067
F4 (m2) 0.917 0.983 1 0.833 0.950 0.950 0.983 -0.172 -0.083 -0.133 -0.106 -0.133 -0.111 -0.044
F4 (m3) 0.783 0.867 0.833 1 0.700 0.700 0.867 -0.083 -0.011 -0.106 -0.033 -0.106 -0.061 0.028
F4 (m4) 0.967 0.933 0.950 0.700 1 1 0.933 -0.206 -0.133 -0.145 -0.150 -0.145 -0.139 -0.100
F4 (m5) 0.967 0.933 0.950 0.700 1 1 0.933 -0.206 -0.133 -0.145 -0.150 -0.145 -0.139 -0.100
F4 (m6) 0.933 1.000 0.983 0.867 0.933 0.933 1 -0.161 -0.100 -0.156 -0.117 -0.156 -0.128 -0.067
M5 (m0) -0.184 -0.161 -0.172 -0.083 -0.206 -0.206 -0.161 1 0.855 0.764 0.891 0.800 0.882 0.736
M5 (m1) -0.128 -0.100 -0.083 -0.011 -0.133 -0.133 -0.100 0.855 1 0.936 0.945 0.945 0.955 0.827
M5 (m2) -0.145 -0.156 -0.133 -0.106 -0.145 -0.145 -0.156 0.764 0.936 1 0.882 0.991 0.909 0.727
M5 (m3) -0.145 -0.156 -0.133 -0.106 -0.145 -0.145 -0.156 0.800 0.945 0.991 1 0.909 0.973 0.882
M5 (m4) -0.145 -0.156 -0.133 -0.106 -0.145 -0.145 -0.156 0.800 0.945 0.991 0.909 1 0.945 0.755
M5 (m5) -0.139 -0.128 -0.111 -0.061 -0.139 -0.139 -0.128 0.882 0.955 0.909 0.973 0.945 1 0.855
M5 (m6) -0.100 -0.067 -0.044 0.028 -0.100 -0.100 -0.067 0.736 0.827 0.727 0.882 0.755 0.855 1
Spearman Rank Correlation Coeffient Matrix (Buccal Swab)
F4 (m0) F4 (m1) F4 (m2) F4 (m3) F4 (m4) F4 (m5) F4 (m6) M5 (m0) M5 (m1) M5 (m2) M5 (m3) M5 (m4) M5 (m5) M5 (m6)
F4 (m0) 1 1 1 0.800 0.400 1 0.400 -0.143 0.143 -0.191 0.238 -0.143 -0.191 -0.048
F4 (m1) 1 1 1 0.800 0.400 1 0.400 -0.143 0.143 -0.191 0.238 -0.143 -0.191 -0.048
F4 (m2) 1 1 1 0.800 0.400 1 0.400 -0.143 0.143 -0.191 0.238 -0.143 -0.191 -0.048
F4 (m3) 0.800 0.800 0.800 1 0.200 0.800 0.800 -0.191 0.191 -0.143 0.095 -0.191 -0.143 0.048
F4 (m4) 0.400 0.400 0.400 0.200 1 0.400 0.400 -0.477 -0.286 -0.524 -0.191 -0.477 -0.524 -0.429
F4 (m5) 1 1 1 0.800 0.400 1 0.400 -0.143 0.143 -0.191 0.238 -0.143 -0.191 -0.048
F4 (m6) 0.400 0.400 0.400 0.800 0.400 0.400 1 -0.524 -0.238 -0.477 -0.334 -0.524 -0.477 -0.334
M5 (m0) -0.143 -0.143 -0.143 -0.191 -0.477 -0.143 -0.524 1 0.771 0.943 0.829 0.943 0.886 0.714
M5 (m1) 0.143 0.143 0.143 0.191 -0.286 0.143 -0.238 0.771 1 0.829 0.714 0.600 0.657 0.600
M5 (m2) -0.191 -0.191 -0.191 -0.143 -0.524 -0.191 -0.477 0.943 0.829 1 0.657 0.886 0.943 0.829
M5 (m3) 0.238 0.238 0.238 0.095 -0.191 0.238 -0.334 0.829 0.714 0.657 1 0.771 0.600 0.486
M5 (m4) -0.143 -0.143 -0.143 -0.191 -0.477 -0.143 -0.524 0.943 0.600 0.886 0.771 1 0.943 0.829
M5 (m5) -0.191 -0.191 -0.191 -0.143 -0.524 -0.191 -0.477 0.886 0.657 0.943 0.600 0.943 1 0.943
M5 (m6) -0.048 -0.048 -0.048 0.048 -0.429 -0.048 -0.334 0.714 0.600 0.829 0.486 0.829 0.943 1
Spearman Rank Correlation Coefficient Matrix (Breath)
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Table 26. Spearman rank correlation coefficients for the peak areas of blood VOCs 
across 6 monthly samplings of F4 and M5 
 
Table 27. Spearman rank correlation coefficients for the peak areas of urine VOCs 
across 6 monthly samplings of F4 and M5 
 
 
  
F4 (m0) F4 (m1) F4 (m2) F4 (m3) F4 (m4) F4 (m5) F4 (m6) M5 (m0) M5 (m1) M5 (m2) M5 (m3) M5 (m4) M5 (m5) M5 (m6)
F4 (m0) 1 0.771 0.829 0.943 0.943 0.943 0.829 0.524 0.238 0.238 0.524 0.477 0.524 0.477
F4 (m1) 0.771 1 0.943 0.886 0.886 0.886 0.943 0.572 0.238 0.238 0.572 0.429 0.572 0.429
F4 (m2) 0.829 0.943 1 0.943 0.943 0.943 1.000 0.715 0.334 0.334 0.715 0.572 0.715 0.572
F4 (m3) 0.943 0.886 0.943 1 1 1 0.943 0.620 0.286 0.286 0.620 0.524 0.620 0.524
F4 (m4) 0.943 0.886 0.943 1 1 1 0.943 0.620 0.286 0.286 0.620 0.524 0.620 0.524
F4 (m5) 0.943 0.886 0.943 1 1 1 0.943 0.620 0.286 0.286 0.620 0.524 0.620 0.524
F4 (m6) 0.829 0.943 1.000 0.943 0.943 0.943 1 0.715 0.334 0.334 0.715 0.572 0.715 0.572
M5 (m0) 0.524 0.572 0.715 0.620 0.620 0.620 0.715 1 0.400 0.400 1.000 0.800 1.000 0.800
M5 (m1) 0.238 0.238 0.334 0.286 0.286 0.286 0.334 0.400 1 1 0.400 0.800 0.400 0.800
M5 (m2) 0.238 0.238 0.334 0.286 0.286 0.286 0.334 0.400 1 1 0.400 0.800 0.400 0.800
M5 (m3) 0.524 0.572 0.715 0.620 0.620 0.620 0.715 1.000 0.400 0.400 1 0.800 1 0.800
M5 (m4) 0.477 0.429 0.572 0.524 0.524 0.524 0.572 0.800 0.800 0.800 0.800 1 0.800 1
M5 (m5) 0.524 0.572 0.715 0.620 0.620 0.620 0.715 1.000 0.400 0.400 1.000 0.800 1 0.800
M5 (m6) 0.477 0.429 0.572 0.524 0.524 0.524 0.572 0.800 0.800 0.800 0.800 1 0.800 1
Spearman Rank Correlation Coefficient Matrix (Blood)
F4 (m0) F4 (m1) F4 (m2) F4 (m3) F4 (m4) F4 (m5) F4 (m6) M5 (m0) M5 (m1) M5 (m2) M5 (m3) M5 (m4) M5 (m5) M5 (m6)
F4 (m0) 1 0.980 0.750 0.540 0.960 0.750 0.829 0.350 0.110 -0.010 -0.180 -0.150 -0.080 0.260
F4 (m1) 0.980 1 0.400 0.320 0.790 0.676 0.310 0.190 0.140 -0.090 -0.290 -0.220 -0.130 -0.010
F4 (m2) 0.750 0.400 1 0.490 0.908 0.680 0.940 0.470 0.160 0.110 0.020 -0.060 0.100 0.440
F4 (m3) 0.540 0.320 0.490 1 0.460 0.930 0.260 0.390 0.120 -0.120 -0.130 -0.220 0.040 0.120
F4 (m4) 0.960 0.790 0.908 0.460 1 0.640 0.938 0.430 0.140 0.050 -0.130 -0.130 -0.040 0.310
F4 (m5) 0.750 0.680 0.680 0.930 0.640 1 0.510 0.290 0.080 -0.140 -0.280 -0.290 0.120 0.120
F4 (m6) 0.860 0.310 0.940 0.260 0.938 0.510 1 0.420 0.180 0.210 0.080 -0.010 0.120 0.480
M5 (m0) 0.350 0.190 0.470 0.390 0.430 0.290 0.420 1 0.270 0.000 0.260 0.060 0.200 0.780
M5 (m1) 0.110 0.140 0.160 0.120 0.140 0.080 0.180 0.270 1 0.510 0.420 0.685 0.520 0.300
M5 (m2) -0.010 -0.090 0.110 -0.120 0.050 -0.140 0.210 0.000 0.510 1 0.886 0.755 0.920 0.337
M5 (m3) -0.180 -0.290 0.020 -0.130 -0.130 -0.280 0.080 0.260 0.420 0.886 1 0.810 0.808 0.320
M5 (m4) -0.150 -0.220 -0.060 -0.220 -0.130 -0.290 -0.010 0.060 0.685 0.755 0.810 1 0.730 0.090
M5 (m5) -0.080 -0.130 0.100 0.040 -0.040 0.120 0.120 0.200 0.410 0.920 0.808 0.730 1 0.350
M5 (m6) 0.260 -0.010 0.440 0.120 0.310 0.120 0.480 0.780 0.300 0.337 0.320 0.090 0.350 1
Spearman Rank Correlation Coefficient Matrix (Urine)
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3.6.2. Principal Component Analysis 
Principal component analysis (PCA) was conducted on the six month time study 
sampling dataset. Figure 60 and Figure 61 shows a three-dimensional plot of the first 
three principal components of subjects Female 4 and Male 5, respectively. Groupings can 
be seen among the different biological specimen samples. As shown in purple in the 
figure, buccal swab samples group together, as do hand odor (blue), breath (green), blood 
(red), and urine (orange) samples. Additionally, PCA was individually conducted on the 
multiple-samplings dataset between Female 4 and Male 5 for each specimen. When the 
first three principal components of these datasets are plotted, groupings can be noted 
among the multiple samples collected from the same individual. Female 4’s samplings 
from the time study group together and Male 5’s samplings group together, but there is 
no overlap between subjects. Figure 62 to Figure 66 display PCA data for the hand odor, 
buccal swab, breath, blood, and urine samples from Female 4 and Male 5 over the six 
month time period. With the exception of a few outliers, each specimen’s samples from 
Female 4 group together as do the samples from Male 5. These three-dimensional plots 
provide a convenient visual aid for identifying the groupings according to specimen or 
individual. 
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Figure 60. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of Female 4 
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Figure 61. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of Male 5 
 
 
  
120 
 
Table 28. PCA results summary for hand odor 
Number 1 2 3 4 5 
Eigenvalue 3.643 1.864 1.458 0.549 0.275 
Percent 45.531 23.306 18.230 6.862 3.438 
Cum Percent 45.531 68.838 87.068 93.929 97.367 
 
 
Figure 62. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of hand odor from 
F4 and M5 over 6 months 
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Table 29. PCA results summary for buccal swab 
Number 1 2 3 4 5 
Eigenvalue 9.739 3.239 0.706 0.468 0.386 
Percent 64.926 21.599 4.705 3.118 2.576 
Cum Percent 64.926 86.526 91.231 94.349 96.925 
 
 
Figure 63. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of buccal swabs 
from F4 and M5 over 6 months 
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Table 30. PCA results summary for breath 
Number 1 2 3 4 5 
Eigenvalue 3.533 2.026 0.886 0.241 0.182 
Percent 50.469 28.940 12.658 3.446 2.606 
Cum Percent 50.469 79.409 92.068 95.514 98.120 
 
 
Figure 64. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of breath from F4 
and M5 over 6 months 
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Table 31. PCA results summary for blood 
Number 1 2 3 4 5 
Eigenvalue 3.636 2.176 0.742 0.252 0.153 
Percent 51.939 31.090 10.602 3.594 2.188 
Cum Percent 51.939 83.029 93.631 97.225 99.413 
 
 
Figure 65. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of blood from F4 
and M5 over 6 months 
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Table 32. PCA results summary for urine 
Number 1 2 3 4 5 
Eigenvalue 2.389 1.023 0.899 0.487 0.202 
Percent 47.781 20.454 17.988 9.737 4.040 
Cum Percent 47.781 68.235 86.223 95.959 100 
 
 
Figure 66. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of urine from F4 
and M5 over 6 months 
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Results from the six-month study of the VOC profiles of two subjects were in agreement 
with the previously reported findings of the similar study done with hand odor. Relative 
peak area ratio comparisons, Spearman rank correlation coefficient comparisons, and 
PCA results all demonstrate that VOC profiles of one individual taken over a period of 
time do not contain as much variation as that seen between different individuals. The 
VOCs from the same specimen over time group together, and VOCs from the same 
individual for different specimens group together. These findings further support the 
hypothesis that human scent, not only hand odor but also extending to other biological 
specimens, is stable over time and distinguishable between individuals. 
3.6.3. Evaluation of the Effect of Fasting Prior to Sampling 
Four unrelated subjects (Female 4, Female 15, Male 2, and Male 15) were sampled intra-
day to evaluate the effect of fasting prior to specimen collections. The “fasting” sampling 
was done in the morning where the subjects had not consumed any food or drinks, with 
the exception of water, since the previous night. The “postprandial” sampling was done 
in the afternoon, immediately after the subject had consumed a meal (within thirty 
minutes after eating). Figure 67 demonstrates the comparison of the average number of 
compounds extracted from each specimen. A small increase in the total number of 
common compounds extracted was observed for each of the five specimens. Buccal swab 
and breath samples were anticipated to have the largest differences between the fasting 
and postprandial samples; however, the differences in the number of compounds 
extracted were not drastic.  
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Figure 67. Average number of compounds extracted from specimens collected after 
fasting and postprandial 
 
Comparisons of compounds that were extracted at fasting and postprandial sampling 
times from the five biological specimens for subject Female 4 are summarized in Table 
33. For each specimen, the compounds that were extracted from both fasting and 
postprandial samplings were subjected to paired t-test of significance to evaluate whether 
the variation in the amounts of the compound extracted was statistically significant or 
not. For hand odor, eight out of the twelve compounds extracted were common across 
fasting and postprandial samplings: benzyl alcohol, nonanal, decanal, tridecane, 
tetradecane, (E)-6,10-dimethyl-5,9-undecadien-2-one, hexadecane, and heptadecane. The 
extracted amounts were statistically significant only for tridecane. For buccal swabs, nine 
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out of the fifteen compounds extracted were common across fasting and postprandial 
samplings: 2-pentylfuran, hexanoic acid, octanoic acid ethyl ester, decanal, nonanoic 
acid, nonanoic acid ethyl ester, (E)- 6,10-dimethyl-5,9-undecadien-2-one, 1-decene, and 
dodecanoic acid ethyl ester. When subjected to paired t-test of significance, the difference 
in the amounts of these nine common extracted compounds was not found to be 
statistically significant. For breath, four out of the six compounds extracted were 
common across fasting and postprandial samplings: toluene, 2-ethyl-1-hexanol, nonanal, 
and decanal. The differences in the amounts of these four compounds extracted between 
samplings were not statistically significant. For blood, nine out of the eighteen 
compounds extracted were common between samplings: undecane, nonanal, tridecane, 
2,4,6-trimethylbenzaldehyde, 2-butyltetrahydrofuran, tetradecane, hexadecane, 
diisopropylnaphthalene, and 2,6-diisopropylnaphthalene. None of the common 
compounds were have to have a statistically significant difference in the amount 
extracted betweens samplings. Finally for urine, two out of the five compounds extracted 
were common between samplings: 4-heptanone and carvone. Carvone was found to be 
statistically significantly different in the amount extracted between fasting and 
postprandial samplings.  
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Table 33. Summary of volatile compounds extracted fasting (AM) vs. postprandial 
(PM) for Female 4 
 
AM PM AM PM AM PM AM PM AM PM
1-Decene x x x
1-Hexanol,2-ethyl- x x
1-Octanol x
2,6-Diisopropylnaphthalene x x
2-Dodecene,(Z)- x
4-Heptanone x x
5,9-Undecadien-2-one,6,10-dimethyl-,(E)- x x x x x
6-Dodecanone x
Acetone x
Benzaldehyde x
Benzaldehyde,2,4,6-trimethyl- x x
BenzylAlcohol x x x
Carvone x x
Caryophyllene x
Cyclododecane x
Cyclopropane,1-ethyl-2-heptyl- x
Decanal x x x x x x x
Diisopropylnaphthalene x x
Dodecane x x
Dodecanoicacid x
Dodecanoicacid,ethylester x x
Furan,2-butyltetrahydro- x x
Furan,2-pentyl- x x x
Heptadecane x x
Heptanoicacid,ethylester x
Hexadecane x x x x
Hexanal x
Hexanoicacid x x
Hexanoicacid,pentylester x
Menthol x
Nonanal x x x x x x
Nonanoicacid x x
Nonanoicacid,ethylester x x
Octadecane x
Octanoicacid,ethylester x x
Octanoicacid,methylester x
Phenol x
Tetradecane x x x x
Toluene x x
Tridecane x x x x
Undecane x x x
Hand Buccal Breath Blood Urine
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Comparisons of compounds that were extracted at fasting and postprandial sampling 
times from the five biological specimens for subject Female 15 are summarized in Table 
34. For each specimen, the compounds that were extracted from both fasting and 
postprandial samplings were subjected to paired t-test of significance to evaluate whether 
the variation in the amounts of the compound extracted was statistically significant or 
not. For hand odor, seven out of the eleven compounds extracted were common across 
fasting and postprandial samplings: benzyl alcohol, undecane, nonanal, decanal, 
tetradecane, (E)-6,10-dimethyl-5,9-undecadien-2-one, and octadecane. The extracted 
amounts were not statistically significant for any of the common compounds. For buccal 
swabs, nine out of the twenty-four compounds extracted were common across fasting and 
postprandial samplings: benzaldehyde, 2-pentylfuran, hexanoic acid, decanal, nonanoic 
acid, nonanoic acid ethyl ester, (E)-6,10-dimethyl-5,9-undecadien-2-one, diethyl 
phthalate, and isopropyl myristate. When subjected to paired t-test of significance, the 
difference in the amounts of these nine common extracted compounds was not found to 
be statistically significant. For breath, eight out of the nine compounds extracted were 
common across fasting and postprandial samplings: toluene, p-xylene, 1,2-
dichlorobenzene, 2-ethyl-1-hexanol, nonanal, decanal, butylated hydroxytoluene, and 
benzophenone. The differences in the amounts of these eight compounds extracted 
between samplings were not statistically significant. For blood, eleven out of the sixteen 
compounds extracted were common between samplings: 2-pentylfuran, nonanal menthol, 
1-dodecene, decanal, (Z)-2-dodecene, tridecane, 2-butyltetrahydrofuran, tetradecane, 
hexadecane, and 2,6-diisopropylnaphthalene. None of the common compounds were have 
to have a statistically significant difference in the amount extracted betweens samplings. 
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Finally for urine, four out of the eight compounds extracted were common between 
samplings: 4-heptanone, menthol, carvone, and N-N-diethylcarbanilide. Menthol and 
carvone were found to be statistically significantly different in the amount extracted 
between fasting and postprandial samplings. 
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Table 34. Summary of compounds extracted fasting (AM) vs. postprandial (PM) for 
Female 15 
 
AM PM AM PM AM PM AM PM AM PM
1,1'-Biphenyl,3-methyl- x
1-Decene x
1-Dodecanol x
1-Dodecene x x x
1-Hexanol,2-ethyl- x x
1-Tetradecene x
2,4-Nonadienal x
2,6-Diisopropylnaphthalene x x
2-Dodecene,(Z)- x x
3-Cyclohexen-1-one2-isopropyl-5-methyl- x
4-Heptanone x x
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- x x x x
6-Dodecanone x
6-Methyl-3,5-heptadiene-2-one x
β-Cadinene x
Acetophenone x
Benzaldehyde x x
Benzaldehyde,2,4,6-trimethyl- x
Benzene,1,2-dichloro- x x
Benzene,1,3-dimethyl- x x
Benzeneacetaldehyde,.alpha.-methyl- x
Benzophenone x x
BenzylAlcohol x x
ButylatedHydroxytoluene x x
Carvone x x
Caryophyllene x
Cedrol x
Decanal x x x x x x x x
DiethylPhthalate x x
Diisopropylnaphthalene x
Furan,2-butyltetrahydro- x x
Furan,2-pentyl- x x x x
Heptadecane x
Heptanoicacid,ethylester x
Hexadecane x x x
Hexanal x
Hexanoicacid x x
Hexanoicacid,pentylester x
IsopropylMyristate x x
Menthol x x x x x
N,N-Diethylcarbanilide x x
Nonanal x x x x x x
Nonanoicacid x x
Nonanoicacid,ethylester x x
Octadecane x x x
Octanoicacid,ethylester x
Pentanoicacid x
Pyrrole x
Tetradecane x x x x x
Toluene x x
Tridecane x x
Undecanal x
Undecane x x x
Hand Buccal Breath Blood Urine
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Comparisons of compounds that were extracted at fasting and postprandial sampling 
times from the five biological specimens for subject Male 2 are summarized in Table 35. 
For each specimen, the compounds that were extracted from both fasting and 
postprandial samplings were subjected to paired t-test of significance to evaluate whether 
the variation in the amounts of the compound extracted was statistically significant or 
not. For hand odor, five out of the seven compounds extracted were common across 
fasting and postprandial samplings: nonanal, decanal, tetradecane, hexadecane, and 
heptadecane. The extracted amounts were not statistically significant for any of the 
common compounds. For buccal swabs, eight out of the fourteen compounds extracted 
were common across fasting and postprandial samplings: 2-pentylfuran, hexanoic acid, 
octanoic acid ethyl ester, decanal, nonanoic acid ethyl ester, 6-dodecanone, (E)-6,10-
dimethyl-5,9-undecadien-2-one, and dodecanoic acid ethyl ester. When subjected to 
paired t-test of significance, the difference in the amounts of dodecanoic acid ethyl ester 
extracted between fasting and postprandial samplings was found to be statistically 
significant. For breath, five out of the eight compounds extracted were common across 
fasting and postprandial samplings: phenol, 2-ethyl-1-hexanol, nonanal, decanal, and 
butylated hydroxytoluene. The differences in the amounts of these five compounds 
extracted between samplings were not statistically significant. For blood, ten out of the 
seventeen compounds extracted were common between samplings: hexanal, nonanal, 
dodecane, tridecane, 2,4,6-trimethylbenzaldehyde, tetradecane, 1-decene, hexadecane, 
2,6-diisopropylnaphthalene, and octadecane. None of the common compounds were have 
to have a statistically significant difference in the amount extracted betweens samplings. 
Finally for urine, three out of the eight compounds extracted were common between 
133 
 
samplings: menthol, 2-isopropylbenzaldehyde, and carvone. 2-Isopropylbenzaldehyde 
was found to be statistically significantly different in the amount extracted between 
fasting and postprandial samplings. 
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Table 35. Summary of compounds extracted fasting (AM) vs. postprandial (PM) for 
Male 2 
 
AM PM AM PM AM PM AM PM AM PM
1-Decene x x
1-Hexanol,2-ethyl- x x
1-Tetradecene x
2,6-Diisopropylnaphthalene x x
2-Cyclohexen-1-one,3-methyl-6-(1-methylethyl)- x
2-Isopropylbenzaldehyde x x
4-Heptanone x
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- x x x x x
6-Dodecanone x x
AllylIsothiocyanate x
Benzaldehyde,2,4,6-trimethyl- x x
Benzene,1,3-dichloro- x
Benzeneacetaldehyde,.alpha.-methyl- x
Benzophenone x
ButylatedHydroxytoluene x x
Carvone x x x
Cyclopropane,nonyl- x
Decanal x x x x x x x
Diisopropylnaphthalene x
Dodecane x x
Dodecanoicacid,ethylester x x
Furan,2-pentyl- x x x
Heptadecane x x x
Hexadecane x x x x
Hexadecanoicacid,ethylester x
Hexanal x x
Hexanoicacid x x
Hexanoicacid,pentylester x
Menthol x x x
Naphthalene x
Nonanal x x x x x x
Nonanoicacid x
Nonanoicacid,ethylester x x
Octadecane x x
Octanoicacid,ethylester x x
Phenol x x
Tetradecane x x x x
Tetradecanoicacid,ethylester x
Tridecane x x
Undecane x x
Hand Buccal Breath Blood Urine
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Comparisons of compounds that were extracted at fasting and postprandial sampling 
times from the five biological specimens for subject Male 5 are summarized in Table 36. 
For each specimen, the compounds that were extracted from both fasting and 
postprandial samplings were subjected to paired t-test of significance to evaluate whether 
the variation in the amounts of the compound extracted was statistically significant or 
not. For hand odor, nine out of the twelve compounds extracted were common across 
fasting and postprandial samplings: undecane, nonanal, decanal, tridecane, tetradecane, 
hexadecane, heptadecane, and octadecane. The extracted amounts were not statistically 
significant for any of the common compounds. For buccal swabs, ten out of the twenty 
compounds extracted were common across fasting and postprandial samplings: 2-
pentylfuran, hexanoic acid, 6-methyl-3,5-heptadiene-2-one, 1-dodecene, decanal, 
nonanoic acid, 6-dodecanone, 1-tetradecene, (E)-6,10-dimethyl-5,9-undecadien-2-one, 
and 1-decene. When subjected to paired t-test of significance, the differences in the 
amounts of these common compounds extracted were not statistically significant. For 
breath, eight out of the thirteen compounds extracted were common across fasting and 
postprandial samplings: toluene, p-xylene, phenol, 1,2-dichlorobenzene, nonanal, 
decanal, tetradecane, and butylated hydroxytoluene. The amount extracted for phenol was 
statistically significantly different between the two samplings. For blood, ten out of the 
twenty-one compounds extracted were common between samplings: hexanal, 
dimethylsulfone, undecane, nonanal, dodecane, tridecane, tetradecane, 1-decene, 
hexadecane, diisopropylnaphthalene, and 2,6-diisopropylnaphthalene. None of the 
common compounds were found to have a statistically significant difference in the 
amount extracted betweens samplings. Finally for urine, five out of the fourteen 
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compounds extracted were common between samplings: pyrrole, 4-heptanone, 
dimethylsulfone, nonanal, and menthol. Menthol was found to be statistically 
significantly different in the amount extracted between fasting and postprandial 
samplings. 
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Table 36. Summary of compounds extracted fasting (AM) vs. postprandial (PM) for 
Male 5 
 
AM PM AM PM AM PM AM PM AM PM
.beta.-Phellandrene x
1,3-Cyclohexadiene,1-methyl-4-(1-methylethyl)- x
1,4-Cyclohexadiene,1-methyl-4-(1-methylethyl)- x
1-Decene x x x x
1-Dodecene x x x
1-Heptanol x
1-Hexadecene x
1-Hexanol x
1-Hexanol,2-ethyl- x
1-Pentanol x
1-Tetradecene x x
2,4-Nonadienal x
2,5-Octanedione x
2,6-Diisopropylnaphthalene x x
4-Heptanone x x
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- x x x
6-Dodecanone x x
6-Methyl-3,5-heptadiene-2-one x x
Benzaldehyde,2,4,6-trimethyl- x
Benzene,1,2-dichloro- x x
Benzene,1,3-dimethyl- x x
Benzene,1-methyl-4-(1-methylethenyl)- x
Benzene,1-methyl-4-(1-methylethyl)- x
Benzenemethanol,.alpha.,.alpha.,4-trimethyl- x
Benzophenone x
BenzylAlcohol x
ButylatedHydroxytoluene x x x
Carvone x
Caryophyllene x
Cedrol x
Cyclopropane,nonyl- x
Decanal x x x x x x x
DiethylPhthalate x
Diisopropylnaphthalene x x
Dimethylsulfone x x x x
Dimethyltrisulfide x
D-Limonene x
Dodecane x x
Dodecanoicacid x
Furan,2-pentyl- x x x
Heptadecane x x
Hexadecane x x x x
Hexanal x x x
Hexanoicacid x x
Menthol x x x x
Naphthalene,2-methyl- x
Nonanal x x x x x x x x
Nonanoicacid x x
Nonanoicacid,ethylester x
Octadecane x x x
Pentadecane x
Phenol x x
Pyrrole x x
Tetradecane x x x x x x
Toluene x x
Tridecane x x x x
Undecanal x
Undecane x x x x
Δ-Cadinene x
Hand Buccal Breath Blood Urine
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3.6.3.1. Cluster Analysis 
Cluster analysis is a statistical method which classifies a set of observations into subsets, 
or clusters, based on similarities or dissimilarities (distances).  The Bray-Curtis Similarity 
Index (BSCI) is a normalization method which measures the resemblance, or similarity, 
between samples. Bray-Curtis, originally a dissimilarity measure that falls between zero 
and one, is multiplied by 100 to give percentage similarity. The equation for BCSI is as 
follows: 
 Equation 5 
Xij is the peak area for the ith compound from sample j. Data classified using BSCI can 
be displayed in the form of a two-dimensional diagram known as a dendogram. 
Hierarchical clusters represented by dendograms were constructed using the Minitab 15 
Statistical Software (Minitab Inc., State College, PA, USA).  
The following figures (Figure 68 through Figure 72) demonstrate, in semi-quantitative 
fashion, examples of the relative ratios of the peak areas of the compounds extracted in 
the headspace above the collected specimen samples along with the corresponding 
dendograms which show the similarity between the VOC profiles in the intra-day (fasting 
vs. postprandial) specimen samples from a male subject and a female subject. The 
greatest variation between the intra-day samples were observed in urine. Urinary volatiles 
should be most susceptible to variation because urinary components are filtered waste 
products being secreted from the body. The intra-day variation of urine is affected by the 
food and beverages consumed by the subject. However, sampling immediately after 
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consuming a meal as it was done in this study should not have influenced the VOC 
profiles, because the metabolites and waste products from the meal consumed prior to 
sampling will not have been secreted yet. Therefore, it should be noted that the intra-day 
variation of urine samples in this study are not results from fasting or postprandial prior 
to sampling.  
Figure 68. Color chart and dendogram for hand odor for M2 and F15 
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Figure 69. Color chart and dendogram for buccal swabs for M2 and F15 
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Figure 70. Color chart and dendogram for breath for M2 and F15 
  
  
  
0%
20%
40%
60%
80%
100%
1 2 1 2
Fasting Postprandial
M2
102ng      116ng      138ng       97ng
0%
20%
40%
60%
80%
100%
1 2 1 2
Fasting Postprandial
F15 
288ng      276ng      259ng    481ng
142 
 
Figure 71. Color chart and dendogram for blood for M2 and F15 
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Figure 72. Color chart and dendogram for urine for M2 and F15 
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medical purposes, particularly for blood testing (i.e., blood glucose or blood cholesterol). 
This is particularly true for patients with diabetes. Food intake disturbs blood glucose 
homeostasis and changes metabolic response of the body to ingested materials. Fasting 
can also affect the presence of ketone bodies in urine, resulting in higher production of 
ketone bodies (ketonuria). Additionally, for medical purposes, first morning urine is 
usually a preferred screening sample because it is most concentrated and prevents false-
negative tests.   
Forensically, fasting prior to sampling is not as important as it would be for medical 
profiling purposes. In real life scenarios, samples collected from suspects or subjects will 
have been sampled at random time of the day and will most likely not be fasting. With 
only a small increase in the number of compounds extracted and the amount of common 
compounds extracted between fasting and postprandial sampling being mostly not 
statistically significant, whether or not the suspect or subject of interest was fasting or 
had just consumed food should not greatly influence the specimen VOC profile in terms 
of forensic applications.  
3.6.4. Population Analysis of the Volatile Organic Compounds Present Above Collected 
Odor Samples 
3.6.4.1. Evaluation of Odor Profiles of Healthy Individuals 
Odor profiles of thirty-one healthy individuals were evaluated using SPME-GC/MS. 
Compounds were identified by spectral library (NIST) and/or by standard reference 
comparison. Thirty-six VOCs were extracted across the hand odor samples collected 
from each of the thirty-one subjects. The compounds ranged in functionality, including: 
145 
 
acids (2.8%), alcohols (11.1%), aldehydes (27.8%), aliphatics (38.9%), esters (11.1%), 
and ketones (8.3%) as shown in Figure 73. The frequency of the occurrence of the VOCs 
extracted in healthy subjects’ hand odor are listed in Table 37 and displayed in the 
histogram in Figure 74. Of the short to mid-chain aldehydes (C5-C14) extracted from hand 
odor, nonanal, decanal, and undecanal were present in more than 90% of the subjects’ 
odor profiles. Hand odor (skin of palms of hands and forearms) is comprised of 
secretions from the sebaceous and the eccrine glands. Aldehydes have been reported to be 
oxidative degradation products of sebaceous secretion components5,14. Likewise, alcohols 
and free fatty acids derive from the interaction of sebaceous secretion components and 
bacteria residing on skin14. Hydrolysis of triglycerides from cutaneous bacterial activity 
results in free fatty acids (mostly shorter than C20, as was the case in the present study). 
Acids however are not as prominent in skin odor as aldehydes or aliphatics, as many of 
the shorter chain free fatty acids (C6-C10) are reduced to alcohols on skin123. Mid- to long-
chain alkanes (C11-C20) were observed in the present study, of which tetradecane, 
hexadecane, and heptadecane were present in over 90% of the subjects. Three ketones 
were extracted, of which (E)-6,10-dimethyl-5,9-undecadien-2-one (geranyl acetone) was 
present in over two thirds of the subjects.  
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Figure 73. Frequency distribution of functional groups of extracted volatile organic 
compounds for hand odor 
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Table 37. Identified VOCs in hand odor of thirty-one healthy individuals ranked by 
frequency of occurrence (Note: * denotes compound was verified by reference 
standard) 
Compound Name 
 
Frequency Occurrence 
Female Male Total (%) 
Decanal* 16 15 31 100 
Nonanal* 16 15 31 100 
Tetradecane* 16 15 31 100 
Hexadecane* 15 15 30 96.8 
Heptadecane* 14 14 28 90.3 
Undecanal* 14 14 28 90.3 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)-* 9 14 23 74.2 
Tridecane* 9 13 22 71.0 
Octadecane* 8 10 18 58.1 
Undecane 8 7 15 48.4 
Dodecane* 9 5 14 45.2 
Benzyl Alcohol* 5 8 13 41.9 
Dodecanal* 5 5 10 32.3 
1,6-Octadien-3-ol,3,7-dimethyl-* 4 3 7 22.6 
1-Hexanol,2-ethyl-* 4 2 6 19.4 
2-Decanone* 3 3 6 19.4 
Benzaldehyde* 3 1 4 12.9 
Nonanoicacid,methylester 2 2 4 12.9 
2-Nonenal,(E)-* 2 1 3 9.7 
Dodecanoicacid,methylester 2 1 3 9.7 
Dodecanoicacid* 0 2 2 6.5 
Eicosane* 0 2 2 6.5 
Furfural* 1 1 2 6.5 
Octanoicacid,methylester* 0 2 2 6.5 
Phenol* 1 1 2 6.5 
1-Pentadecene* 1 0 1 3.2 
Docosane* 0 1 1 3.2 
Heneicosane* 0 1 1 3.2 
Heptanal* 0 1 1 3.2 
Hexanoicacid 0 1 1 3.2 
Octanal* 1 0 1 3.2 
Propanedioicacid,dimethylester* 1 0 1 3.2 
Tetradecanal 1 0 1 3.2 
Acetophenone* 2 1 3 0.1 
Pentadecane* 0 2 2 0.1 
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Figure 74. Histogram of VOCs in hand odor across thirty-one healthy individuals 
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For buccal swab samples, 109 VOCs were extracted across the samples collected from 
the thirty-one healthy individuals. The functionality distribution of the extracted volatile 
compounds was as follows: acids (10.1%), alcohols (5.5%), aldehydes (11.0%), aliphatics 
(26.6%), aromatics (12.8%), esters (21.1%), ketones (11.9%), and others (0.9%). Figure 
75 displays a pie chart of the functionality distribution. The frequency of the occurrence 
of the buccal swab VOCs from the thirty-one healthy individuals are listed in Table 38 
and displayed in the histogram in Figure 76. The compounds with the highest frequency 
of occurrences (>80.0%) were (E)-6,10-dimethyl-5,9-undecadiene-2-one, decanal, 
hexanoic acid, 2-pentylfuran, (E,E)-2,4-nonadienal, nonanoic acid ethyl ester, and (E)-2-
nonenal.  
While aliphatic compounds have the highest frequency distribution of functional groups 
in buccal swab odor, top two-thirds of the compounds detected in the headspace of buccal 
swab samples were fatty acid ester compounds, and specifically ethyl esters of long chain 
fatty acids (C8-C16). Carboxylic acids were also widely present in buccal swab samples. 
Hexanoic acid was the most predominant compound extracted from buccal swabs (and 
present in 100% of the subjects); its chromatographic peaks were usually very large and 
with a wide peak width also. Hexanoic acid peaks in the gas chromatograms of buccal 
swabs were generally not a chromatographically ideal peak, making quantitation for 
hexanoic acid difficult.  
It is difficult to specify the exact origin of the VOCs found in buccal swab, as there are 
many possible routes of VOC entry into the salivary flow. Volatile constituents of oral 
fluids can be attributed to environmental and occupational exposure through inhalation of 
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air and/or water vapor through the lungs, ingestion through the mouth, and transdermal 
absorption through the skin. Putrefactive activities of microorganisms in the mouth also 
affect the production of volatiles in buccal swab samples. Blood-saliva partition must be 
studied from the size and solubility (in water or lipids) of the volatile compounds.  
 
Figure 75. Frequency distribution of functional groups of extracted volatile organic 
compounds for buccal swabs 
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Table 38. Identified VOCs in buccal swab of thirty-one healthy individuals ranked 
by frequency of occurrence (Note: *denotes compound was verified by reference 
standard) 
Compound Frequency Occurrence (%) Female Male Total 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)-* 16 15 31 100 
Decanal* 16 15 31 100 
Hexanoicacid* 16 15 31 100 
Furan,2-pentyl-* 15 15 30 96.8 
2,4-Nonadienal,(E,E)-* 14 14 28 90.3 
Nonanoicacid,ethylester* 13 14 27 87.1 
2-Nonenal,(E)-* 12 13 25 80.7 
6-Dodecanone* 14 10 24 77.4 
Dodecanoicacid,ethylester* 11 13 24 77.4 
Nonanoicacid 13 11 24 77.4 
Hexadecanoicacid,ethylester 8 12 20 64.5 
Hexanoicacid,ethylester 7 13 20 64.5 
Tetradecanoicacid,ethylester 8 12 20 64.5 
Octanoicacid,ethylester* 9 10 19 61.3 
Hexanal* 10 8 18 58.1 
1-Tetradecene* 6 11 17 54.8 
Naphthalene,1-methyl-* 8 6 14 45.2 
1,1'-Biphenyl,2,2'-diethyl- 6 7 13 41.9 
1-Dodecene* 4 9 13 41.9 
Hexanoicacid,pentylester 6 7 13 41.9 
Benzaldehyde* 9 3 12 38.7 
Naphthalene,2-methyl- 6 6 12 38.7 
Dibutanoylmorphine 3 8 11 35.5 
Linalool oxide 5 6 11 35.5 
6-Methyl-3,5-heptadiene-2-one 3 7 10 32.3 
Tetradecane* 5 5 10 32.3 
3-Nonen-2-one 4 6 10 32.2 
1-Octanol* 4 5 9 29.0 
2-Octenoicacid 5 4 9 29.0 
DiethylPhthalate 3 6 9 29.0 
1-Decene* 3 5 8 25.8 
Cyclododecane 6 2 8 25.8 
Furfural* 1 7 8 25.8 
Heptanoicacid,ethylester* 4 4 8 25.8 
1-Hexanol* 2 5 7 22.6 
2-Octenal,(E)-* 1 6 7 22.6 
2-Tetradecene,(E)- 5 2 7 22.6 
Dodecanoicacid* 1 6 7 22.6 
Pentadecanoicacid,ethylester 0 7 7 22.6 
Decanoicacid,ethylester* 2 4 6 19.4 
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Hexadecane* 2 4 6 19.4 
Naphthalene,2,7-dimethyl- 2 4 6 19.4 
Benzoicacid,ethylester 3 2 5 16.1 
Caryophyllene* 2 3 5 16.1 
IsopropylMyristate 3 2 5 16.1 
Vanillin 0 5 5 16.1 
1-Pentadecene* 2 2 4 12.9 
p-Benzoquinone 3 1 4 12.9 
Benzophenone* 1 3 4 12.9 
Cyclopropane,nonyl- 1 3 4 12.9 
2(3H)-Furanone,5-ethyldihydro- 3 0 3 9.7 
2(3H)-Furanone,dihydro-5-pentyl- 0 3 3 9.7 
3,5,9-Undecatrien-2-one,6,10-dimethyl-, (E,Z)- 0 3 3 9.7 
3,7-Dimethyl-octa-1,6-diene 1 2 3 9.7 
Acetophenone* 2 1 3 9.7 
Benzene,1,1'-methylenebis[4-methyl- 2 1 3 9.7 
Benzene,1-methyl-2-[(4-methylphenyl)methyl]- 0 3 3 9.7 
Benzothiazole 2 1 3 9.7 
Calamenene 1 2 3 9.7 
Heptadecane* 1 2 3 9.7 
Hexanoicacid,anhydride 1 2 3 9.7 
Octadecanal 1 2 3 9.7 
OctanoicAcid* 2 1 3 9.7 
β-Bourbonene 2 1 3 9.7 
1,1'-Biphenyl,4-methyl- 0 2 2 6.5 
1-Heptadecene 0 2 2 6.5 
1-Hexadecene 0 2 2 6.5 
1-Pentanol 1 1 2 6.5 
Cyclodecane 0 0 0 6.5 
Cyclotetradecane 1 1 2 6.5 
E-11-Hexadecenoicacid,ethylester 1 1 2 6.5 
Ethyl9-hexadecenoate 0 2 2 6.5 
Galaxolide 1 1 2 6.5 
IsopropylPalmitate 1 1 2 6.5 
Octadecane 1 1 2 6.5 
Pentanoicacid* 1 1 2 6.5 
Phenol* 2 0 2 6.5 
β-Farnesene 1 1 2 6.5 
1,1'-Biphenyl,2-ethyl- 1 0 1 3.2 
1,1'-Biphenyl,3-methyl- 0 1 1 3.2 
2(3H)-Furanone,dihydro-5-propyl- 0 1 1 3.2 
2-Dodecenal,(E)- 0 1 1 3.2 
2-Heptenoicacid 0 1 1 3.2 
3-Eicosene,(E)- 0 1 1 3.2 
3-Heptadecene,(Z)- 1 0 1 3.2 
4,8-Dimethyl-nona-3,8-dien-2-one 1 0 1 3.2 
7-Hexadecene,(Z)- 1 0 1 3.2 
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9-Octadecenoicacid,(E)- 0 1 1 3.2 
Aceticacid 0 1 1 3.2 
Benzaldehyde,4-(1-methylethyl)- 1 0 1 3.2 
Benzene, 1-methyl-2-[(3-methylphenyl)methyl]- 1 0 1 3.2 
ButylatedHydroxytoluene 1 0 1 3.2 
Docosane* 1 0 1 3.2 
Dodecanal* 1 0 1 3.2 
Dodecanoicacid,methylester* 0 1 1 3.2 
Eicosane* 1 0 1 3.2 
Ethyltridecanoate 0 1 1 3.2 
Heneicosane* 1 0 1 3.2 
Heptanoicacid* 0 1 1 3.2 
Hexadecanoicacid,methylester 1 0 1 3.2 
Nonadecanoicacid,ethylester 0 1 1 3.2 
Pentadecane,7-methyl- 1 0 1 3.2 
Tetradecanoicacid,2-methyl-,methyl ester 0 1 1 3.2 
γ-Cadinene 1 0 1 3.2 
Δ-Cadinene 0 1 1 3.2 
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Figure 76. Histogram of VOCs in buccal swab odor from healthy individuals 
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Across the breath samples collected from the healthy subjects, 83 volatile compounds 
were extracted. The functionality distribution of the extracted volatile compounds was as 
follows: acids (2.4%), alcohols (8.4%), aldehydes (10.8%), aliphatics (30.1%), aromatics 
(34.9%), esters (7.2%), and ketones (6.0%). Figure 77 displays a pie chart of the 
distribution of the seven functional groups. The frequency of the occurrence of the breath 
VOCs from the thirty-one healthy individuals are listed in Table 39 and displayed in the 
histogram in Figure 78. The highest frequency occurring VOCs for breath samples were 
decanal, nonanal, styrene, benzophenone, 2-ethyl-1-hexanol, and 1,2-dichlorobezene.  
Exhaled breath VOCs origin can be attributed to the lungs, nasal cavity, or some systemic 
pathway from which the VOCs are exhaled following blood-to-alveolar diffusion. 
Diffusion property depends on the compound’s polarity, fat solubility, volatility, and 
Henry’s constant as described in section 0. Blood-breath partition ratio of a compound 
depends on the compound’s lipid or water solubility. Water soluble compounds such as 
alcohols and ketones can be seen in breath by diffusion through the blood circulation of 
the respiratory tree to the water-bearing membranes. Therefore, higher concentrations of 
water-soluble compounds are expected to be observed in exhaled breath. However, 
water-insoluble (lipophilic) compounds such as straight-chain hydrocarbons can also be 
observed in exhaled breath because of their ability to diffuse through the lungs. High 
lipid soluble compounds are eliminated more slowly than lipophobic compounds because 
they can be deposited and stored in fat before being eliminated62.  
Straight-chain hydrocarbons (C10-C20) were present in the breath odor VOCs extracted 
from the healthy individuals. These compounds are products of lipid peroxidation of the 
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polyunsaturated fatty acids49. Oxidation by enzymes of the polyunsaturated fatty acids 
also produce fatty acid hydroperoxides, which are eventually converted to aldehydes, as 
observed across most subjects (nonanal and decanal are present in 95% of the subjects). 
Branched alkanes (i.e., 2,6-dimethylundecane) and highly substituted benzenes (i.e., 
trimethyl-benzenes) were commonly present across all subjects. These compounds are 
most likely of environmental contaminant origin as they possess negative polarity 
alveolar gradient which are consistent with VOCs that are of exogenous origin48. In other 
words, VOCs with negative alveolar gradient are eliminated faster than the rate they are 
synthesized in the body. Naphthalene and methylnaphthalenes have been suggested to be 
steroid degradation products but the exact origin is still unknown48.  
One compound that is a known volatile constituent of human breath that was not detected 
in the present study is isoprene. Isoprene is present in all human breath resulting from the 
mevalonic pathway of cholesterol synthesis. It is important to note here that under the 
current instrumental conditions isoprene was not detected, most likely due to its high 
vapor pressure (560 mmHg at 20°C) therefore making isoprene a highly volatile 
compound that is also extremely unstable and thermally labile to cause degradation at the 
GC injection port with the current settings.  
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Figure 77. Frequency distribution of functional groups of extracted volatile organic 
compounds for breath 
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Table 39. Identified VOCs in breath odor of thirty-one healthy individuals ranked 
by frequency of occurrence (Note: *denotes compound was verified by reference 
standard) 
Compound Frequency Occurrence (%) Female Male Total 
Decanal* 16 15 31 100 
Nonanal* 15 15 30 96.8 
Styrene* 15 14 29 93.6 
Benzophenone* 13 15 28 90.3 
Benzene,1,2-dichloro-* 13 12 25 80.7 
1-Hexanol,2-ethyl-* 11 12 23 80.7 
ButylatedHydroxytoluene* 14 10 24 77.4 
Xylenes* 11 11 22 71.0 
Phenol* 9 9 18 58.1 
Dibutylphthalate 10 6 16 51.6 
Undecane* 9 4 13 41.9 
Dodecane* 9 4 13 41.9 
2,6-Diisopropylnaphthalene* 7 6 13 41.9 
Tetradecane* 6 5 11 35.5 
Acetophenone* 4 6 10 32.3 
1-Dodecene* 5 5 10 32.3 
Tridecane* 6 4 10 32.3 
Longifolene 6 4 10 32.3 
Undecanal* 5 4 9 29.0 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)-* 6 3 9 29.0 
Dodecanal* 4 4 8 25.8 
Toluene* 5 3 8 25.8 
Phenol,2-(1,1-dimethylethyl)- 5 2 7 22.6 
Indole 2 4 6 19.4 
Naphthalene* 2 3 5 16.1 
Nonanoicacid 3 2 5 16.1 
Benzene,1,3,5-trimethyl- 2 2 4 12.9 
Diisopropylnaphthalene 3 1 4 12.9 
Benzene,1,4-dichloro- 1 2 3 9.7 
Longicyclene 1 2 3 9.7 
Hexadecane* 1 2 3 9.7 
Cyclododecane 2 1 3 9.7 
Limonene* 1 1 2 6.5 
5-Hepten-2-one,6-methyl-* 1 1 2 6.1 
Benzene,1,2,3-trimethyl- 1 1 2 6.1 
Benzene,4-ethyl-1,2-dimethyl- 1 1 2 6.1 
n-Decanoicacid* 2 0 2 6.1 
β-Maaliene 1 1 2 6.1 
1,1'-Biphenyl,4-methyl- 0 2 2 6.1 
Heptadecane* 1 1 2 6.1 
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Hexanal* 0 1 1 3.0 
2-Propanol,1-propoxy- 0 1 1 3.0 
Cyclohexane,methyl- 1 0 1 3.0 
1,3,5,7-Cyclooctatetraene 1 0 1 3.0 
Benzene,propyl- 1 0 1 3.0 
Benzene,1-ethyl-2-methyl- 1 0 1 3.0 
Nonane,3-methyl- 1 0 1 3.0 
Benzaldehyde* 0 1 1 3.0 
Octanal 1 0 1 3.0 
4-Cyanocyclohexene 0 1 1 3.0 
Benzene,diethyl- 1 0 1 3.0 
1S-.alpha.-Pinene 0 1 1 3.0 
Eicosane* 1 0 1 3.0 
Decane,3-methyl- 1 0 1 3.0 
Benzene,1-ethyl-3,5-dimethyl- 1 0 1 3.0 
Undecane,3,6-dimethyl- 1 0 1 3.0 
Benzene,1-ethyl-2,4-dimethyl- 1 0 1 3.0 
Benzene,1-methyl-3-(1-methylethyl)- 1 0 1 3.0 
3-Octanol,3,7-dimethyl-,(.+/-.)- 0 1 1 3.0 
Nonadecane 1 0 1 3.0 
Cyclohexane,pentyl- 1 0 1 3.0 
Benzene,1,3-diethyl-5-methyl- 1 0 1 3.0 
Benzene,1-methyl-4-(1-methylpropyl)- 1 0 1 3.0 
Menthol* 0 1 1 3.0 
MethylSalicylate* 0 1 1 3.0 
Undecane,2,6-dimethyl- 1 0 1 3.0 
Ethanol,2-phenoxy- 0 1 1 3.0 
Benzaldehyde,4-methoxy- 1 0 1 3.0 
Naphthalene,2-methyl- 1 0 1 3.0 
Indolizine 1 0 1 3.0 
Benzene,3-cyclohexen-1-yl- 0 1 1 3.0 
Caryophyllene* 0 1 1 3.0 
β-Gurjunene 1 0 1 3.0 
DiethylPhthalate 1 0 1 3.0 
Tetradecanal 1 0 1 3.0 
p-Benzoquinone 1 0 1 3.0 
Dodecanoicacid,methylester 0 1 1 3.0 
Galaxolide 0 1 1 3.0 
Homomenthylsalicylate 0 1 1 3.0 
IsopropylPalmitate 0 1 1 3.0 
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Figure 78. Histogram of VOCs in breath odor across thirty-one healthy individuals 
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For blood samples, 77 VOCs were extracted across the samples collected from each of 
the thirty-one individuals. The compounds ranged in functionality, including: alcohols 
(18.2%), aldehydes (18.2%), aliphatics (27.3%), aromatics (22.1%), esters (1.3%), 
ketones (14.3%), and others (3.9%) as shown in Figure 79. Volatile compounds included 
in the “others” category included ethers and sulfur compound (dimethylsulfone). The 
frequency of occurrence and histogram of the VOCs found in blood odor from thirty-one 
healthy individuals are shown in Table 40 and Figure 80.  
Among the alcohols that were present in blood odor samples, benzyl alcohol was the only 
compound found at high frequency of 80.6%. Benzyl alcohol is commonly found in 
nature in essential oils and is very widely used in the flavor and fragrance industries and 
thus the exposure of normal humans to benzyl alcohol is very high. 1-Octen-3-ol is a 
secondary alcohol that is produced by mushrooms and also accounted for the odor of 
cows68. The alcohol 1-octen-3-ol has been reported to be a constituent of human sweat 
and breath and has been suggested to be an oxidation product from milk fat. The C7-C10 
aldehydes were commonly observed in the blood odor of healthy individuals. Hexanal 
and heptanal were both observed across the subjects. These two compounds have been 
suggested to be lung cancer biomarkers at elevated levels, but are also known to be 
present in healthy individuals as a breakdown product of lipid peroxidation in the 
body67,68. Aliphatic compounds included C7-C25 cycloalkanes, C11-C25 higher alkanes, 
and C10-C15 higher alkenes, of which C11-C16 straight-chain higher alkanes were present 
in over 90% of subjects.  
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Major sources of aromatic VOCs including substituted and chlorinated benzenes and 
xylenes that are of exogenous origin include tobacco products, automobile exhaust, and 
chlorinated water which today are all extremely difficult to avoid exposure from even for 
nonoccupationally and nonenvironmentally exposed workers. With increasing air 
pollutant levels especially in developed countries such as the U.S. where the present 
study was conducted, it is inevitable to see an above-detection level of exogenous VOCs 
in human biological specimens even for nonoccupational exposure workers. 
Alkylnaphthalenes (diisopropylnaphthalene, 2,6-diisopropylnaphthalane) have seen a 
significant increase in the uses as substitutes for polychlorinated biphenyls (PCBs) over 
the last several decades, resulting in the increase in their concentrations in the 
environment. Concentration of 2,6-diisopropylnaphthalene in blood has been shown to  
be directly proportional to the exposure dosage of the compound, as it is readily absorbed 
and redistributed in blood and tissues of the body and rapidly bioaccumulated124.  
Figure 79. Frequency distribution of functional groups of extracted volatile organic 
compounds for blood 
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Table 40. Identified VOCs in blood odor of thirty-one healthy individuals ranked by 
frequency of occurrence (Note: *denotes compound was verified by reference 
standard) 
Compound 
Frequency Occurrence 
(%) Female Male Total 
Benzaldehyde,2,4,6-trimethyl- 16 15 31 100 
2,6-Diisopropylnaphthalene* 15 15 30 96.8 
Hexadecane* 15 15 30 96.8 
Tetradecane* 15 15 30 96.8 
Tridecane* 14 15 29 93.6 
Undecane* 14 15 29 93.6 
Dodecane* 13 15 28 90.3 
Nonanal* 14 14 28 90.3 
Hexanal 15 11 26 83.9 
BenzylAlcohol* 13 12 25 80.7 
Furan,2-butyltetrahydro- 12 11 23 74.2 
Heptadecane* 13 9 22 71.0 
Furan,2-pentyl-* 9 11 20 64.5 
Cyclohexanone* 10 9 19 61.3 
Diisopropylnaphthalene 10 9 19 61.3 
1-Dodecene* 6 12 18 58.1 
Decanal* 6 9 15 48.4 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)-* 6 8 14 45.2 
1-Pentanol 6 6 12 38.7 
2-Dodecene,(Z)- 6 6 12 38.7 
Benzene,1,2-dichloro-* 6 6 12 38.7 
2-Undecanone 4 7 11 35.5 
Cyclododecane 5 5 10 32.3 
2-Heptanone* 5 3 8 25.8 
1-Octen-3-ol* 4 4 8 25.5 
1-Decene* 1 6 7 22.6 
Cyclopropane,nonyl- 4 3 7 22.6 
Longifolene 4 2 6 19.4 
Octadecane 2 4 6 19.4 
Octanal 2 4 6 19.4 
1-Dodecanol 3 2 5 16.1 
1-Octanol* 1 4 5 16.1 
2-Heptanone,6-methyl- 4 1 5 16.1 
Heptanal* 3 2 5 16.1 
Benzene,1,4-dichloro- 2 2 4 12.9 
Menthol* 2 2 4 12.9 
1-Phenyl-2-butanone 1 2 3 9.7 
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2,4-Diphenyl-4-methyl-1(E)-pentene 2 1 3 9.7 
Benzenemethanol,.alpha.,.alpha.-dimethyl- 1 2 3 9.7 
Ethanol,2-butoxy- 1 2 3 9.7 
4-Cyanocyclohexene 0 2 2 6.5 
4-Heptanone* 2 0 2 6.5 
5-Hepten-2-one,6-methyl-* 1 1 2 6.5 
Benzaldehyde* 1 1 2 6.5 
Benzaldehyde,4-(methylthio)- 0 2 2 6.5 
Heptanol* 1 1 2 6.5 
Phenol* 2 0 2 6.5 
Phenol,2,4,6-trimethyl- 2 0 2 6.5 
Xylenes* 2 0 2 6.5 
1,1'-Biphenyl,2-methyl- 1 0 1 3.2 
1,1'-Biphenyl,4-methyl- 0 1 1 3.2 
1,2-Benzenediol,3,5-bis(1,1-dimethylethyl)- 0 1 1 3.2 
1-Tetradecene* 0 1 1 3.2 
2-Decanone* 1 0 1 3.2 
2-Propanol,1-propoxy- 1 0 1 3.2 
3,7-Dimethyl-octa-1,6-diene 1 0 1 3.2 
3-Isopropylbenzaldehyde 1 0 1 3.2 
Acetone 1 0 1 3.2 
Acetophenone* 0 1 1 3.2 
Benzaldehyde,3-hydroxy- 0 1 1 3.2 
Benzene,1,3-dichloro- 1 0 1 3.2 
Benzene,1-methyl-3-propyl- 1 0 1 3.2 
Benzene,1-methyl-4-(1-methylpropyl)- 1 0 1 3.2 
Benzene,4-ethyl-1,2-dimethyl- 1 0 1 3.2 
Benzene,diethyl- 1 0 1 3.2 
Cyclodecane 1 0 1 3.2 
Cyclooctane 1 0 1 3.2 
Dimethylsulfone 0 1 1 3.2 
D-Limonene* 1 0 1 3.2 
Heptadecane,9-octyl- 0 1 1 3.2 
IsopropylMyristate 0 1 1 3.2 
Naphthalene* 0 1 1 3.2 
Naphthalene,2,3,6-trimethyl- 0 1 1 3.2 
Tetradecanal 1 0 1 3.2 
β-Maaliene 0 1 1 3.2 
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Figure 80. Histogram of VOCs in blood odor across thirty-one healthy individuals 
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For urine, 87 volatile compounds were extracted across the samples collected from thirty-
one individuals. Urinary VOCs were comprised of the widest range in functional groups 
compared to the other specimens. The functionality distribution of the extracted volatile 
compounds was as follows: acids (2.3%), alcohols (24.1%), aldehydes (11.5%), aliphatics 
(13.8%), alkylphenols (AP, 3.4%), aromatics (10.3%), esters (3.4%), ketones (18.4%), 
nitrogen compounds (4.6%), O-heterocyclic compounds (3.4%), and sulfur compounds 
(5.7%) as seen in Figure 81. Where aromatics, aliphatics, and aldehydes comprised about 
75% of the entire functional group distribution other specimens, those major hydrocarbon 
functional groups together only contributed to approximately one-third of the total range 
of functional groups found in urine. Over 20% of the urinary VOCs detected were 
alcohols, which was much higher than the percentage of alcohols present in other 
specimens. Additionally, sulfur compounds, nitrogen compounds, and O-heterocyclic 
compounds were present in urine. These functional groups are not completely absent in 
other specimens, however, they are present at extremely low frequencies or they may be 
present only at below-detection limit levels. The frequency of occurrence and histogram 
of the VOCs found in urine odor from thirty-one healthy individuals are shown in Table 
41 and Figure 82. 4-Heptanone was the only compound with a frequency of occurrence 
higher than 80.0% (96.8%).  
The volatile compounds ranging in the eleven functional groups are found regularly in 
human urine and their presences are mostly accounted for by nutrients, intermediates, and 
environmental contaminants. Many compounds including furans, terpines, pyrroles, 
carvones, and menthols originate from food and food additives. Some compounds such as 
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2-ethyl-1-hexanol, p-benzoquinone, and 2,6-(1,1-dimethylethyl)-4-ethyl-phenol were 
omitted from the urine specimen compound database because they were also present in 
all water-blank samples that were stored in the same specimen collection container that 
the actual urine samples were collected and stored in.  
Ketones are known to be prominent components of urinary volatiles and they are most of 
time decarboxylation products of their corresponding oxo-acids that are produced in 
urine. 4-Heptanone and 2-heptanone have been suggested to be exogenous compounds 
and their specific origins are still unknown. These ketones are widely observed in normal 
human urine and have been attributed to the in vivo metabolism of plasticizers in 
humans70. 2-Heptanone along with 2-pentanone are also known to be a naturally 
occurring VOCs in milk125.  
Dichlorobenzenes which were observed in most healthy subjects’ urine samples are 
unmetabolized VOCs that result from exposure. These compounds have been reported to 
be biomarkers of low level exposure to these chlorinated aromatic VOCs in indoor 
environments80.  Lastly, alkylphenols (AP), 4-nonylphenol (or simply nonylphenol, NP) 
and 4-(1,1,3,3-tetramethylbutyl)-phenol (or 4-tert-octylphenol, OP), are prominent 
constituents of urinary volatiles. These alkylphenols are used as surfactants commonly 
used in pesticides as “inert” ingredients and have been shown to be environmental 
contaminants in sewage wastewater, river water, sea water, and as a results in fish 
tissue77,78,126. Alkylphenols are detected in normal human urine due to exposure from 
daily activities, air, and meals.  
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Figure 81. Frequency distribution of functional groups of extracted volatile organic 
compounds for urine (Note: AP = alkylphenols) 
 
Table 41. Identified VOCs in urine odor of thirty-one healthy individuals ranked by 
frequency of occurrence (Note: * denotes compound was verified by reference 
standard) 
Compound Name 
 
Frequency Occurrence 
Female Male Total (%) 
4-Heptanone* 16 14 30 96.8 
4-Nonylphenol 11 11 22 71.0 
Carvone 11 10 21 67.7 
Pyrrole 9 7 16 51.6 
Benzene,1,4-dichloro- 5 10 15 48.4 
Phenol,4-(1,1,3,3-tetramethylbutyl)-* 7 8 15 48.4 
Nonanal* 5 8 13 41.9 
Menthol* 5 7 12 38.7 
Benzene,1-methyl-4-(1-methylethenyl)- 5 5 10 32.3 
.+/-.-4-Acetyl-1-methylcyclohexene 6 4 10 32.3 
3-Cyclohexen-1-one2-isopropyl-5-methyl- 7 2 9 29.0 
4-Terpineol 5 3 8 25.5 
Benzene,1,2-dichloro-* 3 4 7 22.6 
γ-Terpinene 3 4 7 22.6 
Benzaldehyde,3,5-dimethyl- 4 3 7 22.6 
Acid
2% Alcohol
24%
Aldehyde
12%
Aliphatic
14%
AP
4%
Aromatic
10%
Ester
3%
Ketone
18%
Sulfur compound
6%
N-hetero
5%
O-hetero
2%
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2-Isopropylbenzaldehyde 6 1 7 22.6 
Benzophenone* 3 4 7 22.6 
Cedrol 3 3 6 19.4 
Phenol,nonyl- 2 4 6 19.4 
N,N-Diethylcarbanilide 2 4 6 19.4 
α-Terpinene 1 4 5 16.1 
Benzene,1-methyl-4-(1-methylethyl)- 4 1 5 16.1 
Phenol,4-methyl- (p-Cresol)* 3 2 5 16.1 
p-Menthan-3-one 3 2 5 16.1 
Decanal* 1 4 5 16.1 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)-* 4 1 5 16.1 
Benzaldehyde* 2 2 4 12.9 
p-Menth-1-en-3-one 1 3 4 12.9 
Dodecanoicacid* 1 3 4 12.9 
2-Pentanone 2 1 3 9.7 
Cyclopropane,isothiocyanato- 3 0 3 9.7 
AllylIsothiocyanate 2 1 3 9.7 
2-Heptanone* 3 0 3 9.7 
Dimethyltrisulfide* 3 0 3 9.7 
1,6-Octadien-3-ol,3,7-dimethyl-* 1 2 3 9.7 
Benzeneacetaldehyde,α-methyl- 2 1 3 9.7 
Ethanone,1-(3-methoxyphenyl)- 2 1 3 9.7 
β-Damascenone 2 1 3 9.7 
Dibutylphthalate 1 2 3 9.7 
Benzene,1,3-dichloro- 2 0 2 6.5 
Benzene,1-methyl-3-(1-methylethyl)- 1 1 2 6.5 
β-Thujene 1 1 2 6.5 
Eucalyptol 0 2 2 6.5 
1,3,8-p-Menthatriene 2 0 2 6.5 
(E)-p-2-Menthen-1-ol 1 1 2 6.5 
2-Nonenal,(E)-* 1 1 2 6.5 
Benzenemethanol,.alpha.,.alpha.,4-trimethyl- 1 1 2 6.5 
Benzene,(3-methyl-2-butenyl)- 1 1 2 6.5 
Ethanone,1-(4-methylphenyl)- 1 1 2 6.5 
Dihydrocarvone 1 1 2 6.5 
2-Propenal,3-phenyl- 1 1 2 6.5 
Eugenol 1 1 2 6.5 
1-Dodecanol 2 0 2 6.5 
Dibutanoylmorphine 2 0 2 6.5 
Dimethylsulfone 0 1 1 3.2 
3-Heptanone,6-methyl- 0 1 1 3.2 
2,3-Dehydro-1,8-cineole 0 1 1 3.2 
2,3-Octanedione 1 0 1 3.2 
Benzene,1-methyl-2-(1-methylethyl)- 0 1 1 3.2 
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β-Phellandrene 0 1 1 3.2 
Benzeneacetaldehyde 1 0 1 3.2 
Cyclopentane,(methylthio)- 0 1 1 3.2 
β-Terpineol 1 0 1 3.2 
1-Octanol* 1 0 1 3.2 
trans-p-Mentha-2,8-dienol 1 0 1 3.2 
BenzoicAcid 0 1 1 3.2 
Phenol,2,5-dichloro- 0 1 1 3.2 
(3E,5Z)-1,3,5-Undecatriene 0 1 1 3.2 
Pulegone 1 0 1 3.2 
Cyclodecane 1 0 1 3.2 
Phenol,4-ethyl-2-methoxy- 1 0 1 3.2 
1-Undecanol 0 1 1 3.2 
Thymol 0 1 1 3.2 
p-Mentha-1,8-dien-7-ol 1 0 1 3.2 
2-Methoxy-4-vinylphenol 1 0 1 3.2 
3-Allyl-6-methoxyphenol 1 0 1 3.2 
Butanoicacid,butylester 0 1 1 3.2 
α-Cedrene 0 1 1 3.2 
4'-(2-Methylpropyl)acetophenone 1 0 1 3.2 
α-Cedreneoxide 0 1 1 3.2 
DiethylPhthalate 1 0 1 3.2 
Hexadecane* 0 1 1 3.2 
Benzene,1-pentenyl- 0 1 1 3.2 
Diphenylamine* 0 1 1 3.2 
Heptadecane* 0 1 1 3.2 
Phenol,2-methyl-5-(1-methylethyl) 0 1 1 3.2 
3,5-di-tert-Butyl-4-hydroxybenzaldehyde 0 1 1 3.2 
 
171 
 
 
Figure 82. Histogram of VOCs in urine odor across thirty-one healthy individuals 
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3.6.4.1.1. Inter-Specimen Matching 
The similarities and differences of the VOC profiles of each collected specimens were 
investigated to determine whether inter-specimen samples could be used to match an 
individual (i.e. could subject A’s blood samples be used to match with subject A’s buccal 
swabs?). Figure 83 is a percent stacked column color chart of the relative peak area ratios 
of the VOCs extracted from the five specimens from subject Male 16. The color chart 
shows a visual representation of the similarities among the multiple samples from the 
same specimen (i.e., hand odor samples 1, 2, and 3) as well as the differences among the 
samples from varying specimens (i.e., buccal swab samples and blood samples). A semi-
quantitative method of analysis to represent these data is through Spearman rank 
correlation comparison. Table 42 demonstrates the correlation coefficients for the peak 
areas of the VOCs extracted from the five biological specimens of subject Male 16. The 
correlation coefficient values clearly indicate a high correlation among samples from the 
same specimen (> 0.9); samples from different specimens show low correlations, with the 
Spearman rank correlation coefficient values ranging from 0.142 to -0.495. Similar 
results were obtained from the other twenty-nine subjects sampled. Groupings according 
to specimens were seen through PCA analysis, similar to that demonstrated previously in 
Figure 60. 
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Figure 83. Relative peak area ratios of VOCs extracted from M16 specimens 
 
Table 42. Spearman rank correlation coefficients for the peak areas of the VOCs 
extracted from biological specimens from Male 16 
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HD1 HD2 HD3 CH1 CH2 CH3 BR1 BR2 BL1 BL2 UR1 UR2 UR3
HD1 1.000 0.915 0.927 -0.353 -0.348 -0.358 -0.140 -0.170 0.116 0.142 -0.495 -0.439 -0.495
HD2 0.915 1.000 0.988 -0.334 -0.327 -0.352 -0.147 -0.167 0.092 0.117 -0.470 -0.409 -0.470
HD3 0.927 0.988 1.000 -0.313 -0.306 -0.329 -0.155 -0.170 0.087 0.111 -0.495 -0.439 -0.495
CH1 -0.353 -0.334 -0.313 1.000 0.960 0.947 -0.426 -0.426 -0.380 -0.392 -0.412 -0.412 -0.412
CH2 -0.348 -0.327 -0.306 0.960 1.000 0.945 -0.394 -0.394 -0.352 -0.366 -0.412 -0.412 -0.412
CH3 -0.358 -0.352 -0.329 0.947 0.945 1.000 -0.403 -0.403 -0.356 -0.373 -0.372 -0.372 -0.372
BR1 -0.140 -0.147 -0.155 -0.426 -0.394 -0.403 1.000 0.958 0.093 0.089 -0.047 0.009 -0.047
BR2 -0.170 -0.167 -0.170 -0.426 -0.394 -0.403 0.958 1.000 0.015 0.005 -0.068 -0.016 -0.068
BL1 0.116 0.092 0.087 -0.380 -0.352 -0.356 0.093 0.015 1.000 0.976 -0.248 -0.207 -0.248
BL2 0.142 0.117 0.111 -0.392 -0.366 -0.373 0.089 0.005 0.976 1.000 -0.234 -0.194 -0.234
UR1 -0.495 -0.470 -0.495 -0.412 -0.412 -0.372 -0.047 -0.068 -0.248 -0.234 1.000 0.929 1.000
UR2 -0.439 -0.409 -0.439 -0.412 -0.412 -0.372 0.009 -0.016 -0.207 -0.194 0.929 1.000 0.929
UR3 -0.495 -0.470 -0.495 -0.412 -0.412 -0.372 -0.047 -0.068 -0.248 -0.234 1.000 0.929 1.000
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Results obtained through Spearman rank analysis of the relative peak areas of the 
common VOCs extracted across the five biological specimens from the same individual 
indicate that different specimens from the same individual are too different to be used for 
matching purposes. For instance, the blood sample and the buccal swab sample of subject 
A cannot be compared to one another in attempt to match the samples to be originating 
from subject A. Variations in the volatile organic compounds emanating from different 
biological specimens is most likely the result of distinct glandular secretions and their 
interactions with resident bacteria relative to each specimen. Even when comparing 
VOCs emanating from the skin, it has been previously reported that the site of emanation 
(skin from the back vs. skin from the forearm) influences the abundance of the same 
VOCs collected14. A number of exocrine glands are distributed throughout the body that 
contributes to the VOCs being excreted. Merocrine glands are found throughout the skin 
and include the eccrine (sweat) glands as well as salivary glands. Apocrine glands are 
present in the axillae and the pubic areas and are thought to function as scent glands. 
Holcrine glands include the sebaceous glands and are found mostly on the upper part of 
the body (such as the cheek mucosa, as described in the literature review section on oral 
fluids). Secretions from these various glands and their interactions with the different 
bacterial flora residing in surfaces of the body (skin vs. mouth/cheek mucosa), are the 
likely explanation for the differences in the VOC profiles of the different biological 
specimens. 
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3.6.4.1.2. Intra-Specimen Matching 
It has been demonstrated that volatile organic compound signatures of individuals can be 
differentiated through SPME-GC/MS. Previous research has successfully demonstrated 
the differentiation ability of human scent samples from hand and armpit of individuals 
using SPME-GC/MS13. The goal of the intra-specimen matching study was to investigate 
whether the same holds true for other biological specimens, namely buccal swabs, breath, 
blood, and urine. 
Figure 84 through Figure 88 shows the three-dimensional scatter-plot of principal 
component analysis on correlations from ten randomly selected subjects (5 females and 5 
males) from the healthy population sampled. The PCA plot demonstrates that samples 
from the same subject group together closely. Some samples from different individuals, 
however, clustered closely with one another making it difficult to differentiate between 
these individuals using PCA analysis. An example of samples from different individuals 
clustering together can be seen in Figure 85 for buccal swab samples between subjects 
Male 11 (represented by blue X) and Male 16 (represented by blue open square).  These 
samples will most likely be misidentified.  
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Figure 84. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of hand odor from 
10 randomly selected healthy subjects 
 
Figure 85. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of buccal swabs 
from 10 randomly selected healthy subjects 
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Figure 86. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of breath from 10 
randomly selected healthy subjects 
 
Figure 87. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of blood from 10 
randomly selected healthy subjects 
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Figure 88. Three-dimensional PCA scatter plot of PCs 1, 2, and 3 of urine from 10 
randomly selected healthy subjects 
 
Spearman rank correlation coefficient comparisons were conducted with the samples 
obtained from the five biological specimens of the thirty-one healthy subjects. 
Occurrence of Type I and Type II errors were investigated under different correlation 
thresholds. Type I error is the process of incorrectly rejecting the null hypothesis in favor 
of the alternative, and is often referred to as a “false positive”. In the present study, a 
Type I error is when two samples are implied to be from the same individual, when in 
reality they are from different individuals. This would result in a mismatch of samples 
(i.e. blood sample from subject A be positively identified as blood sample from subject 
B). Type II error is the opposite of Type I error and is the false acceptance of the null 
hypothesis. Often referred to as a “false negative”, a Type II error implies that the two 
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samples from the same individual are not a match to one another. Blood samples 1 and 2 
from subject A would be identified as a non-match in this case.  
3.6.4.1.2.1. Type I Error 
The comparison of triplicate samples (for hand odor, buccal swab, and urine) collected 
from thirty-one subjects generates 4005 possible pairs. The comparison of duplicate 
samples (for breath and blood) collected from thirty-one subjects generates 1770 possible 
pairings. Examples where Type I errors were observed are shown in Table 43. At a 
correlation threshold of 0.8, breath samples of Female 9 and Male 5 could not be 
distinguished. If the correlation threshold were lowered to 0.7, breath samples of Female 
9, Male 5, Female 4, Female 12, and Male 7 were indistinguishable and may result in 
mismatched samples. 
Table 44 is a summary of the number of Type I error occurrences for the comparison of 
the biological specimens scent samples from the thirty-one subjects. When considering a 
correlation threshold of 0.9 the individuals were distinguished in 99.98%  of the cases for 
hand odor (or a mismatch percentage of 0.02%), and 100% of the cases for buccal swabs, 
breath, blood, and urine. At a correlation threshold of 0.8, these percentages were 99.93% 
(0.07% mismatch) of the hand odor cases, 99.99% of the buccal swab and breath cases 
(0.01% mismatch), and 100% of the blood and urine cases (no mismatch). These values 
are promising in supporting the hypothesis the emanations of VOCs are different among 
individuals and can be used as distinguishing profiles among individuals. With the 
current sample size these percentages of distinguish-ability of individuals are extremely 
high. With increasing number of subjects and sample size, the likelihood of the sample 
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pool to include individuals having similar odor profiles will increase resulting in the 
distinguish-ability percentage to decrease with larger sample size.  In order to avoid Type 
I errors (false positives) as much as possible, it is recommended for the match/no-match 
cut-off threshold to be kept at least at 0.8, and wherever possible, a cut-off threshold of 
0.9 would be best.  
Table 43. Example of Type I error occurrences 
  
 
F9,1 1.000 F9,2 1.000
F9,2 0.959 F9,1 0.959
M5,2 0.870 M5,2 0.839
M5,1 0.864 M5,1 0.839
F4,2 0.764 F4,2 0.785
F12,1 0.732 F4,1 0.744
F4,1 0.722 F12,1 0.743
M7,2 0.714 M7,2 0.730
F12,2 0.708 F12,2 0.725
M11,2 0.687 M7,1 0.709
M7,1 0.681 M11,2 0.688
M11,1 0.671 M11,1 0.684
M4,1 0.663 F10,1 0.665
F10,1 0.654 F10,2 0.660
F10,2 0.650 M4,1 0.654
M10,1 0.648 M10,1 0.648
F8,1 0.646 M6,2 0.646
M6,1 0.646 M6,1 0.644
M6,2 0.644 F8,1 0.625
M9,2 0.637 M12,2 0.617
M12,2 0.619 M9,2 0.614
M12,1 0.602 M12,1 0.599
M10,2 0.598 M10,2 0.598
F9 Breath
M9,1 1.000 M9,2 1.000
M9,2 0.947 M9,1 0.947
M6,1 0.732 M6,1 0.718
F4,2 0.662 F4,2 0.682
F8,2 0.612 F4,1 0.641
F4,1 0.609 F11,1 0.547
F11,1 0.578 F9,2 0.541
F9,1 0.574 F8,2 0.538
F11,2 0.572 F11,2 0.531
F9,2 0.563 F9,1 0.530
M6,2 0.550 M6,2 0.518
F8,1 0.520 M8,2 0.469
M16,2 0.504 M16,2 0.466
M16,1 0.503 M16,1 0.464
M5,1 0.496 M5,1 0.456
F7,1 0.494 M5,2 0.442
M8,2 0.481 F8,1 0.439
M5,2 0.480 F7,1 0.438
F6,1 0.478 F6,1 0.426
M1,1 0.464 M7,1 0.421
M1,2 0.459 F15,1 0.416
M8,1 0.451 M1,1 0.413
M7,1 0.445 M8,1 0.413
M9 Blood
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Table 44. Type I error occurrences for three correlation thresholds across biological 
specimens 
 Threshold 
 0.9 0.8 0.7 
Hand Odor 5 32 73 
Buccal Swab 0 1 8 
Breath 0 1 25 
Blood 0 0 3 
Urine 0 0 0 
 
3.6.4.1.2.2. Type II Error 
Table 45 shows the Spearman rank correlation coefficients of buccal swab samples 1 and 
2 from Female 5, breath samples 1 and 2 from Male 16, and blood samples 1 and 2 from 
Male 7. In each of these cases the duplicate samples from the same individual were 
identified as a non-match at all three thresholds of 0.7, 0.8, and 0.9. Table 46 summarizes 
the Type II error occurrences among the thirty-one subjects compared in each of the 
biological specimens. As is expected the number of Type II errors increases as the cut-off 
threshold is raised. If the match/no-match threshold is set too high (i.e. at 0.9), the 
samples from the same individuals that have high correlation coefficients (as they should 
have) would be identified as a non-match, resulting in a false-negative. Breath and urine 
had the lowest number of Type II errors. Blood had the highest number of Type II errors; 
however, this could be due to sampling protocol. For example, there was an obvious 
volume difference between the duplicate blood samples collected onto the two FTA cards 
obtained from Male 7.  
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Table 45. Example of Type II error occurrences 
   
 
Table 46. Type II error occurrences for three correlation thresholds across 
biological specimens 
 Threshold 
 0.9 0.8 0.7 
Hand Odor 15 9 7 
Buccal Swab 9 4 3 
Breath 11 4 1 
Blood 12 6 4 
Urine 8 3 1 
 
F5,1 1.000 F5,2 1.000
F5,2 0.692 F5,1 0.692
F6,2 0.673 F6,2 0.565
F6,1 0.607 F6,1 0.428
M2,2 0.425 F17,3 0.353
M2,1 0.396 F17,2 0.352
F17,3 0.311 F17,1 0.342
F17,2 0.310 M2,1 0.330
M7,1 0.309 F14,2 0.326
F17,1 0.299 M7,1 0.325
F14,2 0.291 F14,1 0.291
F7,1 0.284 M7,2 0.291
M7,2 0.280 M2,2 0.264
F14,1 0.255 F7,1 0.231
F7,2 0.237 F16,2 0.212
F16,2 0.222 F16,3 0.206
F16,3 0.213 F16,1 0.185
F16,1 0.176 F7,2 0.159
F10,2 0.125 F8,2 0.129
F10,1 0.097 F10,2 0.081
F8,2 0.092 F8,1 0.064
M6,1 0.029 F10,1 0.056
M6,2 0.026 M1,2 0.052
F8,1 0.023 M1,1 0.051
F5 Buccal Swab
M15,1 1.000 M15,2 1.000
M15,2 0.600 M15,1 0.600
F5,2 0.442 M9,2 0.596
F5,1 0.442 F2,2 0.534
M9,2 0.440 F2,1 0.527
F2,1 0.395 F5,2 0.487
F2,2 0.388 F5,1 0.487
M9,1 0.387 M9,1 0.460
M16,1 0.290 M16,1 0.396
M16,2 0.286 F10,2 0.382
M4,1 0.260 M4,1 0.380
F14,1 0.234 F10,1 0.365
F14,2 0.207 M16,2 0.364
F17,1 0.205 F14,2 0.328
F4,2 0.197 F14,1 0.322
F15,2 0.189 F17,1 0.298
M4,2 0.184 M5,2 0.298
M14,2 0.179 F4,2 0.292
F10,1 0.179 M5,1 0.286
F15,1 0.174 F4,1 0.276
F4,1 0.166 M12,2 0.270
F10,2 0.159 F15,1 0.257
M12,2 0.157 F15,2 0.249
M14,1 0.153 F17,2 0.245
M15 Breath
M7,1 1.000 M7,2 1.000
M7,2 0.620 M7,1 0.620
M2,1 0.518 F8,2 0.526
F7,1 0.516 M5,2 0.472
F11,1 0.502 M5,1 0.468
F11,2 0.487 F11,1 0.462
F8,2 0.486 F11,2 0.444
F7,2 0.477 M2,1 0.427
M5,1 0.459 F8,1 0.426
M10,1 0.454 F7,1 0.387
M10,2 0.449 M1,1 0.380
M9,1 0.445 F13,1 0.380
M2,2 0.437 M10,2 0.377
M5,2 0.436 M10,1 0.376
M6,1 0.422 F6,1 0.370
M9,2 0.421 M1,2 0.369
M13,1 0.408 M2,2 0.341
F9,1 0.407 F7,2 0.340
M16,1 0.402 F13,2 0.326
M16,2 0.400 M6,1 0.324
F8,1 0.395 M16,2 0.307
M12,1 0.385 M9,1 0.304
M13,2 0.383 M12,1 0.304
F9,2 0.377 M16,1 0.304
M7
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Table 47. Type I and Type II errors for five biological specimens amongst thirty-one 
healthy individuals 
 
 
Prior to the current study, it was not known if one could differentiate individuals by odor 
components other than odor emanating from skin (mainly hand, arm, and armpits) on 
gauze. For the population study of thirty-one healthy individuals, the headspace of scent 
samples collected on various biological specimens (hand odor, buccal swabs, breath, 
blood, and urine) can be distinguished chromatographically based on a combination of 
the relative peak area ratios of the common compounds present in these samples. 
Through the combined methods of chromatogram comparison, Spearman rank correlation 
comparison, and principal component analysis, it is possible to distinguish the VOC 
profiles of individuals for each of the specimens with high confidence. However, VOC 
profiles of different biological specimens from the same individual are too different to be 
used for matching purposes.  
3.6.4.2. Evaluation of Odor Profiles of Individuals with Type 2 Diabetes 
Odor profiles of nineteen individuals with diagnosed type 2 diabetes were evaluated 
using SPME-GC/MS. Compounds were identified by spectral library (NIST) and/or by 
standard reference comparison. Figure 89 demonstrates the frequency distribution of the 
different functional groups of VOCs that were extracted from hand odor, buccal swab, 
Threshold 0.9 0.8 0.7 0.9 0.8 0.7 0.9 0.8 0.7 0.9 0.8 0.7 0.9 0.8 0.7
Type I 3 13 34 0 1 3 0 1 19 0 0 3 0 0 0
Type II 15 9 7 9 4 3 11 4 1 12 6 4 8 3 1
Total Error 18 22 41 9 5 6 11 5 20 12 6 7 8 3 1
% Mismatch 0.89 1.09 2.03 0.45 0.25 0.30 0.58 0.26 1.06 0.63 0.32 0.37 0.36 0.14 0.05
Hand Odor Buccal Swab Breath Blood Urine
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breath, blood, and urine across the 19 subjects. For hand odor, aldehyde and aliphatic 
VOCs (28% each) comprised slightly over half of the total volatile compounds extracted, 
followed by ketones (16%), carboxylic acids (16%), and esters (12%). No carboxylic acid 
VOCs were extracted from hand odor. Decanal and nonanal were extracted from all 19 
diabetic subjects (Table 48). Other high-frequency occurring (>70%) compounds for 
hand odor for type 2 diabetics were heptadecane, hexadecane, and tetradecane, each 
having an 89.5% occurrence among the 19 subjects sampled.  
For buccal swab odor, ester VOCs had the highest frequency of occurrence (24%), 
followed by aromatic (18%), aliphatic (16%), ketones (16%), carboxylic acids (9%), 
alcohols (8%), and ether (1%) compounds. There were eight high-frequency compounds 
across 19 diabetic individuals as seen in Table 49, of which hexanoic acid and decanal 
were present in all 19 diabetic individuals. 
Aromatic compounds comprised about half of the VOCs extracted from breath odor at 
45%. The remaining frequency distribution of functional groups for breath odor was as 
follows: aliphatics (17%), alcohols (10%), ketones (10%), aldehydes (8%), esters (8%), 
and other functional group compounds (2%). Only two compounds (nonanal and decanal) 
were high-frequency compounds for breath, although xylenes were present in 78.9% of 
the 19 diabetic individuals (Table 50). Typical VOCs in exhaled breath are under 1ppb 
concentration range. It has been reported that disease states do not typically result in 
higher VOC concentrations, although there are certain disease states such as untreated 
diabetes or severe renal impairment that do result in significant differences in the VOC 
concentrations in breath49. For the present study, acetone was only detected in the breath 
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samples of three of the diabetic patients sampled, and the amount of acetone extracted 
was not particularly higher than that of healthy individuals. The minimal difference in the 
acetone presence and the amount extracted can be likely explained by the fact that the 
diabetic subjects sampled in the present study were all fairly well-controlled (treated with 
diet and/or medication).  Additionally, detection and measurement of acetone under the 
current instrumental condition are not always consistent due to acetone’s nature of 
volatility and activity. Pre-concentration and/or on-fiber derivatization of acetone may 
need to be considered for future studies in order to effectively extract and accurately 
measure acetone in breath samples.  
For blood, the frequency distribution of functional groups of the VOCs extracted was as 
follows: aromatics (40%), aliphatics (26%), alcohols (13%), ketones (10%), other 
functional groups (4%), and esters (2%). Other functional groups included ethers and 
nitrogen-containing compounds. There were seven high-frequency compounds, of which 
nonanal and hexadecane were present in all 19 diabetic individuals (Table 51).  
Finally for urine, the frequency distribution of functional groups of the extracted VOCs 
was as follows: alcohols (22%), aromatics (20%), ketones (17%), aldehydes (11%), 
nitrogen-containing compounds (11%), sulfur-containing compounds (6%), aliphatics 
(5%), carboxylic acids (4%), and esters (4%). No compound was present in high 
frequency; 4-heptanone was present at highest frequency among the 19 diabetic 
individuals sampled at 73.7% (Table 52).  
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Figure 89. Frequency distribution of functional groups of extracted VOCs in hand 
odor, buccal swab, breath, blood, and urine across twenty individuals diagnosed 
with type 2 diabetes 
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Table 48. Identified VOCs in hand odor of nineteen individuals with diagnosed type 
2 diabetes ranked by frequency of occurrence (Note: *denotes compound was 
verified by reference standard) 
Compound Name Frequency Occurrence 
  Female Male Total (%) 
Decanal* 8 11 19 100% 
Nonanal* 8 11 19 100% 
Heptadecane* 7 10 17 89.5% 
Hexadecane* 7 10 17 89.5% 
Tetradecane* 7 10 17 89.5% 
Octadecane 4 7 11 57.9% 
Undecane* 5 6 11 57.9% 
Tridecane* 3 6 9 47.4% 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)-* 3 6 9 47.4% 
Undecanal* 2 5 7 36.8% 
Dodecane* 2 3 5 26.3% 
2-Nonenal,(E)-* 2 2 4 21.1% 
Dodecanoicacid,methylester 0 4 4 21.1% 
Acetophenone* 2 1 3 15.8% 
1-Hexanol,2-ethyl-* 1 1 2 10.5% 
Benzyl Alcohol* 1 1 2 10.5% 
Dodecanal* 1 1 2 10.5% 
1,6-Octadien-3-ol,3,7-dimethyl-* 0 1 1 5.3% 
Cedrol 0 1 1 5.3% 
Benzaldehyde* 1 0 1 5.3% 
Lilial 1 0 1 5.3% 
Aceticacid,butylester 1 0 1 5.3% 
Octanoicacid,methylester* 0 1 1 5.3% 
2-Pentanone 1 0 1 5.3% 
5-Hepten-2-one,6-methyl-* 0 1 1 5.3% 
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Table 49. Identified VOCs in buccal swabs of nineteen individuals with diagnosed 
type 2 diabetes ranked by frequency of occurrence (Note: *denotes compound was 
verified by reference standard) 
Compound Name 
 
Frequency Occurrence 
Female Male Total (%) 
Hexanoicacid* 8 11 19 100% 
Decanal* 8 11 19 100% 
Nonanoicacid 6 11 17 89.5% 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)-* 7 10 17 89.5% 
Nonanoicacid,ethylester* 6 10 16 84.2% 
Furan,2-pentyl-* 6 9 15 78.9% 
Dodecanoicacid,ethylester 6 8 14 73.7% 
6-Dodecanone 5 9 14 73.7% 
1-Tetradecene* 4 9 13 68.4% 
Tetradecanoicacid,ethylester 3 8 11 57.9% 
1-Decene* 6 5 11 57.9% 
1,1'-Biphenyl,2,2'-diethyl- 4 7 11 57.9% 
2,4-Nonadienal,(E,E)-* 3 7 10 52.6% 
Hexadecanoicacid,ethylester 3 7 10 52.6% 
Tetradecane* 4 6 10 52.6% 
6-Methyl-3,5-heptadiene-2-one 3 7 10 52.6% 
Heptanoicacid* 2 6 8 42.1% 
Benzaldehyde* 3 5 8 42.1% 
Octanoicacid,ethylester* 3 4 7 36.8% 
2-Nonenal,(E)-* 2 4 6 31.6% 
1-Dodecene* 2 4 6 31.6% 
1,1'-Biphenyl,4-methyl- 2 4 6 31.6% 
1-Hexanol* 2 4 6 31.6% 
Cyclododecane 3 2 5 26.3% 
2(3H)-Furanone,dihydro-5-pentyl- 2 3 5 26.3% 
Dodecanoicacid* 3 2 5 26.3% 
2(3H)-Furanone,5-ethyldihydro- 3 2 5 26.3% 
2-Tetradecene,(E)- 3 1 4 21.1% 
2-Octenoicacid 1 3 4 21.1% 
Naphthalene,2-methyl- 1 3 4 21.1% 
Benzothiazole 0 4 4 21.1% 
Benzene,1-methyl-2-[(4-methylphenyl)methyl]- 1 3 4 21.1% 
Phenol* 1 3 4 21.1% 
Hexanoicacid,ethylester 1 2 3 15.8% 
Heptanoicacid,ethylester* 1 2 3 15.8% 
Caryophyllene* 2 1 3 15.8% 
DiethylPhthalate 1 2 3 15.8% 
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Pentanoicacid* 0 3 3 15.8% 
Naphthalene,2,7-dimethyl- 1 2 3 15.8% 
Decanoicacid,ethylester* 1 2 3 15.8% 
Acetophenone* 1 2 3 15.8% 
Pentadecanoicacid,ethylester 1 1 2 10.5% 
IsopropylMyristate 1 0 1 10.5% 
Hexanoicacid,pentylester 0 2 2 10.5% 
Hexadecanoicacid,methylester 1 1 2 10.5% 
Dibutanoylmorphine 1 1 2 10.5% 
Tridecane 1 1 2 10.5% 
Naphthalene,1-methyl-* 0 2 2 10.5% 
ButylatedHydroxytoluene 1 1 2 10.5% 
2(3H)-Furanone,dihydro-5-propyl- 1 1 2 10.5% 
IsopropylPalmitate 1 0 1 5.3% 
Hexanoicacid,propylester 0 1 1 5.3% 
E-11-Hexadecenoicacid,ethylester 1 0 1 5.3% 
Naphthalene,2,6-dimethyl- 0 1 1 5.3% 
Benzene,1-methyl-4-nitro- 1 0 1 5.3% 
Octadecane 1 0 1 5.3% 
Benzene,1,2,4,5-tetramethyl- 0 1 1 5.3% 
p-Menthan-3-one 0 1 1 5.3% 
Hexadecane* 0 1 1 5.3% 
Benzene,1,2,3,5-tetramethyl- 1 0 1 5.3% 
3,5,9-Undecatrien-2-one,6,10-dimethyl-, (E,Z)- 0 1 1 5.3% 
Cyclohexadecane 1 0 1 5.3% 
1,1'-Biphenyl,3-methyl- 0 1 1 5.3% 
Carvone 0 1 1 5.3% 
p-Benzoquinone 0 1 1 5.3% 
1-Octanol* 1 0 1 5.3% 
Hexanal* 0 1 1 5.3% 
Menthol* 1 0 1 5.3% 
Furfural* 0 1 1 5.3% 
Linalool Oxide 0 1 1 5.3% 
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Table 50. Identified VOCs in breath odor of nineteen individuals with diagnosed 
type 2 diabetes ranked by frequency of occurrence (Note: *denotes compound was 
verified by reference standard) 
Compound Name 
Frequency Occurrence 
(%) Female Male Total 
Nonanal* 8 11 19 100% 
Decanal* 7 11 18 94.7% 
Xylenes* 5 10 15 78.9% 
Tridecane* 5 8 13 68.4% 
Tetradecane* 5 8 13 68.4% 
Dodecane* 5 8 13 68.4% 
1-Hexanol,2-ethyl-* 5 6 11 57.9% 
Undecane* 3 7 10 52.6% 
Benzene,1,2-dichloro-* 4 6 10 52.6% 
Benzophenone* 5 5 10 52.6% 
Toluene 4 2 6 31.6% 
Styrene* 2 4 6 31.6% 
ButylatedHydroxytoluene 3 3 6 31.6% 
Benzene,1,3,5-trimethyl- 1 5 6 31.6% 
p-Benzoquinone 2 4 6 31.6% 
Benzene,4-ethyl-1,2-dimethyl- 2 3 5 26.3% 
Benzene,2-ethyl-1,4-dimethyl- 2 3 5 26.3% 
Benzene,1-methyl-3-propyl- 0 5 5 26.3% 
Undecanal* 1 3 4 21.1% 
Benzene,1-ethyl-2,3-dimethyl- 1 3 4 21.1% 
4-Cyanocyclohexene 2 2 4 21.1% 
Phenol* 1 2 3 15.8% 
1,3,5,7-Cyclooctatetraene 2 1 3 15.8% 
Menthol* 2 1 3 15.8% 
Naphthalene* 1 2 3 15.8% 
Limonene* 0 2 2 10.5% 
2-Dodecene,(Z)- 1 1 2 10.5% 
Diisopropylnaphthalene 0 2 2 10.5% 
Benzene,2-ethyl-1,3-dimethyl- 1 1 2 10.5% 
Benzene,1-ethyl-2-methyl- 1 1 2 10.5% 
Benzene,1-ethyl-2,4-dimethyl- 1 1 2 10.5% 
Benzene,1,2,3-trimethyl- 1 1 2 10.5% 
2,6-Diisopropylnaphthalene* 0 2 2 10.5% 
Hexanedioicacid,bis(1-methylethyl) ester 0 2 2 10.5% 
Acetone 1 1 2 10.5% 
2-Propanol,1-propoxy- 1 0 1 5.3% 
Dodecanal* 0 1 1 5.3% 
191 
 
5-Dodecene,(E)- 0 1 1 5.3% 
Naphthalene,2-methyl- 0 1 1 5.3% 
Benzene,1-methyl-4-(1-methylpropyl)- 0 1 1 5.3% 
Benzene,1,4-dichloro- 0 1 1 5.3% 
Benzene,1,3-dichloro- 0 1 1 5.3% 
Benzene,1,2,3,4-tetramethyl- 0 1 1 5.3% 
Isobornylacetate 1 0 1 5.3% 
DiethylPhthalate 0 1 1 5.3% 
Dibutylphthalate 0 1 1 5.3% 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)-* 0 1 1 5.3% 
3-Heptanone* 0 1 1 5.3% 
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Table 51. Identified VOCs in blood odor of nineteen individuals with diagnosed type 
2 diabetes ranked by frequency of occurrence (Note: *denotes compound was 
verified by reference standard) 
Compound Name 
 
Frequency Occurrence 
(%) Female Male Total 
Nonanal* 8 11 19 100% 
Hexadecane* 8 11 19 100% 
Tetradecane* 7 9 16 84.2% 
Undecane* 6 10 16 84.2% 
2,6-Diisopropylnaphthalene* 6 9 15 78.9% 
Tridecane* 6 8 14 73.7% 
Benzophenone* 4 10 14 73.7% 
Dodecane* 6 7 13 68.4% 
Heptadecane* 4 8 12 63.2% 
Benzaldehyde,2,4,6-trimethyl- 4 8 12 63.2% 
Hexanal 4 7 11 57.9% 
Decanal* 7 2 9 47.4% 
Furan,2-butyltetrahydro- 4 5 9 47.4% 
1-Octen-3-ol* 4 5 9 47.4% 
1-Decene* 4 4 8 42.1% 
Longifolene 2 6 8 42.1% 
Benzene,1,3,5-trimethyl- 2 5 7 36.8% 
Diisopropylnaphthalene 3 4 7 36.8% 
Naphthalene* 3 3 6 35.8% 
Benzyl Alcohol* 3 3 6 31.6% 
1-Dodecene* 3 3 6 31.6% 
2-Dodecene,(Z)- 4 2 6 31.6% 
Octadecane 3 3 6 31.6% 
Furan,2-pentyl-* 4 2 6 31.6% 
Benzene,1,2-dichloro-* 2 3 5 26.3% 
Benzene,1-ethyl-2,4-dimethyl- 1 4 5 26.3% 
Naphthalene,2-methyl- 2 3 5 26.3% 
Menthol* 3 1 4 21.1% 
1-Dodecanol* 1 3 4 21.1% 
Heptanal* 2 2 4 21.1% 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)-* 1 3 4 21.1% 
2-Propanol,1-propoxy- 0 3 3 15.8% 
Benzene,1,2,3,5-tetramethyl- 1 2 3 15.8% 
2-Undecanone 2 1 3 15.8% 
3-Heptanone* 1 2 3 15.8% 
Cyclohexanone* 1 2 3 15.8% 
4-Cyanocyclohexene 2 1 3 15.8% 
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1-Octanol* 2 0 2 10.5% 
1-Pentanol 0 2 2 10.5% 
3-Dodecene,(Z)- 0 2 2 10.5% 
Cyclododecane 2 0 2 10.5% 
Benzene,1,2,3-trimethyl- 1 1 2 10.5% 
Benzene,1,2,4,5-tetramethyl-* 0 2 2 10.5% 
Benzene,1-ethyl-3,5-dimethyl- 2 0 2 10.5% 
Benzene,2-ethyl-1,4-dimethyl- 0 2 2 10.5% 
Naphthalene,1-methyl-* 1 1 2 10.5% 
Naphthalene,2,7-dimethyl- 1 1 2 10.5% 
p-Xylene* 1 1 2 10.5% 
2,5-Octanedione 2 0 2 10.5% 
2-Heptanone* 1 1 2 10.5% 
1-Heptanol* 0 1 1 5.3% 
2-Propanol,1-butoxy- 1 0 1 5.3% 
Ethanol,2-butoxy- 1 0 1 5.3% 
1-Hexadecene 1 0 1 5.3% 
3,7-Dimethyl-octa-1,6-diene 1 0 1 5.3% 
Cyclopropane,nonyl- 0 1 1 5.3% 
Cyclotetradecane 1 0 1 5.3% 
Decane 0 1 1 5.3% 
Dodecane,2,6,10-trimethyl- 1 0 1 5.3% 
Z-8-Hexadecene 0 1 1 5.3% 
1,1'-Biphenyl,2-methyl- 0 1 1 5.3% 
1,1'-Biphenyl,3-methyl- 0 1 1 5.3% 
Benzene,1,2,3,4-tetramethyl- 0 1 1 5.3% 
Benzene,1,3-dimethyl-5-(1-methylethyl)- 0 1 1 5.3% 
Benzene,1,4-dichloro- 0 1 1 5.3% 
Benzene,1-ethyl-2,3-dimethyl- 1 0 1 5.3% 
Benzene,1-ethyl-2-methyl- 0 1 1 5.3% 
Benzene,1-ethyl-3-methyl- 0 1 1 5.3% 
Benzene,1-methyl-4-(1-methylethyl)- 0 1 1 5.3% 
Benzene,1-methyl-4-(1-methylpropyl)- 0 1 1 5.3% 
Benzene,2,4-dimethyl-1-(1-methylethyl)- 1 0 1 5.3% 
Benzene,4-ethyl-1,2-dimethyl- 0 1 1 5.3% 
Benzene,ethyl-1,2,4-trimethyl- 0 1 1 5.3% 
Naphthalene,1,7-dimethyl- 1 0 1 5.3% 
Naphthalene,2,3,6-trimethyl- 1 0 1 5.3% 
4-tert-Butylcyclohexylacetate 0 1 1 5.3% 
Hexanedioicacid,bis(1-methylethyl) ester 0 1 1 5.3% 
2-Heptanone,6-methyl- 1 0 1 5.3% 
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Table 52. Identified VOCs in urine odor of nineteen individuals with diagnosed type 
2 diabetes ranked by frequency of occurrence (Note: *denotes compound was 
verified by reference standard) 
Compound Name 
Frequency Occurrence 
(%) Female Male Total 
4-Heptanone* 5 9 14 73.7% 
Cedrol 4 7 11 57.9% 
Nonanal* 2 9 11 57.9% 
Menthol* 4 4 8 42.1% 
Carvones 3 4 7 36.8% 
ButylatedHydroxytoluene* 2 3 5 26.3% 
Butanoicacid,butylester 3 2 5 26.3% 
4-Terpineol 3 2 5 26.3% 
Benzaldehyde* 3 1 4 21.1% 
Decanal* 1 3 4 21.1% 
Benzene,1-methyl-4-(1-methylethenyl)- 0 4 4 21.1% 
2-Pentanone 2 2 4 21.1% 
2-Isopropylbenzaldehyde 1 2 3 15.8% 
1,4-Cyclohexadiene,1-methyl-4-(1-methylethyl)- 2 1 3 15.8% 
Benzene,1-methyl-4-(1-methylethyl)- 1 2 3 15.8% 
3-Heptanone* 1 2 3 15.8% 
ValproicAcid 1 1 2 10.5% 
2-Methoxy-4-vinylphenol 2 0 2 10.5% 
Phenol,4-methyl- (p-Cresol)* 2 0 2 10.5% 
Benzaldehyde,3,5-dimethyl- 0 2 2 10.5% 
1,3-Cyclohexadiene,1-methyl-4-(1-methylethyl)- 2 0 2 10.5% 
p-Menth-1-en-3-one 1 1 2 10.5% 
Cyclopropane,isothiocyanato- 0 2 2 10.5% 
N,N-Diethylcarbanilide 2 0 2 10.5% 
Pyrrole 2 0 2 10.5% 
Nonanoicacid 1 0 1 5.3% 
α-Terpineol 0 1 1 5.3% 
BenzylAlcohol* 0 1 1 5.3% 
E-2-Tetradecen-1-ol 1 0 1 5.3% 
Eucalyptol 0 1 1 5.3% 
Eugenol 1 0 1 5.3% 
Phenol,2-methoxy- 0 1 1 5.3% 
3,5-di-tert-Butyl-4-hydroxybenzaldehyde 0 1 1 5.3% 
α-Cubebene 0 1 1 5.3% 
Benzene,-(1-formylethyl)- 1 0 1 5.3% 
Benzene,(2-isothiocyanatoethyl)- 1 0 1 5.3% 
Benzene,1-(1,5-dimethyl-4-hexenyl)-4-methyl- 1 0 1 5.3% 
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Benzene,1,2-dichloro-* 1 0 1 5.3% 
Benzene,1,3-dichloro- 0 1 1 5.3% 
Benzene,1-methyl-3-(1-methylethyl)- 1 0 1 5.3% 
Naphthalene,2,3-dimethyl- 1 0 1 5.3% 
Naphthalene,2-methyl- 1 0 1 5.3% 
Isobornylacetate 0 1 1 5.3% 
3-Nonen-2-one 1 0 1 5.3% 
4-Hepten-3-one,4-methyl- 1 0 1 5.3% 
Acetone 0 1 1 5.3% 
Benzophenone* 1 0 1 5.3% 
1-Butene,4-isothiocyanato- 0 1 1 5.3% 
Dibutanoylmorphine 0 1 1 5.3% 
 
 
3.6.4.3. Evaluation of Odor Profiles of Individuals with Major Depressive 
Disorder 
Odor profiles of twenty individuals with diagnosed Major Depressive Disorder (MDD) 
were evaluated using SPME-GC/MS. Compounds were identified by spectral library 
(NIST) and/or by standard reference comparisons. Figure 90 demonstrates the frequency 
distribution of the different functional groups of VOCs that were extracted from hand 
odor, buccal swab, breath, blood, and urine across the 20 subjects. Aliphatics (alkanes, 
alkenes, cycloalkanes) and aldehydes constructed over half (64%) of the hand odor 
VOCs. Nonanal and decanal were present in all subjects, followed by tetradecane, 
hexadecane, heptadecane, and octadecane being present in more than 80% of the subjects 
sampled (Table 53).  
For buccal swab, esters constructed slightly less than a third of the extracted VOCs 
(27%), followed by aromatics (17%) and aliphatics (14%). Hexanoic acid and decanal 
were present in 100% of sampled subjects. Other VOCs present in high frequency 
196 
 
(<70%) were 2-pentylfuran, (E)-6,10-dimethyl-5-9-undecadien-2-one, nonanoic acid, 
nonanoic acid ethyl ester, (E,E)-2,4-nonadienal, dodecanoicacid ethyl ester, and 2,2’-
diethyl-1,1’-biphenyl (Table 54).  
Aromatic VOCs comprised approximately half of the breath odor of the MDD subject 
group at 49%. The remaining was comprised of aliphatics (17%), ketones (9%), 
carboxylic acids (8%), esters (7%), aldehydes (6%), and alcohols (4%). The two 
compounds that were present in all subjects were both aldehydes, namely nonanal and 
decanal (Table 55). Other breath VOCs with high frequency of occurrence were xylenes 
(p-xylene and m-xylene), 1,2-dichlorobezene, and 2-ethyl-1-hexanol, and benzophenone.  
For blood, two-thirds of the VOCs extracted from the MDD subjects’ blood samples were 
aromatics (35%) and aromatics (26%). The remainder of the functional groups present in 
the headspace of blood odor VOCs were aldehydes (17%), alcohols (10%), ketones (9%), 
and ethers (3%). Hexadecane and 2,6-diisopropylnaphthalene were present in all MDD 
subjects. Other compounds with high frequency of occurrence were undecane, nonanal, 
dodecane, 2,4,6-trimethylbenzaldehyde, tridecane, tetradecane, hexane, 
diisopropylnaphthalene, and heptadecane (Table 56).  
Lastly for urine of MDD subjects, ketones had the highest frequency (23%) in the 
extracted VOCs of urine odor, followed by aldehydes (17%), aromatics (16%) and 
alcohols (16%). Nitrogen-containing VOCs were also present in urine odor (9%), which 
were not found in the other specimens from the MDD group. 4-Heptanone and cedrol 
were the only two compounds that were present in over 70% of the depressed subjects 
sampled (Table 57).  
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Figure 90. Frequency distribution of functional groups of extracted VOCs in hand 
odor, buccal swab, breath, blood, and urine across twenty individuals diagnosed 
with Major Depressive Disorder 
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Table 53. Identified VOCs in hand odor of twenty individuals with diagnosed Major 
Depressive Disorder ranked by frequency of occurrence (Note: * denotes compound 
was verified by reference standard) 
Compound Name 
  
Frequency Occurrence 
(%) Female Male Total 
Nonanal* 10 10 20 100 
Decanal* 10 10 20 100 
Tetradecane* 10 9 19 95.0 
Hexadecane* 9 9 18 90.0 
Heptadecane* 9 9 18 90.0 
Octadecane 8 9 17 85.0 
Undecane* 6 6 12 60.0 
Tridecane* 6 6 12 60.0 
Undecanal* 6 6 12 60.0 
5,9-Undecadien-2-one-6,10-dimethyl-(E)-* 6 6 12 60.0 
Dodecane* 2 5 7 35.0 
Benzyl Alcohol* 3 2 5 25.0 
Dodecanal* 2 2 4 20.0 
1-Hexanol,2-ethyl- 3 0 3 15.0 
1,6-Octadien-3-ol,3,7-dimethyl-* 2 1 3 15.0 
Dodecanoicacid,methylester 0 3 3 15.0 
Benzaldehyde* 2 0 2 10.0 
Acetophenone* 1 1 2 10.0 
Heptanal 1 0 1 5.0 
5-Hepten-2-one,6-methyl-* 0 1 1 5.0 
Hexanoicacid* 1 0 1 5.0 
Octanoicacid,methylester* 1 0 1 5.0 
2-Nonenal, (E)-* 0 1 1 5.0 
1-Pentadecene* 0 1 1 5.0 
Pentadecane* 1 0 1 5.0 
 
  
199 
 
Table 54. Identified VOCs in buccal swab of twenty individuals with diagnosed 
Major Depressive Disorder ranked by frequency of occurrence (Note: *denotes 
compound was verified by reference standard) 
Compound Name Frequency Occurrence 
  Female Male Total (%) 
Hexanoicacid* 10 10 20 100 
Decanal* 10 10 20 100 
Furan,2-pentyl-* 9 10 19 95.0 
5,9-Undecadien-2-one,6,10-dimethyl,(E)-* 10 9 19 95.0 
Nonanoicacid 8 10 18 90.0 
Nonanoicacid,ethylester* 9 9 18 90.0 
2,4-Nonadienal, (E,E)-v 6 10 16 80.0 
Dodecanoicacid,ethylester 6 10 16 80.0 
1,1'-Biphenyl,2,2'-diethyl- 5 10 15 75.0 
2-Nonenal, (E)-* 5 8 13 65.0 
Hexadecanoicacid,ethylester 5 8 13 65.0 
1-Tetradecene* 7 5 12 60.0 
Tetradecanoicacid,ethylester 4 8 12 60.0 
6-Dodecanone 7 4 11 55.0 
6-Methyl-3,5-heptadiene-2-one 3 7 10 50.0 
1-Dodecene* 3 6 9 45.0 
Octanoicacid,ethylester* 6 3 9 45.0 
Heptanoicacid* 2 6 8 40.0 
1-Decene* 4 4 8 40.0 
1,1'-Biphenyl, 4-methyl- 2 6 8 40.0 
Pentanoicacid* 1 6 7 35.0 
Tetradecane* 1 6 7 35.0 
Hexanoicacid,ethylester 2 4 6 30.0 
Heptanoicacid,ethylester* 3 3 6 30.0 
Hexanoicacid,pentylester 4 2 6 30.0 
Naphthalene,1-methyl-* 3 3 6 30.0 
2-Tetradecene, (E)- 1 5 6 30.0 
Hexanal* 3 2 5 25.0 
Benzaldehyde* 2 3 5 25.0 
Decanoicacid,ethylester* 2 3 5 25.0 
Dodecanoicacid* 0 5 5 25.0 
Pentadecanoicacid,ethylester 2 3 5 25.0 
E-11-Hexadecenoicacid,ethylester 1 4 5 25.0 
Phenol* 1 3 4 20.0 
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Acetophenone* 2 2 4 20.0 
Naphthalene,2-methyl- 2 2 4 20.0 
Naphthalene,2,7-dimethyl- 2 2 4 20.0 
Hexadecane* 3 1 4 20.0 
Furfural* 0 3 3 15.0 
1-Hexanol* 0 3 3 15.0 
2-Octenal, (E)-* 3 0 3 15.0 
3-Nonen-2-one 2 1 3 15.0 
2-Octenoicacid 1 2 3 15.0 
Benzene,1,2,4,5-tetramethyl- 1 2 3 15.0 
p-Benzoquinone 2 1 3 15.0 
Galaxolide 3 0 3 15.0 
Homomenthylsalicylate 3 0 3 15.0 
Benzothiazole 1 1 2 10.0 
2(3H)-Furanone, 5-ethyldihydro- 2 0 2 10.0 
2(3H)-Furanone, dihydro-5-pentyl- 1 1 2 10.0 
Vanillin 2 0 2 10.0 
DiethylPhthalate 2 0 2 10.0 
Benzene,1-methyl-2-[(4-methylphenyl)methyl]- 1 1 2 10.0 
Dibutanoylmorphine 0 2 2 10.0 
IsopropylPalmitate 2 0 2 10.0 
Linalool Oxide 1 0 1 5.0 
1-Octanol* 1 0 1 5.0 
Benzene,1-ethyl-2,3-dimethyl- 0 1 1 5.0 
Benzoicacid,ethylester 0 1 1 5.0 
2-Decenal, (E)- 1 0 1 5.0 
Naphthalene,2,6-dimethyl- 1 0 1 5.0 
Dodecanal* 1 0 1 5.0 
Octadecanal 1 0 1 5.0 
3,7-Dimethyl-octa-1,6-diene 1 0 1 5.0 
Caryophyllene* 1 0 1 5.0 
β-Cadinene 1 0 1 5.0 
ButylatedHydroxytoluene 1 0 1 5.0 
Octadecane 1 0 1 5.0 
1-Hexadecene 1 0 1 5.0 
Hexadecanoicacid,methylester 1 0 1 5.0 
11-Octadecenoicacid,methylester 1 0 1 5.0 
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Table 55. Identified VOCs in breath of twenty individuals with diagnosed Major 
Depressive Disorder ranked by frequency of occurrence (Note: *denotes compound 
was verified by reference standard) 
Compound Name 
 
Frequency Occurrence  
(%) Female Male Total 
Nonanal* 10 10 20 100 
Decanal* 10 10 20 100 
Xylenes* 7 9 16 80 
Benzene,1,2-dichloro-* 6 10 16 80 
1-Hexanol,2-ethyl-* 7 8 15 75 
Benzophenone* 6 8 14 70 
Dodecane* 5 8 13 65 
Tetradecane* 5 8 13 65 
Styrene* 5 7 12 60 
Phenol* 5 7 12 60 
Undecane* 4 8 12 60 
Tridecane* 4 8 12 60 
ButylatedHydroxytoluene* 6 6 12 60 
Toluene 3 4 7 35 
Benzene,1,3,5-trimethyl- 2 5 7 35 
Benzene,1-methyl-3-propyl- 1 6 7 35 
Benzene,1,2,3-trimethyl- 1 4 5 25 
Benzene,4-ethyl-1,2-dimethyl- 2 3 5 25 
Benzene,1-ethyl-2,4-dimethyl- 1 4 5 25 
Undecanal* 1 4 5 25 
p-Benzoquinone 0 5 5 25 
Benzene,1-ethyl-2-methyl- 1 3 4 20 
Nonanoicacid 2 2 4 20 
Benzene,1,2,4,5-tetramethyl-* 2 2 4 20 
Naphthalene,2-methyl- 1 3 4 20 
5,9-Undecadien-2-one, 6,10-dimethyl-(E)-* 1 3 4 20 
Naphthalene* 1 3 4 20 
Limonene* 1 2 3 15 
Benzene,1,2,3,4-tetramethyl- 0 3 3 15 
Dodecanal* 0 3 3 15 
1,1'-Biphenyl,4-methyl- 2 1 3 15 
5-Hepten-2-one,6-methyl-* 1 1 2 10 
Benzene,diethyl-* 0 2 2 10 
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Acetophenone* 1 1 2 10 
Benzene,1-methyl-2-(1-methylethyl)- 0 2 2 10 
Benzene,1-ethyl-2,3-dimethyl- 1 1 2 10 
Benzene,1,2,3,5-tetramethyl- 0 2 2 10 
Triacetin 0 2 2 10 
DiethylPhthalate 1 1 2 10 
Acetone 1 0 1 5 
Aceticacid 0 1 1 5 
Hexanal* 0 1 1 5 
Tetrachloroethylene 1 0 1 5 
2-Propanol,1-propoxy- 0 1 1 5 
3-Heptanone* 0 1 1 5 
Benzene,(1-methylethyl)- 0 1 1 5 
Benzene,propyl-* 0 1 1 5 
Benzene,1-ethyl-3-methyl- 0 1 1 5 
Benzene,1,2,4-trimethyl- 0 1 1 5 
Benzene,1,4-dichloro- 1 0 1 5 
Benzene,2-ethyl-1,4-dimethyl- 0 1 1 5 
Decane,2-methyl- 1 0 1 5 
Benzene,1-methyl-4-propyl- 0 1 1 5 
Benzene,2-ethyl-1,3-dimethyl- 0 1 1 5 
Benzene,1-methyl-4-(1-methylethyl)- 0 1 1 5 
1-Dodecene* 0 1 1 5 
Benzene,1-methyl-4-(1-methylpropyl)- 0 1 1 5 
Undecane,2,6-dimethyl- 1 0 1 5 
2-Dodecene, (Z)- 0 1 1 5 
3-Dodecene, (Z)- 0 1 1 5 
Benzene,pentamethyl- 0 1 1 5 
Indole 1 0 1 5 
n-Decanoicacid* 0 1 1 5 
Hexanedioicacid,bis(1-methylethyl) ester 0 1 1 5 
Dodecanoicacid* 0 1 1 5 
Hexadecane* 0 1 1 5 
Methyldihydrojasmonate 1 0 1 5 
Diisopropylnaphthalene 0 1 1 5 
2,6-Diisopropylnaphthalene* 0 1 1 5 
Tetradecanoicacid 0 1 1 5 
Galaxolide 1 0 1 5 
Homomenthylsalicylate 1 0 1 5 
n-Hexadecanoicacid* 0 1 1 5 
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Table 56. Identified VOCs in blood odor of twenty individuals with diagnosed 
Major Depressive Disorder ranked by frequency of occurrence (Note: *denotes 
compound was verified by reference standard) 
Compound Name 
 
Frequency Occurrence 
(%) Female Male Total 
Hexadecane* 10 10 20 100 
2,6-Diisopropylnaphthalene* 10 10 20 100 
Undecane* 9 10 19 95.0 
Nonanal* 9 10 19 95.0 
Dodecane* 9 10 19 95.0 
Benzenaldehyde,2,4,6-trimethyl- 9 10 19 95.0 
Tridecane* 9 10 19 95.0 
Tetradecane* 9 9 18 90.0 
Hexanal 9 7 16 80.0 
Diisopropylnaphthalene 7 7 14 70.0 
Heptadecane* 5 9 14 70.0 
Benzyl Alcohol* 6 5 11 55.0 
Longifolene 2 7 9 45.0 
Benzene,4-ethyl-1,2-dimethyl- 1 7 8 40.0 
Benzene,1,2,4,5-tetramethyl- 2 6 8 40.0 
5,9-Undecadien-2-one,6,10-dimethyl,(E)- 2 6 8 40.0 
Octadecane 2 6 8 40.0 
Cyclohexanone* 4 3 7 35.0 
Furan,2-pentyl-* 4 3 7 35.0 
Benzene,1,3,5-trimethyl- 2 5 7 35.0 
Benzene,1,2,3,5-tetramethyl- 3 4 7 35.0 
1-Decene* 3 4 7 35.0 
2-Dodecene,(Z)- 2 5 7 35.0 
Decanal* 3 4 7 35.0 
2-Undecanone 3 4 7 35.0 
Furan,2-butyltetrahydro- 3 4 7 35.0 
Naphthalene,2-methyl- 2 4 6 30.0 
2-Heptanone* 1 4 5 25.0 
Heptanal* 3 2 5 25.0 
1-Octen-3-ol* 1 4 5 25.0 
1-Dodecene* 3 2 5 25.0 
1-Pentanol 1 3 4 20.0 
p-Xylene* 1 3 4 20.0 
Benzene,1-ethyl-2,4-dimethyl- 0 4 4 20.0 
Naphthalene,1-methyl-* 2 2 4 20.0 
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Benzene,1-ethyl-2-methyl- 1 2 3 15 
Benzene,1,2,3-trimethyl- 1 2 3 15 
Benzene,1,2-dichloro-* 2 1 3 15 
4-Cyanocyclohexene 1 2 3 15 
Benzene,2-ethyl-1,4-dimethyl- 3 0 3 15 
Benzene,1,2,3,4-tetramethyl- 2 1 3 15 
Decane,1-chloro- 1 2 3 15 
1-Dodecanol* 0 3 3 15 
Naphthalene* 0 3 3 15 
2-Propanol,1-propoxy- 0 2 2 10 
Octanal 0 2 2 10 
Benzenemethanol,α,α-dimethyl- 2 0 2 10 
Benzaldehyde,4-(methylthio)- 2 0 2 10 
2,4-Diphenyl-4-methyl-1(E)-pentene 1 1 2 10 
Tetrachloroethylene 1 0 1 5 
3-Heptanone* 0 1 1 5 
Nonane* 1 0 1 5 
Ethanol,2-butoxy- 1 0 1 5 
Benzaldehyde* 1 0 1 5 
Benzene,1-ethyl-3-methyl- 0 1 1 5 
2,5-Octanedione 1 0 1 5 
Phenol* 1 0 1 5 
Decane 0 1 1 5 
Benzene,1,4-dichloro- 1 0 1 5 
Benzaldehyde,2-hydroxy- 1 0 1 5 
Benzene,1-methyl-3-propyl- 0 1 1 5 
3-Isopropylbenzaldehyde 1 0 1 5 
3-Dodecene,(Z)- 0 1 1 5 
1-Cyclohexene-1-carboxaldehyde,2,6,6-trimethyl- 1 0 1 5 
Benzaldehyde,ethyl- 1 0 1 5 
1-Phenyl-2-butanone 1 0 1 5 
Naphthalene,1,6-dimethyl- 1 0 1 5 
Naphthalene,2,7-dimethyl- 0 1 1 5 
Naphthalene,2,6-dimethyl- 1 0 1 5 
Naphthalene,2,3-dimethyl- 1 0 1 5 
Cyclododecane 1 0 1 5 
1,1'-Biphenyl,4-methyl- 0 1 1 5 
1,1'-Biphenyl,2-methyl- 0 1 1 5 
Z-8-Hexadecene 0 1 1 5 
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Table 57. Identified VOCs in urine odor of twenty individuals with diagnosed Major 
Depressive Disorder ranked by frequency of occurrence (Note: *denotes compound 
was verified by reference standard) 
Compound Name 
  
Frequency Occurrence 
(%) Female Male Total 
4-Heptanone* 10 9 19 95.0 
Cedrol 6 8 14 70.0 
Nonanal* 5 7 12 60.0 
Carvones 6 5 11 55.0 
2-Pentanone 2 3 5 25.0 
Phenol,4-methyl- (p-Cresol)* 3 2 5 25.0 
Benzene,1-methyl-4-(1-methylethenyl)- 3 2 5 25.0 
2-Isopropylbenzaldehyde 1 4 5 25.0 
Pyrrole 2 2 4 20.0 
Menthol* 5 5 10 20.0 
Decanal* 2 2 4 20.0 
Benzaldehyde,3,5-dimethyl- 2 2 4 20.0 
4-Nonylphenol 3 1 4 20.0 
Benzene,1,4-dichloro- 2 1 3 15.0 
.+/-.-4-Acetyl-1-methylcyclohexene 1 2 3 15.0 
p-Menthan-3-one 3 0 3 15.0 
4-Terpineol 1 2 3 15.0 
ButylatedHydroxytoluene* 0 3 3 15.0 
3-Heptanone* 0 2 2 10.0 
Benzaldehyde* 0 2 2 10.0 
Benzene,1,2-dichloro-* 2 0 2 10.0 
Benzene,1-methyl-3-(1-methylethyl)- 1 1 2 10.0 
Benzeneacetaldehyde,.alpha.-methyl- 2 0 2 10.0 
ValproicAcid 0 2 2 10.0 
α-Terpineol 2 0 2 10.0 
p-Chloroaniline 0 2 2 10.0 
3-Cyclohexen-1-one,2-isopropyl-5-methyl- 1 1 2 10.0 
p-Menth-1-en-3-one 1 1 2 10.0 
Dodecanoicacid* 1 1 2 10.0 
Benzophenone* 2 0 2 10.0 
Phenol,4-(1,1,3,3-tetramethylbutyl)-* 1 1 2 10.0 
Toluene 0 1 1 5.0 
α-Terpinene 1 0 1 5.0 
Benzene,1,3-dichloro- 1 0 1 5.0 
Benzene,4-ethyl-1,2-dimethyl- 0 1 1 5.0 
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Benzene,1-methyl-4-(1-methylethyl)- 0 1 1 5.0 
Benzeneacetaldehyde 1 0 1 5.0 
3-Octen-2-one 0 1 1 5.0 
γ-Terpinene 1 0 1 5.0 
Benzene,-(1-formylethyl)- 0 1 1 5.0 
1,6-Octadien-3-ol,3,7-dimethyl-* 1 0 1 5.0 
Benzaldehyde,3-chloro- 1 0 1 5.0 
Benzaldehyde,4-chloro- 0 1 1 5.0 
Ethanone,1-(2-hydroxyphenyl)- 1 0 1 5.0 
Benzenamine,4-chloro-2-(trifluoromethyl)- 1 0 1 5.0 
Phenol,2,5-dichloro- 1 0 1 5.0 
Benzenamine,2,6-dimethyl- 0 1 1 5.0 
Limonene 0 1 1 5.0 
Dihydrocarvone 1 0 1 5.0 
2,4-Cycloheptadien-1-one,2,6,6-trimethyl- 0 1 1 5.0 
Isobornylacetate 0 1 1 5.0 
2-Propenal,3-phenyl- 1 0 1 5.0 
2-Methoxy-4-vinylphenol 0 1 1 5.0 
Ethanone,1-(4-chlorophenyl)- 1 0 1 5.0 
Benzoicacid,2-amino-,methylester 1 0 1 5.0 
Damascenone 0 1 1 5.0 
Butanoicacid,butylester 1 0 1 5.0 
5,9-Undecadien-2-one,6,10-dimethyl,(E)-* 1 0 1 5.0 
Dibutanoylmorphine 0 1 1 5.0 
Cyclotetradecane 0 1 1 5.0 
IsopropylPalmitate 1 0 1 5.0 
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3.6.4.4. Comparison of the Volatile Organic Compounds Present Above Collected 
Odor Samples from Five Biological Specimens across Populations 
As investigated in sections 3.6.4.1.2.1 and 3.6.4.1.2.2, Type I and Type II errors were 
calculated for each of the five biological specimens for the type 2 diabetic and MDD 
subject groups. Summary of the total number of errors and the percentage of mismatching 
of individuals are shown in Table 58 through  
Table 60 for healthy, type 2 diabetic and MDD subject groups, respectively.  For all three 
subject groups, the number of total errors was highest for hand odor. However, this can 
be attributed to the fact that for hand odor, the volatile compounds categorized as “human 
scent compounds” have previously been determined and therefore the human compound 
database for hand odor holds a much smaller number of VOCs compared to the other 
specimens that were newly investigated in the present study. All extracted volatile 
compounds were included in the data analysis for the remaining four biological 
specimens investigated in the present study, resulting in a greater array of compounds and 
higher variations in the relative peak area ratios of compounds present in the headspace 
of each individual’s specimen odor profiles, thereby lowering the Type I and Type II 
error occurrences. 
The low percentages in the mismatch occurrences further support the hypothesis that 
VOCs emanations are different among individuals for the five biological specimens and 
can be used as distinguishing profiles among individuals. As previously mentioned in 
section 3.6.4.1.2.1 the match/no-match cut-off threshold is recommended to be kept at 
least at 0.8 correlation, and wherever possible, a cut-off threshold of 0.9 should be 
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utilized. Preliminary comparison of the three subject groups at 0.9 correlation threshold 
as shown in Table 61 demonstrates that having a medical condition did not greatly affect 
in the mismatch occurrences for any of the biological specimens. Percentages of 
mismatch occurrences were almost identical across the three study groups for hand odor 
and buccal swabs. For breath and blood, misidentification occurrences were slightly 
higher in the diabetic and depressed study groups than in the healthy control group. For 
urine, diabetics had the lowest percentage of misidentification occurrence, while the 
depressed study group had the highest percentage of misidentification occurrence, 
although all are still under 1%. There were no particular patterns in the increase or 
decrease in the percentage of misidentification of individuals relative to their 
physiological or psychological health statuses.  
Thus far the present study has demonstrated that odor profiles from human biological 
specimens other than hand odor can differentiate individuals with high certainty. 
Specimen odor profiles from individuals with the same diagnosed medical condition were 
also found to achieve good differentiation which is important for forensic consideration. 
Because certain diseases are known to be associated with certain odors, it is expected that 
the odor profiles of individuals who are diagnosed with the same disease or disorder to 
have similar VOC profiles with one another than individuals who do not have the same 
disease or disorder. From the medical perspective this could be important as it could lead 
to identifying key volatile biomarkers for certain medical conditions. From the 
legal/forensic perspective, the ability to identify individuals with a given medical 
condition is potentially significant because the possibility of mismatching two individuals 
209 
 
with the same medical condition becomes unlikely. This leads to less chance of false 
identification of suspects, for example by canine detection, on the basis of the two 
individuals having the same medical condition. With the sample size of the present study, 
having a diagnosed medical/psychological condition did not affect the misidentification 
rate of individuals. If an argument was made where suspect mismatching occurred 
because of the individual’s health statuses, results from this preliminary study can be 
used as a counterargument on the basis that a high distinguish-ability of specimen VOC 
profiles was still achieved regardless of the subjects’ health statuses.  
Further studies with larger sample sizes for the three subject groups are needed to obtain 
a more definitive indication on whether physiological or psychological health statuses 
have an effect on the misidentification occurrences of individuals. Future studies should 
include individuals with extreme conditions from the diabetic and depressed subject 
groups. For the diabetic population, it would be desirable to collect samples from 
uncontrolled (by medication or diet) diabetic patients and perhaps even diabetic patients 
recently suffered from diabetic ketoacidosis. Similarly for the depressed population, 
sample collection from patients who are in severe depressed state at the time of sampling 
is desirable. The present study was not able to include such subjects as access to diabetic 
inpatients admitted as a result of uncontrolled diabetes was prohibited, and the severely 
depressed patients were unresponsive and unable to give consent for sample collection 
during the course of the study.  
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Table 58. Type I and Type II errors for five biological specimens amongst healthy 
individuals 
  Hand Odor Buccal Swab Breath Blood Urine 
Threshold 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.8 
Type I 3 13 0 1 0 1 0 0 0 0 
Type II 15 9 9 4 11 4 12 6 8 3 
Total Error 18 22 9 5 11 5 12 6 8 3 
% Mismatch 0.89 1.09 0.45 0.25 0.58 0.26 0.63 0.32 0.36 0.14 
 
Table 59. Type I and Type II errors for five biological specimens amongst type 2 
diabetic patients 
  Hand Odor Buccal Swab Breath Blood Urine 
Threshold 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.8 
Type I 7 39 0 0 0 0 0 0 0 0 
Type II 7 4 7 2 8 3 7 4 2 0 
Total Error 14 43 7 2 8 3 7 4 2 0 
% Mismatch 0.88 2.69 0.44 0.13 1.14 0.43 1.00 0.57 0.13 0 
 
Table 60. Type I and Type II errors for five biological specimens amongst 
individuals diagnosed with Major Depressive Disorder 
  Hand Odor Buccal Swab Breath Blood Urine 
Threshold 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.8 
Type I 4 28 0 0 0 1 0 0 0 0 
Type II 10 9 5 3 7 4 15 8 11 8 
Total Error 14 37 5 3 7 5 15 8 11 8 
% Mismatch 0.79 2.09 0.28 0.17 0.90 0.64 1.92 1.03 0.62 0.45 
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Table 61. Comparison of mismatch occurrences for the five biological specimens 
across populations at 0.9 correlation cutoff threshold 
 Hand Odor Buccal Swab Breath Blood Urine 
Healthy 0.89% 0.45% 0.58% 0.63% 0.36% 
Type 2 Diabetes 0.88% 0.44% 1.14% 1.00% 0.13% 
MDD 0.79% 0.28% 0.90% 1.92% 0.62% 
 
 
3.6.4.4.1. Chi-Square Significance Test 
Table 62 to Table 66 give the frequencies of the VOCs extracted from individuals within 
their population subgroups (healthy control, type 2 diabetics (T2DB), and clinically 
depressed (MDD)). From the entire list of compounds detected from each specimen, 
those compounds that appeared at least once in each subgroup were considered for 
further data analysis.  
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Table 62. Frequency of occurrence of hand odor VOCs in total population and 
within subgroups (Notes: an=70, bn=31, cn=19, dn=20) 
Compound Name 
Occurrence in 
Total 
Populationa 
Occurrence within Group 
Healthyb T2DBc MDDd 
Decanal 100% 31 19 20 
Nonanal 100% 31 19 20 
Tetradecane 96% 31 17 19 
Hexadecane 93% 30 17 18 
Heptadecane 90% 28 17 18 
Undecanal 67% 30 7 10 
Octadecane 66% 18 11 17 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 63% 23 9 12 
Tridecane 61% 22 9 12 
Undecane 54% 15 11 12 
Dodecane 37% 14 5 7 
BenzylAlcohol 29% 13 2 5 
Dodecanal 23% 10 2 4 
1,6-Octadien-3-ol,3,7-dimethyl- 16% 7 1 3 
1-Hexanol,2-ethyl- 16% 6 2 3 
Dodecanoicacid,methylester 14% 3 4 3 
2-Nonenal,(E)- 11% 3 4 1 
Acetophenone 11% 3 3 2 
Benzaldehyde 10% 4 1 2 
2-Decanone 9% 6 0 0 
Nonanoicacid,methylester 6% 4 0 0 
Octanoicacid,methylester 6% 2 1 1 
Pentadecane 4% 2 0 1 
1-Pentadecene 3% 1 0 1 
5-Hepten-2-one,6-methyl- 3% 0 1 1 
Dodecanoicacid 3% 2 0 0 
Eicosane 3% 2 0 0 
Furfural 3% 2 0 0 
Heptanal 3% 1 0 1 
Hexanoicacid 3% 1 0 1 
Phenol 3% 2 0 0 
2-Pentanone 1% 0 1 0 
Aceticacid,butylester 1% 0 1 0 
Cedrol 1% 0 1 0 
Docosane 1% 1 0 0 
Heneicosane 1% 1 0 0 
Lilial 1% 0 1 0 
Octanal 1% 1 0 0 
Propanedioicacid,dimethylester 1% 1 0 0 
Tetradecanal 1% 1 0 0 
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Table 63. Frequency of occurrence of buccal swab odor VOCs in total population 
and within subgroups (Notes: an=70, bn=31, cn=19, dn=20) 
Compound Name 
Occurrence 
in Total 
Populationa 
Occurrence within Group 
Healthyb T2DBc MDDd 
Decanal 100% 31 19 20 
Hexanoicacid 100% 31 19 20 
Furan,2-pentyl- 91% 30 15 19 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 90% 28 16 19 
Nonanoicacid,ethylester 87% 27 16 18 
Nonanoicacid 84% 24 17 18 
2,4-Nonadienal,(E,E)- 77% 28 10 16 
Dodecanoicacid,ethylester 77% 24 14 16 
6-Dodecanone 70% 24 14 11 
2-Nonenal,(E)- 63% 25 6 13 
Hexadecanoicacid,ethylester 61% 20 10 13 
Tetradecanoicacid,ethylester 61% 20 11 12 
1-Tetradecene 60% 17 13 12 
1,1'-Biphenyl,2,2'-diethyl- 56% 13 11 15 
Octanoicacid,ethylester 50% 19 7 9 
6-Methyl-3,5-heptadiene-2-one 43% 10 10 10 
Hexanoicacid,ethylester 41% 20 3 6 
1-Dodecene 40% 13 6 9 
1-Decene 39% 8 11 8 
Tetradecane 39% 10 10 7 
Benzaldehyde 36% 12 8 5 
Hexanal 34% 18 1 5 
Naphthalene,1-methyl- 31% 14 2 6 
Hexanoicacid,pentylester 30% 13 2 6 
Naphthalene,2-methyl- 29% 12 4 4 
2-Tetradecene,(E)- 24% 7 4 6 
Dodecanoicacid 24% 7 5 5 
Heptanoicacid 24% 1 8 8 
Heptanoicacid,ethylester 24% 8 3 6 
1,1'-Biphenyl,4-methyl- 23% 2 6 8 
1-Hexanol 23% 7 6 3 
2-Octenoicacid 23% 9 4 3 
Dibutanoylmorphine 21% 11 2 2 
Pentanoicacid 21% 5 3 7 
214 
 
Decanoicacid,ethylester 20% 6 3 5 
DiethylPhthalate 20% 9 3 2 
Linalool Oxide 20% 11 1 2 
Pentadecanoicacid,ethylester 20% 7 2 5 
3-Nonen-2-one 19% 10 0 3 
Cyclododecane 19% 8 5 0 
Naphthalene,2,7-dimethyl- 19% 6 3 4 
Furfural 17% 8 1 3 
1-Octanol 16% 9 1 1 
Hexadecane 16% 6 1 4 
2(3H)-Furanone,5-ethyldihydro- 14% 3 5 2 
2(3H)-Furanone,dihydro-5-pentyl- 14% 3 5 2 
2-Octenal,(E)- 14% 7 0 3 
Acetophenone 14% 3 3 4 
Phenol 14% 2 4 4 
Benzene,1-methyl-2-[(4-methylphenyl)methyl]- 13% 3 4 2 
Benzothiazole 13% 3 4 2 
Caryophyllene 13% 5 3 1 
2,5-Cyclohexadiene-1,4-dione,2,6-bis(1,1-
dimethylethyl)- 11% 4 1 3 
E-11-Hexadecenoicacid,ethylester 11% 2 1 5 
IsopropylMyristate 10% 5 2 0 
Vanillin 10% 5 0 2 
5,9-Undecadien-2-one,6,10-dimethyl-, (Z)- 9% 5 1 0 
Benzoicacid,ethylester 9% 5 0 1 
Galaxolide 7% 2 0 3 
IsopropylPalmitate 7% 2 1 2 
1-Pentadecene 6% 4 0 0 
3,5,9-Undecatrien-2-one,6,10-dimethyl-, (E,Z)- 6% 3 1 0 
3,7-Dimethyl-octa-1,6-diene 6% 3 0 1 
5,9-Undecadien-2-one,6,10-dimethyl- 6% 4 0 0 
Benzene,1,2,4,5-tetramethyl- 6% 0 1 3 
Benzophenone 6% 4 0 0 
ButylatedHydroxytoluene 6% 1 2 1 
Cyclopropane,nonyl- 6% 4 0 0 
Hexadecanoicacid,methylester 6% 1 2 1 
Octadecanal 6% 3 0 1 
Octadecane 6% 2 1 1 
1-Hexadecene 4% 2 0 1 
2(3H)-Furanone,dihydro-5-propyl- 4% 1 2 0 
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Benzene,1,1'-methylenebis[4-methyl- 4% 3 0 0 
β-Bourbonene 4% 3 0 0 
Calamenene 4% 3 0 0 
Heptadecane 4% 3 0 0 
Hexanoicacid,anhydride 4% 3 0 0 
Homomenthylsalicylate 4% 0 0 3 
OctanoicAcid 4% 3 0 0 
Tributylphosphate 4% 1 1 1 
1,1'-Biphenyl,3-methyl- 3% 1 1 0 
1,6,10-Dodecatriene,7,11-dimethyl-3-methylene-, 
(Z)- 3% 2 0 0 
1-Heptadecene 3% 2 0 0 
1-Pentanol 3% 2 0 0 
Cyclodecane 3% 2 0 0 
Cyclotetradecane 3% 2 0 0 
Dodecanal 3% 1 0 1 
Ethyl9-hexadecenoate 3% 2 0 0 
Naphthalene,2,6-dimethyl- 3% 0 1 1 
Tridecane 3% 0 2 0 
γ-Cadinene 3% 1 0 1 
1,1'-Biphenyl,2-ethyl- 1% 1 0 0 
11-Octadecenoicacid,methylester 1% 0 0 1 
2,4-Decadienal,(E,E)- 1% 1 0 0 
2-Decenal,(E)- 1% 0 0 1 
2-Dodecenal,(E)- 1% 1 0 0 
2-Heptenoicacid 1% 1 0 0 
3-Eicosene,(E)- 1% 1 0 0 
3-Heptadecene,(Z)- 1% 1 0 0 
4,8-Dimethyl-nona-3,8-dien-2-one 1% 1 0 0 
7-Hexadecene,(Z)- 1% 1 0 0 
9-Octadecenoicacid,(E)- 1% 1 0 0 
Aceticacid 1% 1 0 0 
Benzaldehyde,4-(1-methylethyl)- 1% 1 0 0 
Benzene, 1-methyl-2-[(3-methylphenyl)methyl]- 1% 1 0 0 
Benzene,1,2,3,5-tetramethyl- 1% 0 1 0 
Benzene,1-ethyl-2,3-dimethyl- 1% 0 0 1 
Benzene,1-methyl-4-nitro- 1% 0 1 0 
Carvone 1% 0 1 0 
Cyclododecanol,1-ethenyl- 1% 1 0 0 
Cyclohexadecane 1% 0 1 0 
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trans-p-Menthan-3-one 1% 0 1 0 
Δ-Cadinene 1% 1 0 0 
Docosane 1% 1 0 0 
Dodecanoicacid,methylester 1% 1 0 0 
Eicosane 1% 1 0 0 
Ethyltridecanoate 1% 1 0 0 
Glycocyanidine 1% 1 0 0 
Heneicosane 1% 1 0 0 
Hexanoicacid,propylester 1% 0 1 0 
Menthol 1% 0 1 0 
Nonadecanoicacid,ethylester 1% 1 0 0 
Pentadecane,7-methyl- 1% 1 0 0 
Tetradecanoicacid,2-methyl-,methyl ester 1% 1 0 0 
 
 
 
 
 
 
 
 
 
 
 
  
217 
 
Table 64. Frequency of occurrence of breath odor VOCs in total population and 
within subgroups (Notes: an=70, bn=31, cn=19, dn=20) 
Compound Name Occurrence in Total Populationa 
Occurrence within Group 
Healthyb T2DBc MDDd 
Decanal 99% 31 18 20 
Nonanal 99% 30 19 20 
Xylenes 76% 22 15 16 
Benzophenone 76% 29 10 14 
1-Hexanol,2-ethyl- 73% 25 11 15 
Benzene,1,2-dichloro- 73% 25 10 16 
Styrene 66% 29 6 11 
ButylatedHydroxytoluene 60% 24 6 12 
Dodecane 56% 13 13 13 
Tetradecane 53% 11 13 13 
Tridecane 50% 10 13 12 
Undecane 50% 13 10 12 
Phenol 47% 18 3 12 
Toluene 30% 8 6 7 
Undecanal 26% 9 4 5 
Benzene,1,3,5-trimethyl- 24% 4 6 7 
Dibutylphthalate 24% 16 1 0 
2,6-Diisopropylnaphthalene 23% 13 2 1 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 20% 9 1 4 
p-Benzoquinone 17% 1 6 5 
Acetophenone 17% 10 0 2 
Benzene,1-methyl-3-propyl- 17% 0 5 7 
Benzene,4-ethyl-1,2-dimethyl- 17% 2 5 5 
Dodecanal 17% 8 1 3 
1-Dodecene 16% 10 0 1 
Longifolene 14% 10 0 0 
Naphthalene 14% 5 3 2 
Benzene,1,2,3-trimethyl- 13% 2 2 5 
Nonanoicacid 13% 5 0 4 
Benzene,1-ethyl-2,4-dimethyl- 11% 1 2 5 
Benzene,1-ethyl-2-methyl- 10% 1 2 4 
Diisopropylnaphthalene 10% 4 2 1 
Indole 10% 6 0 1 
Phenol,2-(1,1-dimethylethyl)- 10% 7 0 0 
Limonene 10% 2 2 3 
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Benzene,1-ethyl-2,3-dimethyl- 9% 0 4 2 
Benzene,2-ethyl-1,4-dimethyl- 9% 0 5 1 
Naphthalene,2-methyl- 9% 1 1 4 
1,1'-Biphenyl,4-methyl- 7% 2 0 3 
1,3,5,7-Cyclooctatetraene 7% 1 3 1 
4-Cyanocyclohexene 7% 1 4 0 
Benzene,1,4-dichloro- 7% 3 1 1 
5-Hepten-2-one,6-methyl- 6% 2 0 2 
Benzene,1,2,3,4-tetramethyl- 6% 0 1 3 
Benzene,1,2,4,5-tetramethyl- 6% 0 0 4 
DiethylPhthalate 6% 1 1 2 
Hexadecane 6% 3 0 1 
Menthol 6% 1 3 0 
2-Dodecene,(Z)- 4% 0 2 1 
2-Propanol,1-propoxy- 4% 1 1 1 
Acetone 4% 0 2 1 
Benzene,1-methyl-4-(1-methylpropyl)- 4% 1 1 1 
Benzene,2-ethyl-1,3-dimethyl- 4% 0 2 1 
Benzene,diethyl- 4% 1 0 2 
Cyclododecane 4% 3 0 0 
Hexanedioicacid,bis(1-methylethyl) ester 4% 0 2 1 
Longicyclene 4% 3 0 0 
n-Decanoicacid 4% 2 0 1 
3-Heptanone 3% 0 1 1 
Benzene,1,2,3,5-tetramethyl- 3% 0 0 2 
Benzene,1-methyl-2-(1-methylethyl)- 3% 0 0 2 
Benzene,propyl- 3% 1 0 1 
β-Maaliene 3% 2 0 0 
Galaxolide 3% 1 0 1 
Heptadecane 3% 2 0 0 
Hexanal 3% 1 0 1 
Homomenthylsalicylate 3% 1 0 1 
Triacetin 3% 0 0 2 
Undecane,2,6-dimethyl- 3% 1 0 1 
1S-α-Pinene 1% 1 0 0 
3-Dodecene,(Z)- 1% 0 0 1 
3-Octanol,3,7-dimethyl-,(.+/-.)- 1% 1 0 0 
5-Dodecene,(E)- 1% 0 1 0 
Aceticacid 1% 0 0 1 
Benzaldehyde 1% 1 0 0 
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Benzaldehyde,4-methoxy- 1% 1 0 0 
Benzene,(1-methylethyl)- 1% 0 0 1 
Benzene,1,2,4-trimethyl- 1% 0 0 1 
Benzene,1,3-dichloro- 1% 0 1 0 
Benzene,1,3-diethyl-5-methyl- 1% 1 0 0 
Benzene,1-ethyl-3,5-dimethyl- 1% 1 0 0 
Benzene,1-ethyl-3-methyl- 1% 0 0 1 
Benzene,1-methyl-3-(1-methylethyl)- 1% 1 0 0 
Benzene,1-methyl-4-(1-methylethyl)- 1% 0 0 1 
Benzene,1-methyl-4-propyl- 1% 0 0 1 
Benzene,3-cyclohexen-1-yl- 1% 1 0 0 
Benzene,pentamethyl- 1% 0 0 1 
β-Gurjunene 1% 1 0 0 
Caryophyllene 1% 1 0 0 
Cyclohexane,methyl- 1% 1 0 0 
Decane,2-methyl- 1% 0 0 1 
Decane,3-methyl- 1% 1 0 0 
Dodecanoicacid 1% 0 0 1 
Dodecanoicacid,methylester 1% 1 0 0 
Eicosane 1% 1 0 0 
Ethanol,2-phenoxy- 1% 1 0 0 
Indolizine 1% 1 0 0 
Isobornylacetate 1% 0 1 0 
IsopropylPalmitate 1% 1 0 0 
Methyldihydrojasmonate 1% 0 0 1 
MethylSalicylate 1% 1 0 0 
n-Hexadecanoicacid 1% 0 0 1 
Nonadecane 1% 1 0 0 
Nonane,3-methyl- 1% 1 0 0 
Octanal 1% 1 0 0 
Tetrachloroethylene 1% 0 0 1 
Tetradecanal 1% 1 0 0 
Tetradecanoicacid 1% 0 0 1 
Undecane,3,6-dimethyl- 1% 1 0 0 
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Table 65. Frequency of occurrence of breath odor VOCs in total population and 
within subgroups (Notes: an=70, bn=31, cn=19, dn=20) 
Compound Name Occurrence in Total Populationa 
Occurrence within Group 
Healthyb T2DBc MDDd 
Hexadecane 99% 30 19 20 
Nonanal 94% 28 19 19 
2,6-Diisopropylnaphthalene 93% 30 15 20 
Tetradecane 91% 30 16 18 
Undecane 91% 29 16 19 
Benzaldehyde,2,4,6-trimethyl- 89% 31 12 19 
Tridecane 89% 29 14 19 
Dodecane 86% 28 13 19 
Hexanal 76% 26 11 16 
Heptadecane 69% 22 12 14 
BenzylAlcohol 60% 25 6 11 
Diisopropylnaphthalene 57% 19 7 14 
Furan,2-butyltetrahydro- 56% 23 9 7 
Furan,2-pentyl- 47% 20 6 7 
Decanal 44% 15 9 7 
1-Dodecene 41% 18 6 5 
Cyclohexanone 41% 19 3 7 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 37% 14 4 8 
2-Dodecene,(Z)- 36% 12 6 7 
Longifolene 33% 6 8 9 
1-Decene 31% 7 8 7 
1-Octen-3-ol 31% 8 9 5 
2-Undecanone 30% 11 3 7 
Benzene,1,2-dichloro- 29% 12 5 3 
Octadecane 29% 6 6 8 
1-Pentanol 26% 12 2 4 
2-Heptanone 21% 8 2 5 
Benzene,1,3,5-trimethyl- 20% 0 7 7 
Heptanal 20% 5 4 5 
Cyclododecane 19% 10 2 1 
1-Dodecanol 17% 5 4 3 
Naphthalene,2-methyl- 16% 0 5 6 
Benzene,1,2,3,5-tetramethyl- 14% 0 3 7 
Benzene,1,2,4,5-tetramethyl- 14% 0 2 8 
Benzene,4-ethyl-1,2-dimethyl- 14% 1 1 8 
Naphthalene 14% 1 6 3 
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Benzene,1-ethyl-2,4-dimethyl- 13% 0 5 4 
Xylenes 13% 3 2 4 
4-Cyanocyclohexene 11% 2 3 3 
Cyclopropane,nonyl- 11% 7 1 0 
Menthol 11% 4 4 0 
Octanal 11% 6 0 2 
1-Octanol 10% 5 2 0 
2-Heptanone,6-methyl- 9% 5 1 0 
2-Propanol,1-propoxy- 9% 1 3 2 
Benzene,1,4-dichloro- 9% 4 1 1 
Naphthalene,1-methyl- 9% 0 2 4 
2,4-Diphenyl-4-methyl-1(E)-pentene 7% 3 0 2 
Benzenemethanol,.alpha.,.alpha.-dimethyl- 7% 3 0 2 
Ethanol,2-butoxy- 7% 3 1 1 
1-Phenyl-2-butanone 6% 3 0 1 
3-Heptanone 6% 0 3 1 
Benzaldehyde,4-(methylthio)- 6% 2 0 2 
Benzene,1,2,3,4-tetramethyl- 6% 0 1 3 
Benzene,1,2,3-trimethyl- 6% 0 1 3 
Benzene,1-ethyl-2-methyl- 6% 0 1 3 
Benzene,2-ethyl-1,4-dimethyl- 6% 0 1 3 
Heptanol 6% 3 1 0 
1,1'-Biphenyl,2-methyl- 4% 1 1 1 
2,5-Octanedione 4% 0 2 1 
3-Dodecene,(Z)- 4% 0 2 1 
Benzaldehyde 4% 2 0 1 
Dodecane,1-chloro- 4% 0 0 3 
Naphthalene,2,7-dimethyl- 4% 0 2 1 
Phenol 4% 2 0 1 
1,1'-Biphenyl,4-methyl- 3% 1 0 1 
3,7-Dimethyl-octa-1,6-diene 3% 1 1 0 
3-Isopropylbenzaldehyde 3% 1 0 1 
4-Heptanone 3% 2 0 0 
5-Hepten-2-one,6-methyl- 3% 2 0 0 
Benzene,1,4-diethyl-2-methyl- 3% 0 1 1 
Benzene,1-ethyl-3,5-dimethyl- 3% 0 2 0 
Benzene,1-ethyl-3-methyl- 3% 0 1 1 
Benzene,1-methyl-3-propyl- 3% 1 0 1 
Benzene,1-methyl-4-(1-methylpropyl)- 3% 1 1 0 
Decane 3% 0 1 1 
Naphthalene,2,3,6-trimethyl- 3% 1 1 0 
Phenol,2,4,6-trimethyl- 3% 2 0 0 
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Phenol,4-methoxy-2-nitro- 3% 2 0 0 
Z-8-Hexadecene 3% 0 1 1 
1,1'-Biphenyl,3-methyl- 1% 0 1 0 
1,2-Benzenediol,3,5-bis(1,1-dimethylethyl)- 1% 1 0 0 
β-Cyclocitral 1% 0 0 1 
1-Hexadecene 1% 0 1 0 
1-Tetradecene 1% 1 0 0 
2-Decanone 1% 1 0 0 
2-Propanol,1-butoxy- 1% 0 1 0 
4-tert-Butylcyclohexylacetate 1% 0 1 0 
Acetone 1% 1 0 0 
Acetophenone 1% 1 0 0 
Benzaldehyde,2-hydroxy- 1% 0 0 1 
Benzaldehyde,3-hydroxy- 1% 1 0 0 
Benzaldehyde,ethyl- 1% 0 0 1 
Benzene,1,3-dichloro- 1% 1 0 0 
Benzene,1,3-dimethyl-5-(1-methylethyl)- 1% 0 1 0 
Benzene,1-ethyl-2,3-dimethyl- 1% 0 1 0 
Benzene,1-methyl-4-(1-methylethyl)- 1% 0 1 0 
Benzene,2,4-dimethyl-1-(1-methylethyl)- 1% 0 1 0 
Benzene,diethyl- 1% 1 0 0 
Benzene,ethyl-1,2,4-trimethyl- 1% 0 1 0 
Cyclodecane 1% 1 0 0 
Cyclooctane 1% 1 0 0 
Cyclooctane,1,2-dimethyl- 1% 1 0 0 
Cyclotetradecane 1% 0 1 0 
Dimethylsulfone 1% 1 0 0 
Limonene 1% 1 0 0 
Dodecane,2,6,10-trimethyl- 1% 0 1 0 
Heptadecane,9-octyl- 1% 1 0 0 
Hexanedioicacid,bis(1-methylethyl) ester 1% 0 1 0 
IsopropylMyristate 1% 1 0 0 
Naphthalene,1,6-dimethyl- 1% 0 0 1 
Naphthalene,1,7-dimethyl- 1% 0 1 0 
Naphthalene,2,3-dimethyl- 1% 0 0 1 
Naphthalene,2,6-dimethyl- 1% 0 0 1 
Nonane 1% 0 0 1 
Tetrachloroethylene 1% 0 0 1 
Tetradecanal 1% 1 0 0 
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Table 66. Frequency of occurrence of breath odor VOCs in total population and 
within subgroups (Notes: an=70, bn=31, cn=19, dn=20) 
Compound Name Occurrence in Total Populationa 
Occurrence within Group 
Healthyb T2DBc MDDd 
4-Heptanone 90% 30 14 19 
Carvone 56% 21 7 11 
Nonanal 51% 13 11 12 
Cedrol 44% 6 11 14 
Menthol 43% 12 8 10 
4-Nonylphenol 37% 22 0 4 
Pyrrole 31% 16 2 4 
Benzene,1-methyl-4-(1-methylethenyl)- 27% 10 4 5 
Benzene,1,4-dichloro- 26% 15 0 3 
Phenol,4-(1,1,3,3-tetramethylbutyl)- 24% 15 0 2 
4-Terpineol 23% 8 5 3 
2-Isopropylbenzaldehyde 21% 7 3 5 
.+/-.-4-Acetyl-1-methylcyclohexene 19% 10 0 3 
Benzaldehyde,3,5-dimethyl- 19% 7 2 4 
Decanal 19% 5 4 4 
2-Pentanone 17% 3 4 5 
p-Cresol 17% 5 2 5 
3-Cyclohexen-1-one2-isopropyl-5-methyl- 16% 9 0 2 
γ-Terpinene 16% 7 3 1 
Benzaldehyde 14% 4 4 2 
Benzene,1,2-dichloro- 14% 7 1 2 
Benzophenone 14% 7 1 2 
Benzene,1-methyl-4-(1-methylethyl)- 13% 5 3 1 
p-Menthan-3-one 13% 6 0 3 
ButylatedHydroxytoluene 11% 0 5 3 
N,N-Diethylcarbanilide 11% 6 2 0 
p-Menth-1-en-3-one 11% 4 2 2 
α-Terpinene 11% 5 2 1 
Butanoicacid,butylester 10% 1 5 1 
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 9% 5 0 1 
Dodecanoicacid 9% 4 0 2 
Phenol,nonyl- 9% 6 0 0 
3-Heptanone 7% 0 3 2 
Benzene,1-methyl-3-(1-methylethyl)- 7% 2 1 2 
Benzeneacetaldehyde,.alpha.-methyl- 7% 3 0 2 
Cyclopropane,isothiocyanato- 7% 3 2 0 
1,6-Octadien-3-ol,3,7-dimethyl- 6% 3 0 1 
2-Methoxy-4-vinylphenol 6% 1 2 1 
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Benzene,1,3-dichloro- 6% 2 1 1 
Dibutanoylmorphine 6% 2 1 1 
ValproicAcid 6% 0 2 2 
β-Damascenone 6% 3 0 1 
2-Heptanone 4% 3 0 0 
2-Propenal,3-phenyl- 4% 2 0 1 
AllylIsothiocyanate 4% 3 0 0 
Dibutylphthalate 4% 3 0 0 
Dihydrocarvone 4% 2 0 1 
Dimethyltrisulfide 4% 3 0 0 
Ethanone,1-(3-methoxyphenyl)- 4% 3 0 0 
Eucalyptol 4% 2 1 0 
Eugenol 4% 2 1 0 
α-Terpineol 4% 0 1 2 
(E)-p-2-Menthen-1-ol 3% 2 0 0 
1,3,8-p-Menthatriene 3% 2 0 0 
1-Dodecanol 3% 2 0 0 
2-Nonenal,(E)- 3% 2 0 0 
3,5-di-tert-Butyl-4-hydroxybenzaldehyde 3% 1 1 0 
3-Ethylcyclopentanone 3% 2 0 0 
Benzene,-(1-formylethyl)- 3% 0 1 1 
Benzene,(3-methyl-2-butenyl)- 3% 2 0 0 
Benzeneacetaldehyde 3% 1 0 1 
Benzenemethanol,α,α,4-trimethyl- 3% 2 0 0 
Ethanone,1-(2-hydroxyphenyl)- 3% 0 1 1 
Ethanone,1-(4-methylphenyl)- 3% 2 0 0 
Isobornylacetate 3% 0 1 1 
p-Chloroaniline 3% 0 0 2 
Phenol,2,5-dichloro- 3% 1 0 1 
β-Thujene 3% 2 0 0 
(3E,5Z)-1,3,5-Undecatriene 1% 1 0 0 
1-Butene,4-isothiocyanato- 1% 0 1 0 
p-Mentha-1,8-dien-7-ol 1% 1 0 0 
1-Octanol 1% 1 0 0 
1-Undecanol 1% 1 0 0 
2,3-Dehydro-1,8-cineole 1% 1 0 0 
2,3-Octanedione 1% 1 0 0 
2,4-Cycloheptadien-1-one,2,6,6-trimethyl- 1% 0 0 1 
3-Allyl-6-methoxyphenol 1% 1 0 0 
3-Heptanone,6-methyl- 1% 1 0 0 
3-Nonen-2-one 1% 0 1 0 
3-Octen-2-one 1% 0 0 1 
4'-(2-Methylpropyl)acetophenone 1% 1 0 0 
4-Hepten-3-one,4-methyl- 1% 0 1 0 
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Acetone 1% 0 1 0 
Benzaldehyde,3-chloro- 1% 0 0 1 
Benzaldehyde,4-chloro- 1% 0 0 1 
Benzenamine,2,6-dimethyl- 1% 0 0 1 
Benzenamine,4-chloro-2-(trifluoromethyl)- 1% 0 0 1 
Benzene,(2-isothiocyanatoethyl)- 1% 0 1 0 
Benzene,1-(1,5-dimethyl-4-hexenyl)-4-
methyl- 1% 0 1 0 
Benzene,1-methyl-2-(1-methylethyl)- 1% 1 0 0 
Benzene,1-pentenyl- 1% 1 0 0 
Benzene,4-ethyl-1,2-dimethyl- 1% 0 0 1 
BenzoicAcid 1% 1 0 0 
Benzoicacid,2-amino-,methylester 1% 0 0 1 
BenzylAlcohol 1% 0 1 0 
cis-β-Terpineol 1% 1 0 0 
Cyclodecane 1% 1 0 0 
Cyclopentane,(methylthio)- 1% 1 0 0 
Cyclotetradecane 1% 0 0 1 
DiethylPhthalate 1% 1 0 0 
Dimethylsulfone 1% 1 0 0 
Diphenylamine 1% 1 0 0 
E-2-Tetradecen-1-ol 1% 0 1 0 
Ethanone,1-(4-chlorophenyl)- 1% 0 0 1 
Heptadecane 1% 1 0 0 
Hexadecane 1% 1 0 0 
IsopropylPalmitate 1% 0 0 1 
Naphthalene,2,3-dimethyl- 1% 0 1 0 
Naphthalene,2-methyl- 1% 0 1 0 
Nonanoicacid 1% 0 1 0 
Phenol,2-methoxy- 1% 0 1 0 
Phenol,2-methyl-5-(1-methylethyl) 1% 1 0 0 
Phenol,4-ethyl-2-methoxy- 1% 1 0 0 
Pulegone 1% 1 0 0 
Thymol 1% 1 0 0 
Toluene 1% 0 0 1 
trans-p-Mentha-2,8-dienol 1% 1 0 0 
α-Cedrene 1% 1 0 0 
α-Cedreneoxide 1% 1 0 0 
α-Cubebene 1% 0 1 0 
β-Phellandrene 1% 1 0 0 
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The chi-square significance test was performed on the frequency of occurrences of each 
of the volatile compounds extracted from the headspace above the collected biological 
specimen samples across the three population subgroups of interest. The chi-square test 
was used to test whether the observed frequencies of occurrence (proportions of the 
compound occurrence within the subgroup) differ significantly from those which would 
be expected on the null hypothesis. The null hypothesis (H0) in this case is that there is no 
significant difference in the proportion of the volatile compound subjected to the chi-
square test between the compared population subgroups. The alternate hypothesis (Ha) is 
that the population subgroups do not have the same proportions of the volatile 
compounds subjected to the chi-square test (statistically significantly different). The chi-
square equation for two-way tables is as follows: 
  Equation 6 
Table 67 to Table 71 list the compounds that were found to be different (p<0.05) between 
the healthy, diabetic, and depressed subgroups on the basis of results of chi-square tests. 
At a 95% confidence interval and two degrees of freedom, compounds with a chi-square 
value of greater than 5.99 was assumed to be significant in the proportion of that 
particular compound being present in a given specimen across the three subgroups. For 
the five biological specimens studied, the number of compounds that were assumed to be 
significantly different between three subgroups was as follows: fifteen for hand odor, 
fourty-seven for buccal swabs, twenty-nine for both breath and blood, and twenty-seven 
for urine. It should be noted that the frequency differences in majority of the compounds 
227 
 
listed in Table 62 through Table 66 are not statistically significant and therefore will not 
be used for future studies.  
Performing the chi-square test to the data obtained through the present study is a way of 
data mining in order to reduce the data volume for further future statistical analyses. The 
greater the dataset size, the greater the probability of encountering errors, where a greater 
number of compounds will be found to be significantly different by chance. Therefore, by 
reducing the dataset size, the chances of error can thereby be reduced also. The reduced 
dataset obtained from the chi-square test will be utilized in the future statistical analyses 
using principal component analysis and discriminant analysis, in an attempt to identify 
any potential biomarker that would eventually help in identifying the difference in the 
VOC profiles of the samples collected from the different population subgroups.  
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Table 67. Occurrences of 15 VOCs with significant difference between population 
subgroups for hand odor through the chi-square test (p=0.05, dF=2) 
 
Healthy T2DB MDD Healthy T2DB MDD
Undecanal 30 7 10 31 19 20 12.61
Octadecane 18 11 17 31 19 20 9.27
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 23 9 12 31 19 20 10.53
Tridecane 22 9 12 31 19 20 11.08
Undecane 15 11 12 31 19 20 14.83
Dodecane 14 5 7 31 19 20 28.09
BenzylAlcohol 13 2 5 31 19 20 36.91
Dodecanal 10 2 4 31 19 20 42.24
1,6-Octadien-3-ol,3,7-dimethyl- 7 1 3 31 19 20 50.08
1-Hexanol,2-ethyl- 6 2 3 31 19 20 49.82
Dodecanoicacid,methylester 3 4 3 31 19 20 51.58
2-Nonenal,(E)- 3 4 1 31 19 20 55.18
Acetophenone 3 3 2 31 19 20 54.96
Benzaldehyde 4 1 2 31 19 20 56.77
Octanoicacid,methylester 2 1 1 31 19 20 62.23
Compound Name
Observed Expected
χ2 value
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Table 68. Occurrences of 47 VOCs with significant difference between population 
subgroups for buccal swab through the chi-square test (p=0.05, dF=2) 
 
Healthy T2DB MDD Healthy T2DB MDD
6-Dodecanone 24 14 11 30 19 20 6.57
2-Nonenal,(E)- 25 6 13 30 19 20 12.18
Hexadecanoicacid,ethylester 20 10 13 30 19 20 10.05
Tetradecanoicacid,ethylester 20 11 12 30 19 20 9.90
1-Tetradecene 17 13 12 30 19 20 10.73
1,1'-Biphenyl,2,2'-diethyl- 13 11 15 30 19 20 14.25
Octanoicacid,ethylester 19 7 9 30 19 20 17.66
6-Methyl-3,5-heptadiene-2-one 10 10 10 30 19 20 22.60
Hexanoicacid,ethylester 20 3 6 30 19 20 26.61
1-Dodecene 13 6 9 30 19 20 24.58
1-Decene 8 11 8 30 19 20 26.70
Tetradecane 10 10 7 30 19 20 26.05
Benzaldehyde 12 8 5 30 19 20 28.42
Hexanal 18 1 5 30 19 20 33.10
Naphthalene,1-methyl- 14 2 6 30 19 20 33.54
Hexanoicacid,pentylester 13 2 6 30 19 20 34.64
Naphthalene,2-methyl- 12 4 4 30 19 20 35.44
2-Tetradecene,(E)- 7 4 6 30 19 20 39.28
Dodecanoicacid 7 5 5 30 19 20 39.20
Heptanoicacid 1 8 8 30 19 20 41.60
Heptanoicacid,ethylester 8 3 6 30 19 20 39.41
1,1'-Biphenyl,4-methyl- 2 6 8 30 19 20 42.23
1-Hexanol 7 6 3 30 19 20 40.98
2-Octenoicacid 9 4 3 30 19 20 40.99
Dibutanoylmorphine 11 2 2 30 19 20 43.44
Pentanoicacid 5 3 7 30 19 20 42.76
Decanoicacid,ethylester 6 3 5 30 19 20 43.92
DiethylPhthalate 9 3 2 30 19 20 44.37
Linalool Oxide 11 1 2 30 19 20 45.29
Pentadecanoicacid,ethylester 7 2 5 30 19 20 44.09
Naphthalene,2,7-dimethyl- 6 3 4 30 19 20 45.47
Furfural 8 1 3 30 19 20 47.64
1-Octanol 9 1 1 30 19 20 49.80
Hexadecane 6 1 4 30 19 20 49.05
2(3H)-Furanone,5-ethyldihydro- 3 5 2 30 19 20 50.82
2(3H)-Furanone,dihydro-5-pentyl- 3 5 2 30 19 20 50.82
Acetophenone 3 3 4 30 19 20 50.57
Phenol 2 4 4 30 19 20 50.78
Benzene,1-methyl-2-[(4-methylphenyl)methyl]- 3 4 2 30 19 20 52.34
Benzothiazole 3 4 2 30 19 20 52.34
Caryophyllene 5 3 1 30 19 20 52.36
2,5-Cyclohexadiene-1,4-dione,2,6-bis(1,1-dimethylethyl)- 4 1 3 30 19 20 54.04
E-11-Hexadecenoicacid,ethylester 2 1 5 30 19 20 54.44
IsopropylPalmitate 2 1 2 30 19 20 59.39
ButylatedHydroxytoluene 1 2 1 30 19 20 61.29
Hexadecanoicacid,methylester 1 2 1 30 19 20 61.29
Tributylphosphate 1 1 1 30 19 20 63.14
χ2 valueCompound Name
Observed Expected
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Table 69. Occurrences of 29 VOCs with significant difference between population 
subgroups for breath through the chi-square test (p=0.05, dF=2) 
 
Healthy T2DB MDD Healthy T2DB MDD
Benzophenone 29 10 14 31 19 20 6.19
Benzene,1,2-dichloro- 25 10 16 31 19 20 6.22
Styrene 29 6 11 31 19 20 13.07
ButylatedHydroxytoluene 24 6 12 31 19 20 13.68
Dodecane 13 13 13 31 19 20 14.80
Tetradecane 11 13 13 31 19 20 17.25
Tridecane 10 13 12 31 19 20 19.32
Undecane 13 10 12 31 19 20 17.91
Phenol 18 3 12 31 19 20 22.13
Toluene 8 6 7 31 19 20 34.41
Undecanal 9 4 5 31 19 20 38.71
Benzene,1,3,5-trimethyl- 4 6 7 31 19 20 40.86
2,6-Diisopropylnaphthalene 13 2 1 31 19 20 43.71
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 9 1 4 31 19 20 45.47
p-Benzoquinone 1 6 5 31 19 20 49.18
Benzene,4-ethyl-1,2-dimethyl- 2 5 5 31 19 20 48.69
Dodecanal 8 1 3 31 19 20 48.57
Naphthalene 5 3 2 31 19 20 51.48
Benzene,1,2,3-trimethyl- 2 2 5 31 19 20 53.59
Benzene,1-ethyl-2,4-dimethyl- 1 2 5 31 19 20 55.49
Benzene,1-ethyl-2-methyl- 1 2 4 31 19 20 57.04
Diisopropylnaphthalene 4 2 1 31 19 20 56.78
Limonene 1 2 3 31 19 20 58.69
Naphthalene,2-methyl- 1 1 4 31 19 20 58.88
1,3,5,7-Cyclooctatetraene 1 3 1 31 19 20 60.56
Benzene,1,4-dichloro- 3 1 1 31 19 20 60.39
DiethylPhthalate 1 1 2 31 19 20 62.28
2-Propanol,1-propoxy- 1 1 1 31 19 20 64.13
Benzene,1-methyl-4-(1-methylpropyl)- 1 1 1 31 19 20 64.13
Compound Name
Observed Expected
χ2 value
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Table 70. Occurrences of 29 VOCs with significant difference between population 
subgroups for blood through the chi-square test (p=0.05, dF=2) 
 
Healthy T2DB MDD Healthy T2DB MDD
Heptadecane 22 12 14 31 19 20 6.99
BenzylAlcohol 25 6 11 31 19 20 14.11
Diisopropylnaphthalene 19 7 14 31 19 20 14.02
Furan,2-butyltetrahydro- 23 9 7 31 19 20 15.78
Furan,2-pentyl- 20 6 7 31 19 20 21.25
Decanal 15 9 7 31 19 20 21.97
1-Dodecene 18 6 5 31 19 20 25.60
Cyclohexanone 19 3 7 31 19 20 26.57
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- 14 4 8 31 19 20 28.36
2-Dodecene,(Z)- 12 6 7 31 19 20 28.99
Longifolene 6 8 9 31 19 20 32.58
1-Decene 7 8 7 31 19 20 33.40
1-Octen-3-ol 8 9 5 31 19 20 33.58
2-Undecanone 11 3 7 31 19 20 34.83
Benzene,1,2-dichloro- 12 5 3 31 19 20 36.41
Octadecane 6 6 8 31 19 20 36.26
1-Pentanol 12 2 4 31 19 20 39.66
2-Heptanone 8 2 5 31 19 20 43.53
Heptanal 5 4 5 31 19 20 44.90
Cyclododecane 10 2 1 31 19 20 47.49
1-Dodecanol 5 4 3 31 19 20 48.10
Benzene,4-ethyl-1,2-dimethyl- 1 1 8 31 19 20 53.28
Naphthalene 1 6 3 31 19 20 52.38
Xylenes 3 2 4 31 19 20 53.30
4-Cyanocyclohexene 2 3 3 31 19 20 55.05
2-Propanol,1-propoxy- 1 3 2 31 19 20 58.71
Benzene,1,4-dichloro- 4 1 1 31 19 20 58.62
Ethanol,2-butoxy- 3 1 1 31 19 20 60.39
1,1'-Biphenyl,2-methyl- 1 1 1 31 19 20 64.13
Compound Name
Observed Expected
χ2 value
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Table 71. Occurrences of 27 VOCs with significant difference between population 
subgroups for urine through the chi-square test (p=0.05, dF=2) 
 
 
 
 
 
  
Healthy T2DB MDD Healthy T2DB MDD
Carvone 21 7 11 31 19 20 14.85
Nonanal 13 11 12 31 19 20 17.02
Cedrol 6 11 14 31 19 20 25.33
Menthol 12 8 10 31 19 20 23.01
Pyrrole 16 2 4 31 19 20 35.27
Benzene,1-methyl-4-(1-methylethenyl)- 10 4 5 31 19 20 37.32
4-Terpineol 8 5 3 31 19 20 41.83
2-Isopropylbenzaldehyde 7 3 5 31 19 20 43.30
Benzaldehyde,3,5-dimethyl- 7 2 4 31 19 20 46.59
Decanal 5 4 4 31 19 20 46.45
2-Pentanone 3 4 5 31 19 20 48.38
p-Cresol 5 2 5 31 19 20 48.27
γ-Terpinene 7 3 1 31 19 20 50.10
Benzaldehyde 4 4 2 31 19 20 51.56
Benzene,1,2-dichloro- 7 1 2 31 19 20 51.83
Benzophenone 7 1 2 31 19 20 51.83
Benzene,1-methyl-4-(1-methylethyl)- 5 3 1 31 19 20 53.33
α-Terpinene 5 2 1 31 19 20 55.07
p-Menth-1-en-3-one 4 2 2 31 19 20 54.93
Butanoicacid,butylester 1 5 1 31 19 20 57.40
Benzene,1-methyl-3-(1-methylethyl)- 2 1 2 31 19 20 60.38
2-Methoxy-4-vinylphenol 1 2 1 31 19 20 62.29
Benzene,1,3-dichloro- 2 1 1 31 19 20 62.23
Dibutanoylmorphine 2 1 1 31 19 20 62.23
Compound Name
Observed Expected
χ2 value
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3.7. Human Biological Specimen Compound Database 
Four hundred fifty three (453) compounds were extracted across all samples of hand 
odor, buccal swab, breath, blood, and urine from the 70 subjects (31 healthy, 19 diabetic, 
20 depressed) taken during this study. Of these 453 compounds, 111 have been omitted 
from the biological specimen database for one or more of the following reasons: 
compound identity was questionable or completely unidentifiable, compound was a 
known background compound of environment and/or collection material, compound was 
a known laboratory solvent. The remaining 342 compounds extracted and identified from 
the headspace of five biological specimen samples from all 70 subjects of this study are 
presented in Table 72. Compounds were identified by the standard mass spectrum in the 
NIST library. Where standard reference compounds were available, the compounds were 
identified by using both the standard mass spectrum in the NIST library and the 
corresponding reference standard retention time and spectrum. As noted in Table 72, 
many of the identified compounds can be attributed to exogenous sources, as the majority 
of the identified compounds are used in the flavor and fragrance industries. Common 
names for some of the compounds are given in parentheses and italicized. Many of the 
presented compounds have been previously reported to be volatile emanation compounds 
of human skin5,14,28,29,123, saliva127, breath44,48,97,128, volatile constituents of human 
blood18,62,66,67, and urine70-72. Compounds denoted by “en” are possibly endogenous 
compounds, while compounds denoted by “ex” are possibly of exogenous origin. 
Compounds denoted by “food” are known to be present in food and beverages 
(vegetables, fruits, dairy, meat, alcohol, beverages, etc.). The compounds that are denoted 
with both “en” and “ex” are compounds used in flavor and/or fragrance industry, but can 
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also be found occurring naturally in the body. However, whether those compounds are 
actually occurring naturally in the body or seem to be occurring naturally due to food 
consumption or exposure to the exogenous-origin compounds is unclear.   
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Table 72 Biological specimen compound database (Notes:*Identity verified by standard comparison; en=possibly 
endogenous; ex=probably exogenous; food=food origin) 
 
HD BS BR BL UR
(3E,5Z)-1,3,5-Undecatriene x 51447-08-6
.+/-.-4-Acetyl-1-methylcyclohexene x 6090-09-1 natural
1,1'-Biphenyl,2,2'-diethyl- x
1,1'-Biphenyl,2-ethyl- x 1812-51-7
1,1'-Biphenyl,2-methyl- x x 643-58-3
1,1'-Biphenyl,3-methyl- x x 643-93-6
1,1'-Biphenyl,4-methyl- x x x x 644-08-6 not found in nature flavor food
1,2-Benzenediol,3,5-bis(1,1-dimethylethyl)- x x 1020-31-1
1,3,5,7-Cyclooctatetraene (Annulene) x 629-20-9 fungi
1,3,8-p-Menthatriene x 21195-59-5 food flavor, chinese medicine food/ex
1,3-Cyclohexadiene,1-methyl-4-(1-methylethyl)- (α-Terpinene) x 99-86-5 plant flavor/fragrance food
1,4-Cyclohexadiene,1-methyl-4-(1-methylethyl)- (γ-Terpinene) x 99-85-4 plant oil f lavor/fragrance food/ex
1,6,10-Dodecatriene,7,11-dimethyl-3-methylene-, (Z)- ((Z)-β-Farnesene) x 28973-97-9 plant oil
1,6-Octadien-3-ol,3,7-dimethyl- (Linalool; Linalool oxide) x x x 78-70-6 plant flavor/fragrance en/food/ex
11-Octadecenoicacid,methylester x 52380-33-3
1-Butene,4-isothiocyanato- x 3386-97-8 natural, food flavor food
1-Cyclohexene-1-carboxaldehyde,2,6,6-trimethyl- ( β -Cyclocitral) x 432-25-7 natural, food flavor/fragrance ex
1-Cyclohexene-1-methanol,4-(1-methylethenyl)- (p-Mentha-1,8-dien-7-ol) x 536-59-4 plant oil f lavor/fragrance ex
1-Decene* x x x 872-05-9
1-Dodecanol* x x x 112-53-8 plant oil f lavor/fragrance; pharmaceuticals food/ex
1-Dodecene* x x x x 112-41-4 plant flavor; solvent; viscosity controlling agent ex
1-Heptadecene x 6765-39-5
1-Hexadecene x x 629-73-2
1-Hexanol* x 111-27-3 plant oil, alcohol
1-Hexanol,2-ethyl-* x x x x 104-76-7 plant ex
1-Octanol* x x x x 111-87-5 plant oil f lavor/fragrance ex
1-Octen-3-ol* x x 3391-86-4 plant oil, food en/ex
1-Pentadecene* x x 13360-61-7
1-Pentanol x x x 71-41-0 plant oil, food
1-Phenyl-2-butanone (Benzyl ethyl ketone) x x 1007-32-5
1S-α-Pinene* x 7785-26-4 turpentine flavor/fragrance
1-Tetradecene* x x x 1120-36-1
1-Undecanol x 112-42-5 plant oil
2(3H)-Furanone,5-ethyldihydro- (γ-Caprolactone) x 695-06-7 natural, insect pheromone flavor/fragrance ex
2(3H)-Furanone,dihydro-5-pentyl- (γ-Amylbutyrolactone) x 104-61-0 natural, food flavor/fragrance ex
2(3H)-Furanone,dihydro-5-propyl- (γ-Heptanolactone) x 105-21-5 natural, food flavor/fragrance ex
2,3-Dehydro-1,8-cineole x 66113-06-2 flavor
2,3-Octanedione x 585-25-1 fermentation byproduct flavor food
2,4-Cycloheptadien-1-one,2,6,6-trimethyl- (Eucarvone) x 503-93-5 natural; pheromone food
ClassCompound Name
Specimen
CAS # Natural Occurrence Use
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2,4-Nonadienal x 6750-03-4 coffee
2,4-Nonadienal,(E,E)-* x 5910-87-2 food
2,5-Cyclohexadiene-1,4-dione,2,6-bis(1,1-dimethylethyl)- (p-Benzoquinone) x x x x x 719-22-2 pharmaceutical, herbicide, cosmetics ex
2,5-Octanedione x 3214-41-3 food
2,6-Diisopropylnaphthalene* x x x 24157-81-1
2-Cyclohexen-1-ol,1-methyl-4-(1-methylethyl)-, trans- ((E)-p-2-Menthen-1-ol) x 29803-81-4
2-Cyclohexen-1-one,2-methyl-5-(1-methylethenyl)- (DL-Carvone) x 99-49-0 plant oil f lavor/fragrance food/ex
2-Cyclohexen-1-one,2-methyl-5-(1-methylethenyl)-, (S)- ((+)-Carvone) x x 2244-16-8 plant oil f lavor/fragrance food/ex
2-Cyclohexen-1-one,3-methyl-6-(1-methylethyl)- (p-Menth-1-en-3-one) x 89-81-6 plant oil f lavor/fragrance food/ex
2-Decanone* x x 693-54-9 plant oil
2-Decenal,(E)- x 3913-81-3 plant oil, food flavor/fragrance food/ex
2-Dodecenal,(E)- x 20407-84-5 plant oil, food flavor/fragrance food/ex
2-Dodecene,(Z)- x x x 7206-26-0
2-Heptanone* x x x 110-43-0 plant oil, alcohol, cheese flavor/fragrance food/ex
2-Heptanone,6-methyl- x x 928-68-7 found in nature flavor/fragrance food/ex
2-Heptenoicacid x 18999-28-5
2-Isopropylbenzaldehyde x 6502-22-3
2-Methoxy-4-vinylphenol x 7786-61-0 natural, food flavor/fragrance ex
2-Nonenal,(E)-* x x x 18829-56-6 food flavor/fragrance food/ex
2-Octenal,(E)-* x 2548-87-0 food flavor/fragrance food/ex
2-Octenoicacid x 1470-50-4
2-Pentanone* x x 107-87-9 food flavor/fragrance food/ex
2-Propanol,1-butoxy- x 5131-66-8 fragrance ex
2-Propanol,1-propoxy- x x x 1569-01-3 fragrance ex
2-Propenal,3-phenyl- (Cinnamaldehyde) x 104-55-2 plant flavor/fragrance ex
2-Tetradecene,(E)- x 35953-53-8
2-Undecanone (Methyl nonyl ketone) x x 112-12-9 plant flavor/fragrance; insect /animal repellent food/ex
3,5,9-Undecatrien-2-one,6,10-dimethyl-, (E,Z)- ((E,Z)-Pseudoionone) x plant flavor ex
3,5-di-tert-Butyl-4-hydroxybenzaldehyde x 1620-98-0
3,7-Dimethyl-octa-1,6-diene (Dyhydromyrcene) x x x 2436-90-0 plant fragrance food/ex
3-Allyl-6-methoxyphenol x 501-19-9
3-Cyclohexen-1-ol,4-methyl-1-(1-methylethyl)- (4-Terpineol) x 562-74-3 plant oil f lavor/fragrance food/ex
3-Cyclohexen-1-ol,4-methyl-1-(1-methylethyl)-, (R)- ((-)-4-Terpineol) x 20126-76-5
3-Cyclohexen-1-one2-isopropyl-5-methyl- x food additive food
3-Cyclohexene-1-methanol,α,α,4-trimethyl-, (S)- (α-Terpineol) x 98-55-5 plant oil/fruits flavor/fragrance en/food/ex
3-Dodecene,(Z)- x x 7239-23-8
3-Eicosene,(E)- x 74685-33-9
3-Ethylcycl opentanone x 10264-55-8 urine
3-Heptadecene,(Z)- x
3-Heptanone* x x x 106-35-4 natural flavor/fragrance
3-Heptanone,6-methyl- x 624-42-0 pheromone, urine
3-Isopropylbenzaldehyde x x 34246-57-6
3-Nonen-2-one x x 14309-57-0 natural flavor/fragrance
3-Octanol,3,7-dimethyl-,(.+/-.)- x 57706-88-4 synthetic flavor/fragrance ex
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3-Octen-2-one x 1669-44-9 natural cigarette ingredient; f lavor/fragrance ex
4'-(2-Methylpropyl)acetophenone x 38861-78-8 Ibuprofen related food
4,8-Dimethyl-nona-3,8-dien-2-one (Citrinone) x 817-88-9 not found in nature flavor
4-Cyanocycl ohexene x x x 100-45-8 en/ex
4-Heptanone (GBL)* x x x 123-19-3 food flavor/fragrance food/ex
4-Nonylphenol x 104-40-5 synthetic,  sewage ex
4-tert-Butylcyclohexylacetate x 32210-23-4 synthetic fragrance ex
5,9-Undecadien-2-one,6,10-dimethyl- (Geranyl acetone)* x x 689-67-8 plant oil f lavor/fragrance food/ex
5,9-Undecadien-2-one,6,10-dimethyl-, (E)- (trans-Geranyl acetone)* x x x x x 3796-70-1 plant fragrance food/ex
5,9-Undecadien-2-one,6,10-dimethyl-, (Z)- (Neryl acetone)* x 3879-26-3 coffee flavor/fragrance food
5-Dodecene,(E)- x 7206-16-8
5-Hepten-2-one,6-methyl- (Sulcaatone)* x x x 110-93-0 natural, pheromone
6-Dodecanone x 6064-27-3
6-Methyl-3,5-heptadiene-2-one x 1604-28-0 plant oil, plant flavor/fragrance en/food/ex
7-Hexadecene,(Z)- x 35507-09-6
9-Octadecenoicacid,(E)- x 112-79-8
Aceticacid x x 64-19-7 plant flavor en/food/ex
Aceticacid,butylester x 123-86-4 food flavor/fragrance (cosmetic solvent) food/ex
Acetone x x x x 67-64-1 plant oil, food flavor, extraction solvent en/food/ex
Acetophenone* x x x x 98-86-2 plant oil, food flavor/fragrance food/ex
AllylIsothiocyanate x 57-06-7 plant oil food
Azulene x x 275-51-4
Benzaldehyde* x x x x x 100-52-7 plant oil, food flavor/fragrance en/food/ex
Benzaldehyde,2,4,5-trimethyl- (Duraldehyde) x x 5779-72-6
Benzaldehyde,2,4,6-trimethyl- (Mesitaldehyde) x x 487-68-3
Benzaldehyde,2-hydroxy-  (Salicylaldehyde) x 90-02-8 plant oil f lavor/fragrance ex
Benzaldehyde,3,5-dimethyl- x 5779-95-3
Benzaldehyde,3-chloro- x 587-04-2
Benzaldehyde,3-hydroxy- x x 100-83-4
Benzaldehyde,4-(1-methylethyl)- (p-Cumic aldehyde) x 122-03-2 plant oil f lavor/fragrance ex
Benzaldehyde,4-(methylthio)- x x 3446-89-7 intermediate (pharmaceuticals, pesticides) ex
Benzaldehyde,4-chloro- x 104-88-1
Benzaldehyde,4-methoxy- x 123-11-5 plant oil, plant flavor/fragrance food/ex
Benzaldehyde,ethyl - x 53951-50-1
Benzenamine,2,6-dimethyl- x 87-62-7 synthesis of lidocane ex
Benzenamine,4-chloro-2-(trif luoromethyl)- x 445-03-4 dye ex
Benzene,(1-formylethyl)- (Cumene aldehyde) x 93-53-8 not found in nature flavor/fragrance ex
Benzene,(1-methylethyl )- (Cumene) x 98-82-8 crude oil; refined fuels varnish, cement, primer, auto product ex
Benzene,(2-isothiocyanatoethyl)- x 2257-09-2 food flavor food
Benzene,(3-methyl-2-butenyl)- x 4489-84-3
Benzene,1-(1,5-dimethyl-4-hexenyl)-4-methyl- x 644-30-4 plant oil f lavor/fragrance
Benzene,1,1'-methylenebis[4-methyl- (α-Curcumene) x 4957-14-6
Benzene,1,2,3,4-tetramethyl- (Prehnitene) x x 488-23-3
Benzene,1,2,3,5-tetramethyl- (Isodurene) x x x 527-53-7
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Benzene,1,2,3-trimethyl- x x 526-73-8
Benzene,1,2,4,5-tetramethyl- (Durene)* x x x 95-93-2 natural ex
Benzene,1,2,4-trimethyl- (ψ-Cumene) x 95-63-6 fragrance
Benzene,1,2-dichloro-* x x x x 95-50-1
Benzene,1,3,5-trimethyl- (Mesitylene) x x 108-67-8 fragrance ex
Benzene,1,3-dichloro- x x x x 541-73-1
Benzene,1,3-diethyl-5-methyl- x 2050-24-0
Benzene,1,3-dimethyl- (m-Xylene)* x x x 108-38-3
Benzene,1,3-dimethyl-5-(1-methylethyl)- x 4706-90-5
Benzene,1,4-dichloro- x x x x 106-46-7
Benzene,1-ethyl-2,3-dimethyl- x x x 933-98-2
Benzene,1-ethyl-2,4-dimethyl- x x 874-41-9
Benzene,1-ethyl-2-methyl- x x 611-14-3
Benzene,1-ethyl-3,5-dimethyl- x x 934-74-7
Benzene,1-ethyl-3-methyl- x x 620-14-4
Benzene,1-methyl-2-(1-methylethyl)- x x 527-84-4
Benzene,1-methyl-2-[(3-methylphenyl)methyl]- x 21895-13-6
Benzene,1-methyl-2-[(4-methylphenyl)methyl]- x 21895-17-0
Benzene,1-methyl-3-(1-methylethyl)- (β-Cymene) x x 535-77-3 species pheromone
Benzene,1-methyl-3-propyl- x x x 1074-43-7
Benzene,1-methyl-4-(1-methylethenyl)- (α,p-Dimethylstyrene) x 1195-32-0 plant oil f lavor/fragrance food/ex
Benzene,1-methyl-4-(1-methylethyl)- (p-Cymene) x x x 99-87-6 plant oil f lavor/fragrance ex
Benzene,1-methyl-4-(1-methylpropyl)- x x x 1595-16-0
Benzene,1-methyl-4-nitro- x 99-99-0
Benzene,1-methyl-4-propyl- x 1074-55-1
Benzene,1-pentenyl- x 826-18-6
Benzene,2,4-dimethyl-1-(1-methylethyl)- x 4706-89-2
Benzene,2-ethyl-1,3-dimethyl- x 2870-04-4
Benzene,2-ethyl-1,4-dimethyl- x x 1758-88-9
Benzene,3-cycl ohexen-1-yl- x 4994-16-5
Benzene,4-ethyl-1,2-dimethyl- x x x x 934-80-5
Benzene,diethyl - x x x 25340-17-4 not found in nature fragrance ex
Benzene,pentamethyl - x 700-12-6
Benzene,propyl-* x 103-65-1
Benzeneacetaldehyde x 122-78-1 plant oil f lavor/fragrance ex
Benzeneacetaldehyde,α-methyl - (Cumene aldehyde) x 93-53-8 not found in nature flavor/fragrance ex
Benzeneethanol,2-methyl- 19819-98-8 not found in nature fragrance ex
Benzenemethanol,α,α,4-trimethyl- (p-Cymenol) x 1197-01-9 plant oil f lavor/fragrance food/ex
Benzenemethanol,α,α-dimethyl- (α-Cumyl alcohol) x x 617-94-7 cocoa flavor/fragrance ex
BenzoicAcid x 65-85-0 plant food preservative; antimicrobial food
Benzoicacid,2-amino-,methylester x 134-20-3 plant oil f lavor/fragrance, bird repellant for plants ex
Benzophenone* x x x x x 119-61-9 plant photo-initiator, UV blocker food/ex
Benzothiazole x 95-16-9 plant oil f lavor/pharmaceuticals ex
BenzylAlcohol* x x x 100-51-6 plants, plant oil f lavor/fragrance, preservative, solvent food/ex
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Bicycl o[3.1.0]hex-2-ene,4-methyl-1-(1-methylethyl)- (β-Thujene) x 28634-89-1 plant oil food
Butanoicacid,butylester x 109-21-7 fruits flavor/fragrance food/ex
ButylatedHydroxytoluene* x x x 128-37-0 antioxidant additive, preservative food/ex
Calamenene x 483-77-2 plant oil food
Caryophyllene* x x 87-44-5 plant oil f lavor/fragrance food
Cedrol x x 77-53-2 plant oil f lavor/fragrance en/ex
cis-β-Terpineol x 7299-40-3
Cyclodecane x x x x 293-96-9
Cyclododecane x x x x 294-62-2 not found in nature intermediate, volatile binding media ex
Cycl ohexadecane x 295-65-8
Cycl ohexane,methyl - x 108-87-2 organic solvent, jet fuel ex
Cyclohexane,pentyl- x 4292-92-6
Cyclohexanol,5-methyl-2-(1-methylethyl)-, (1α,2β,5α)- (DL-Menthol)* x x x x x 89-78-1 not found in nature flavor/fragrance food/ex
Cyclohexanol,5-methyl-2-(1-methylethyl)-, (1α,2β,5α)-(.+/-.)- (DL-Menthol)* x x x x 15356-70-4 not found in nature flavor/fragrance food/ex
Cyclohexanol,5-methyl-2-(1-methylethyl)-, [1R-(1α,2β,5α)]- ((-)-Menthol) x x x x 2216-51-5 plant oil f lavor/fragrance food/ex
Cyclohexanol,5-methyl-2-(1-methylethyl)-, [1S-(1α,2α,5β)]- (Menthol) x x x 2216-52-6 not found in nature flavor/fragrance food/ex
Cyclohexanol,5-methyl-2-(1-methylethyl)-, [1S-(1α,2β,5α)]- ((+)-Menthol) x not found in nature flavor/fragrance food/ex
Cyclohexanol,5-methyl-2-(1-methylethyl)-, [1S-(1α,2β,5β)]- (Menthol) x 23283-97-8 not found in nature flavor/fragrance food/ex
Cyclohexanone* x x 108-94-1 plant oil precursor to nylon ex
Cyclohexanone,2-methyl-5-(1-methylethenyl)- (Dihydrocarvone) x 7764-50-3 plant oil f lavor/fragrance food/ex
Cyclohexanone,2-methyl-5-(1-methylethenyl)-, trans- (trans-Dihydrocarvone) x 5948-04-9 plant oil
Cyclohexanone,5-methyl-2-(1-methylethyl)- (p-Menthan-3-one) x 10458-14-7 plant oil fragrance ex
Cyclohexanone,5-methyl-2-(1-methylethyl)-, cis- (cis-p-Menthan-3-one) x 491-07-6 plant oil fragrance ex
Cyclohexanone,5-methyl-2-(1-methylethyl)-, trans- (trans-p-Menthan-3-one) x x 89-80-5 plant oil fragrance ex
Cyclohexene,1-methyl-4-(1-methylethenyl)-, (.+/-.)- (DL-Limonene)* x x x 138-86-3 plant oil/fruits flavor/fragrance food/ex
Cyclooctane x x 292-64-8
Cyclopentane,(methylthio)- x 7133-36-0
Cyclopropane,isothiocyanato- x 56601-42-4
Cyclopropane,nonyl- x x x 74663-85-7
Cycl otetradecane x x x 295-17-0 
Decanal* x x x x x 112-31-2 plant oil, fruits flavor/fragrance en/food/ex
Decane x 124-18-5 natural solvent/diluent; fragrance food/ex
Decane,2-methyl - x 6975-98-0 plant species
Decane,3-methyl - x 13151-34-3
Decanoicacid,ethylester* x 110-38-3 plant oil f lavor/fragrance ex
Dibutanoylmorphine x x 66641-03-0 synthetic diester of morphine
Dibutylphthalate x x 84-74-2 plant oil solvent/diluent for f lavor/fragrance agents ex
DiethylPhthalate x x x 84-66-2 not found in nature solvent (cosmetics); plasticizer ex
Diisopropylnaphthalene x x x 38640-62-9
Dimethylsulfone x x x 67-71-0 plant food; solvent en/food/ex
Dimethyltrisulfide* x 3658-80-8 food flavor/fragrance food
Diphenylamine* x 122-39-4 natural, species pheromone scald-inhibitant for apples
Docosane* x 629-97-0 plant oil fragrance ex
Dodecanal* x x x 112-54-9 plant oil f lavor/fragrance ex
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Dodecane* x x x 112-40-3 plant oil, food solvent/diluent; fragrance ex
Dodecane,1-chloro- x 112-52-7
Dodecane,2,6,10-trimethyl- x 3891-98-3
Dodecanoicacid* x x x 143-07-7 plant oil, human milk en
Dodecanoicacid,ethylester x 106-33-2 plant oil, alcohol flavor/fragrance ex
Dodecanoicacid,methylester* x x x 111-82-0 natural; food flavor/fragrance ex
Eicosane* x x 112-95-8 plant oil fragrance ex
Ethanol,2-butoxy- x x 111-76-2 cheese sanitizing agent, solvent (cosmetics) ex
Ethanol,2-phenoxy- x 122-99-6 plant preservative (flavor/fragrance) food/ex
Ethanone,1-(2-hydroxyphenyl)- x 118-93-4 food flavor/fragrance food
Ethanone,1-(3-methoxyphenyl)- x 586-37-8 plant oil f lavor/fragrance food/ex
Ethanone,1-(4-chlorophenyl)- x 99-91-2
Ethanone,1-(4-methylphenyl)- x 122-00-9 plant oil, food flavor/fragrance food/ex
Ethyl9-hexadecenoate x 54546-22-4 species pheromone
Ethyltridecanoate x 28267-29-0
Eucalyptol x 470-82-6 plant oil f lavor/fragrance ex
Eugenol x 97-53-0 plant oil f lavor/fragrance
Furan,2-butyltetrahydro- x x 1004-29-1 not found in nature flavor
Furan,2-pentyl-* x x x 3777-69-3 natural; food flavor/fragrance ex
Furfural* x 98-01-1 plant oil f lavor, solvent (cosmetics) ex
Galaxolide x x 1222-05-5 not found in nature fragrance ex
Heneicosane* x 629-94-7 plant oil fragrance ex
Heptadecane* x x x x x 629-78-7 plant oil fragrance food/ex
Heptadecane,9-oct yl - x x 7225-64-1 plant oil food
Heptanal* x x 111-71-7 fruits, food flavor/fragrance food/ex
Heptanoicacid* x 111-14-8 fruits, alcohol flavor/fragrance, cigarette additive food/ex
Heptanoicacid,ethylester* x 106-30-9 food, alcohol flavor/fragrance food/ex
Heptanol* x x 111-70-6 food, alcohol flavor/fragrance food/ex
Hexadecane* x x x x x 544-76-3 plant oil fragrance food/ex
Hexadecanoicacid,ethylester (Ethyl palmitate) x 628-97-7 plant oil, rice, vanilla flavor/fragrance ex
Hexadecanoicacid,methylester (Methyl palmitate) x 112-39-0 plant oil f lavor/fragrance ex
Hexanal* x x x x 66-25-1 plant oil, food flavor/fragrance food/ex
Hexanedioicacid,bis(1-methylethyl ) ester (Diisopropyl adipate) x x 230-072-0 not found in nature solvent for f lavor/fragrance agents ex
Hexanoicacid* x x 142-62-1 plant oil, food flavor/fragrance food/ex
Hexanoicacid,anhydride x 2051-49-2
Hexanoicacid,ethylester x 123-66-0 fruits, food flavor/fragrance food/ex
Hexanoicacid,pentylester x 540-07-8 fruits, cheese flavor/fragrance food/ex
Hexanoicacid,propylester x 626-77-7 food, alcohol flavor/fragrance food
Hexatriacontane x 630-06-8 ex
Homomenthylsalicylate x x 52253-93-7 not found in nature UV adsorbing agent (sunscreen) ex
Indole x 120-72-9 plant oil, food flavor/fragrance ex
Indolizine x 274-40-8
Isobornylacetate x x 125-12-2 plant oil f lavor/fragrance food/ex
IsopropylMyristate x x x 110-27-0 plant oil solvent/diluent for f lavor/fragrance agents food/ex
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IsopropylPalmitate x x x 142-91-6 not found in nature solvent/diluent for f lavor/fragrance agents ex
Lilial x 80-54-6 not found in nature fragrance ex
Longicycl ene x 1137-12-8 plant oil ex
Longifolene x x x 475-20-7 plant oil f lavor/fragrance ex
Methyldihydrojasmonate x 24851-98-7 plant flavor/fragrance ex
MethylSalicyl ate* x x 119-36-8 plant oil, fruits flavor/fragrance, aspirin food/ex
N,N-Diethylcarbanilide (Ethyl centralite) x 85-98-3 celluloid plasticizer, explosives stabilizer ex
Naphthalene* x x x 91-20-3 natural
Naphthalene,1,6-dimethyl- x 575-43-9
Naphthalene,1,7-dimethyl- x 575-37-1
Naphthalene,1-methyl-* x x 90-12-0 food flavor food
Naphthalene,2,3,6-trimethyl- x x 829-26-5
Naphthalene,2,3-dimethyl- x x 581-40-8
Naphthalene,2,6-dimethyl- x x 581-42-0
Naphthalene,2,7-dimethyl- x x 582-16-1
Naphthalene,2-methyl- x x x x 91-57-6 plant/fruits flavor/fragrance ex
n-Decanoicacid* x 334-48-5 plant oil, food, mamalian milk flavor/fragrance, food additive, phamaceuticals food/ex
n-Hexadecanoicacid* x 57-10-3 plant oil, food thickener, emulsifier,stabilizer,pharmaceuticals food/ex
Nonadecane x 629-92-5 plant fragrance food/ex
Nonadecanoicacid,ethylester x 18281-04-4 alcohol food
Nonanal* x x x x 124-19-6 plant oil, food flavor/fragrance en/food/ex
Nonane* x 111-84-2 plant oil fragrance ex
Nonane,3-methyl- x 5911-04-6
Nonanoicacid x x x 112-05-0 plant oil, fruits flavor, cosmetic (solvent, perfumery) food/ex
Nonanoicacid,ethylester* x 123-29-5 fruits, alcohol flavor/fragrance ex
Octadecanal x 638-66-4 plant oil, insect pheromone cosmetic food
Octadecane x x x 593-45-3 plant oil fragrance en/food/ex
Octanal x x x 124-13-0 plant oil, food flavor/fragrance, antimicr obial food/ex
OctanoicAcid* x 124-07-2 plant oil, fruits, mamalian milk flavor/fragrance food/ex
Octanoicacid,ethylester* x 106-32-1 fruits, alcohol flavor/fragrance food/ex
Octanoicacid,methylester x 111-11-5 plant/fruits, species pheromone flavor/fragrance food/ex
p-Chloroaniline x 106-47-8 precursor to antiseptic ex
Pentadecane* x 629-62-9 plant oil, food fragrance food/ex
Pentadecane,7-methyl - x 6165-40-8
Pentadecanoicacid,ethylester x 41114-00-5 not found in nature flavor ex
Pentanoicacid (Valeric acid)* x 109-52-4 fruits, food flavor/fragrance food/ex
Phenol* x x x x 108-95-2 plant oil plastics production, pharmaceuticals food
Phenol,2-(1,1-dimethylethyl)- x 88-18-6 fragrance ex
Phenol,2,4,6-trimethyl- (Mesitol) x x 527-60-6 not found in nature flavor/fragrance ex
Phenol,2,5-dichloro- x 583-78-8 p-dichlorobenzene metabolite
Phenol,2,6-bis(1,1-dimethylethyl)-4-ethyl- x 4130-42-1
Phenol,2-methoxy-  (o-guaiacol) x 90-05-1 food flavor/fragrance food/ex
Phenol,2-methyl-5-(1-methylethyl) (p-Cymen-2-ol) x 499-75-2 plant oil f lavor/fragrance
Phenol,4-(1,1,3,3-tetramethylbutyl)-* x 140-66-9 not found in nature adjuvant for pesticide ex
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Phenol,4-ethyl-2-methoxy- x 2785-89-9 alcohol, produced by yeast flavor/fragrance ex
Phenol,4-methyl- (p-Cresol)* x 106-44-5 plant oil, food flavor/fragrance (costmetics) en/food
Phenol,nonyl- x 25154-52-3
Propanoicacid,2-methyl-,butylester x 97-87-0 plant oil f lavor/fragrance ex
Pulegone x 15932-80-6 plant oil f lavor/fragrance food/ex
p-Xylene (Benzene,1,4-dimethyl-)* x x x 106-42-3
Pyrrole x 109-97-7 plant flavor food
Styr ene* x 100-42-5 plant, food cosmetics, plastics food/ex
Tetrachloroethylene x x 127-18-4 environmental/soil contaminant solvent; dry cleaning ex
Tetradecanal (Myristaldehyde) x x x 124-25-4 plant oil, food flavor/fragrance food/ex
Tetradecane* x x x x 629-59-4 plant, food flavor/fragrance en/food/ex
Tetradecanoicacid (Myristic acid) x 544-63-8 plant oil, food food additive; fragrance ex
Tetradecanoicacid,2-methyl -,methyl  ester x 55554-09-1
Tetradecanoicacid,ethylester x 124-06-1 food flavor/fragrance food/ex
Thymol (p-Cymen-3-ol) x 89-83-8 plant oil f lavor/fragrance; antiseptic , cigarette additive ex
Toluene x x 108-88-3 plant, plant oil solvent; antioxidant food/ex
trans-p-Mentha-2,8-dienol x
Triacetin x 102-76-1 not found in nature solvent (flavor); food additive; cigarette additive ex
Tridecane* x x x x 629-50-5 plant oil fragrance food/ex
Undecanal* x x 112-44-7 plant oil, food flavor/fragrance en/food/ex
Undecane* x x x 1120-21-4 plant oil fragrance food
Undecane,2,6-dimethyl- x 17301-23-4
ValproicAcid x 99-66-1 synthetic pharmaceutical (anticonvulsant) ex
Vanillin x 148-53-8 plant flavor/fragrance
Z-8-Hexadecene x plant
α-Cedrene x 469-61-4 plant oil f lavor/fragrance
α-Cedreneoxide x 29597-36-2 not found in nature fragrance ex
α-Cubebene x 17699-14-8 plant oil food/ex
β-Bourbonene x 5208-59-3 plant oil, species pheromone flavor/fragrance ex
β-Cadinene x 523-47-7 plant oil, plant species food
β-Damascenone x 23696-85-7 plant fragrance ex
β-Damascenone x 23726-93-4 plant/fruits flavor ex
β-Gurjunene x 17334-55-3 plant oil f lavor/fragrance
β-Maaliene x 489-29-2 plant oil f lavor/fragrance
β-Phellandrene x 555-10-2 plant oil fragrance ex
γ-Cadinene x 39029-41-9 fruits food
Δ-Cadinene x 483-76-1 plant oil food
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4. CONCLUSIONS 
The SPME-GC/MS method developed and optimized has been demonstrated to be 
capable of sampling, identifying and differentiating the VOCs present in various 
biological specimens of forensic and medical importance. While previous studies have 
generally looked at individual or pairs of biological specimens for diagnostic purposes, 
the current method allows for the direct comparison between the major samples 
consisting of hand odor, buccal swabs, breath, blood, blood, and urine taken from the 
same individuals. 
The pre-treatment method developed allowed the removal of the targeted VOCs from the 
sampling kits prior to sampling, extraction and analysis. Optimized SPME-GC/MS 
conditions yielded excellent detection limits for the VOCs from blood, breath, buccal 
cells, and urine with average limits of detection of 8.3 ng. The VOCs from breath were 
detected with the lowest limit of detection while urine samples showing the highest limit 
of detection which was four times higher than breath for breath samples. The data 
obtained using this optimized method yielded promising results as for each of the 
specimens investigated, the VOC profiles of different subjects are distinct and show 
reproducible ratios of characteristic VOCs present. Visual, spearman rank correlation, 
and PCA comparisons of the most abundant and frequent VOCs (from replicate samples 
of the same individuals) demonstrates that each specimen has characteristic VOCs and 
that within specimens there is correlation of VOCs for replicates from individuals and 
differentiation (lack of correlation) among individuals. The present method, for the first 
time, allows for a large scale study to be completed simultaneously comparing these five 
biological specimens from a larger population of individuals over an extended period of 
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time in order to evaluate the utility of these biological specimens for profiling 
(individualization) and diagnostic (disease state) purposes. 
Prior to this study, no work had been done to investigate the potential for differentiating 
people in terms of odor components other than skin emanations (mainly hand, arm, and 
armpits) on gauze. Through the combined methods of chromatogram comparison, 
Spearman rank correlation comparison, and principal component analysis, it is possible to 
distinguish the VOC profiles of individuals for each of the specimens with high 
confidence. The data obtained from this study also revealed that VOC profiles of 
different biological specimens from the same individual are too different to be used for 
the purpose of individual profiling.  
Comparison of VOC profiles of healthy individuals, patients with Type 2 diabetes, and 
patients with MDD revealed that it was possible to distinguish individuals even when 
they are diagnosed with the same physiological or psychological condition. Chi-square 
test on the preliminary comparison of VOCs present in odor profiles across the three 
populations revealed a group of volatile compounds that could be used for potential 
biomarkers to differentiate between the healthy, diabetic, and clinically depressed study 
groups.  
Finally, a human biological specimen compound database has been created compiling the 
volatile compounds present in the emanations of human hand odor, oral fluids (buccal 
cells and saliva), breath, blood, and urine. Compounds were classified as possibly 
endogenous, exogenous, originating from food and beverage sources, or a combination of 
any of the three. Majority of the volatile compounds are of plant origin and are widely 
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used in the flavor and/or fragrance industries. Because the VOCs emanated from the 
human body may be the results of exogenous VOC inhalation and/or absorption or the 
production of endogenous VOCs by the body’s metabolic processes, it is unwise to 
attempt to derive/determine the genetic basis of human odor compounds at the present 
time.  
Results from the present study all further support the individual odor hypothesis in that 
each individual possesses a scent profile that is distinguishable from others. However, 
because many of the extracted VOCs are known to be exogenous and/or from food or 
food additives while the metabolic origins of the other extracted volatile compounds 
remain unclear, individual human odor should be considered as an “extended phenotype” 
as initially mentioned in the introduction of this research study. Extended phenotype is 
most suitable to describe human odor, as variations in the volatile compounds present in 
the human odor may be due to either genetic or environmental factors or a combination 
of both.  
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APPENDICES 
Appendix A 
A1  Calibration curves for selected VOCs found in hand odor 
Figure 91. Calibration curve for furfural 
 
Figure 92. Calibration curve for 2-furanmethanol 
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Figure 93. Calibration curve for dimethyl malonate 
 
Figure 94. Calibration curve for undecane 
 
Figure 95. Calibration curve for (E)-6,10-Dimethyl-5,9-undecadien-2-one 
 
y = 39630x - 3E+06
R² = 0.998
0.0E+00
1.0E+07
2.0E+07
3.0E+07
4.0E+07
0 20 40 60 80 100
Pe
ak
 A
re
a
Mass (ng)
y = 1E+06x + 12878
R² = 0.998
0.0E+00
5.0E+07
1.0E+08
1.5E+08
0 20 40 60 80 100
Pe
ak
 A
re
a
Mass (ng)
y = 69079x - 2E+06
R² = 0.999
0.0E+00
2.0E+07
4.0E+07
6.0E+07
0 20 40 60 80 100
Pe
ak
 A
re
a
Mass (ng)
 259 
 
Figure 96. Calibration curve for dodecanoic acid 
 
 
A2   Calibration curves for selected VOCs found in buccal swab 
Figure 97. Calibration curve for hexanal 
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Figure 98. Calibration curve for hexanoic acid 
 
Figure 99. Calibration curve for acetophenone 
 
Figure 100. Calibration curve for 1-octanol 
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Figure 101. Calibration curve for octanoic acid, ethyl ester 
 
Figure 102. Calibration curve for 1-methylnaphthalene 
 
Figure 103. Calibration curve for tetradecane 
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A3  Calibration curves for selected VOCs found in breath 
Figure 104. Calibration curve for 3-heptanone 
 
Figure 105. Calibration curve for styrene 
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Figure 106. Calibration curve for phenol 
 
Figure 107. Calibration curve for nonanal 
 
Figure 108. Calibration curve for 1-methylnaphthalene 
 
y = 39899x - 87888
R² = 0.998
0.0E+00
1.0E+07
2.0E+07
3.0E+07
4.0E+07
0 20 40 60 80 100
Pe
ak
 A
re
a
Mass (ng)
y = 61168x - 1E+06
R² = 0.998
0.0E+00
2.0E+07
4.0E+07
6.0E+07
0 20 40 60 80 100
Pe
ak
 A
re
a
Mass (ng)
y = 2E+06x - 4E+06
R² = 0.996
0.0E+00
5.0E+07
1.0E+08
1.5E+08
0 20 40 60 80 100
Pe
ak
 A
re
a
Mass (ng)
 264 
 
Figure 109. Calibration curve for caryophyllene 
 
 
A4   Calibration curves for selected VOCs found in blood 
Figure 110. Calibration curve for cyclohexanone 
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Figure 111. Calibration curve for heptanal 
 
Figure 112. Calibration curve for 1-octen-3-ol 
 
Figure 113. Calibration curve for 2-pentylfuran 
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Figure 114. Calibration curve for 1-tetradecene 
 
Figure 115. Calibration curve for 2,6-diisopropylnaphthalene 
 
 
 
 
 
 
 
 
 
y = 2E+06x - 3E+06
R² = 0.999
0.0E+00
5.0E+07
1.0E+08
1.5E+08
0 20 40 60 80 100
Pe
ak
 A
re
a
Mass (ng)
y = 3E+06x - 30423
R² = 0.998
0.0E+00
9.0E+07
1.8E+08
2.7E+08
0 20 40 60 80 100
Pe
ak
 A
re
a
Mass (ng)
 267 
 
A5  Calibration curves for selected VOCs found in urine 
Figure 116. Calibration curve for 4-heptanone 
 
Figure 117. Calibration curve for dimethyl trisulfide 
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Figure 118. Calibration curve for 1,2-dichlorobenzene 
 
Figure 119. Calibration curve for linalool 
 
Figure 120. Calibration curve for (E)-2-nonenal 
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Figure 121. Calibration curve for diphenylamine 
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Appendix B 
B1  Table 73. Target ion and qualifying ions for frequently occurring hand odor 
VOCs used for identification and quantitation 
 
 
RT (min) Compound Name Target Q1 Q2 Q3 MW (g/mol)
2-Pentanone 43 86 41 58 86
6.25 Furfural 96 96 95 39 96
6.93 2-Furanmethanol 98 81 53 41 98
8.10 Heptanal 70 44 55 81 114
8.85 Propanedioicacid,dimethylester 101 59 74 42 132
9.44 Benzaldehyde 106 77 51 105 106
9.98 Phenol 94 66 65 39 94
10.06 6-Methyl-5-hepten-2-one 43 108 69 55 126
10.25 Hexanoicacid 60 73 41 87 116
10.36 Octanal 41 43 57 84 128
10.97 BenzylAlcohol 79 108 107 77 108
11.56 Acetophenone 105 77 120 51 120
12.14 Undecane 57 43 71 85 156
12.16 3,7-dimethyl-1,6-Octadien-3-ol 71 41 55 93 154
12.22 Nonanal 57 41 56 98 142
12.56 Octanoicacid,methylester 74 87 127 55 158
13.14 (E)-2-Nonenal 41 55 70 43 140
13.31 Nonanol 56 55 43 70 144
13.65 2-Decanone 58 43 71 59 156
13.75 Dodecane 57 43 71 41 170
13.85 Decanal 41 57 43 55 156
15.21 Tridecane 57 43 71 85 184
15.33 Undecanal 57 43 71 85 170
16.57 Tetradecane 57 43 71 85 198
16.70 Dodecanal 57 41 43 55 184
17.04 (Z)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
17.27 (E)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
17.74 1-Pentadecene 55 41 83 97 210
17.83 Pentadecane 57 43 71 85 212
18.65 Dodecanoic acid 73 60 43 129 200
19.02 Hexadecane 57 71 43 85 226
20.16 Heptadecane 57 43 71 85 240
23.23 Eicosane 57 71 43 85 282
24.17 Heneicosane 57 71 43 85 296
25.06 Docosane 57 71 43 281 310
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B2  Table 74. Target ion and qualifying ions for frequently occurring buccal 
swab VOCs for identification and quantitation 
 
RT (min) Compound Name Target Q1 Q2 Q3 MW (g/mol)
Aceticacid 43 45 60 42 60
Nonanoicacid 60 73 57 115 158
1-Pentanol 42 55 70 41 88
Ethanol 31 29 45 46 46
5.24 Hexanal 44 56 41 57 100
6.25 Furfural 96 96 95 39 96
7.29 1-Hexanol 56 55 43 41 102
8.46 Pentanoicacid 60 73 41 45
9.43 Benzaldehyde 106 105 77 51 106
9.95 Phenol 94 66 65 95 94
10.12 2-Pentylfuran 81 82 138 53 138
10.13 1-Decene 56 55 41 70 140
10.4 Hexanoicacid 60 73 41 87 116
11.41 (E)-2-Octenal 55 57 70 83 126
11.57 Acetophenone 105 77 120 51 120
11.66 1-Octanol 56 55 41 69 130
12.07 Heptanoicacid 60 73 43 41 130
12.13 Heptanoicacid,ethylester 88 43 113 60 158
13.14 (E)-2-Nonenal 41 55 70 43 140
13.41 Menthol 71 81 95 41 156
13.55 OctanoicAcid 60 73 55 144 144
13.63 1-Dodecene 55 41 69 56 168
13.72 Octanoicacid,ethylester 88 101 127 57 172
13.86 Decanal 41 57 43 55 156
13.99 (E,E)-2,4-Nonadienal 81 41 67 138 138
15.18 Nonanoicacid,ethylester 88 101 141 41 186
15.23 Tridecane 57 43 71 85 184
15.47 1-Methylnaphthalene 142 141 115 143 142
16.48 1-Tetradecene 55 41 83 69 196
16.52 Decanoicacid,ethylester 88 101 43 155 200
16.58 Tetradecane 57 43 71 85 198
16.72 Dodecanal 57 41 43 55 184
16.98 Caryophyllene 93 133 91 79 204
17.04 (Z)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
17.28 (E)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
17.75 1-Pentadecene 55 43 83 69 210
18.14 Dodecanoicacid,methylester 74 87 43 55 214
18.65 Dodecanoicacid 73 60 200 43 200
19.04 Hexadecane 57 71 43 85 226
19.49 Benzophenone 105 182 77 51 182
20.17 Heptadecane 57 71 43 85 240
23.25 Eicosane 57 71 43 85 282
24.18 Heneicosane 57 71 43 85 296
25.08 Docosane 57 71 43 85 310
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B3 Table 75. Target ion and qualifying ions for frequently occurring breath 
VOCs for identification and quantitation 
 
RT (min) Compound Name Target Q1 Q2 Q3 MW (g/mol)
Acetone 43 58 42 58
Carbon dioxide 44 28 16 44
Carbon disulfide 76 78 44 32 76
Heptane 43 100 71 57 100
Isoprene 67 68 53 39 68
Pentane 43 72 57 42 72
Toluene 91 92 65 63 92
4.16 Octane 43 85 41 57 114
4.28 Hexanal 44 56 41 57 100
5.28 Ethylbenzene 91 106 51 106
5.42 p-Xylene 91 106 105 77 106
5.75 3-Heptanone 57 85 114 72 114
5.79 Styrene 104 103 78 51 104
6.52 α-Pinene 93 91 92 77 136
6.89 Propylbenzene 91 120 92 120
7.01 Benzaldehyde 106 105 77 51 106
7.37 Phenol 94 66 65 39 94
7.48 6-Methyl-5-hepten-2-one 43 41 108 55 126
8.16 D-Limonene 68 93 67 79 136
8.26 1,2-Dichlorobenzene 147 111 112 75 146
8.80 Acetophenone 105 77 120 51 120
9.29 Undecane 57 43 71 41 156
9.37 Nonanal 57 41 56 55 142
9.59 1,2,4,5-Tetramethylbenzene 119 134 91 133 134
10.48 Menthol 71 81 95 41 156
10.65 Naphthalene 128 127 129 102 128
10.70 1-Dodecene 55 41 83 97 168
10.82 Dodecane 57 43 71 170 170
10.91 Decanal 41 57 43 55 156
12.25 Tridecane 57 43 71 85 184
12.36 Undecanal 43 57 41 55 170
12.50 1-Methylnaphthalene 142 141 115 143 142
13.26 n-Decanoicacid 73 60 129 41 172
13.58 Tetradecane 57 43 71 85 198
13.72 Dodecanal 41 55 43 57 184
13.99 Caryophyllene 93 133 91 41 204
14.04 (Z)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
14.28 (E)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
15.08 ButylatedHydroxytoluene 205 220 206 57 220
15.65 Dodecanoicacid 73 60 41 43 200
16.04 Hexadecane 57 71 43 85 226
16.50 Benzophenone 105 182 77 51 182
17.17 Heptadecane 57 71 43 85 240
17.59 2,6-Diisopropylnaphthalene 197 212 155 198 212
19.74 n-Hexadecanoicacid 73 60 43 41 256
20.03 Eicosane 57 71 43 85 282
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B4 Table 76. Target ion and qualifying ions for frequently occurring blood 
VOCs for identification and quantitation 
 
RT (min) Compound Name Target Q1 Q2 Q3 MW (g/mol)
Acetone 43 58 42 58
Octanal 43 44 56 84 128
Hexanal 44 41 56 57 100
1-Pentanol 42 55 70 41 88
4.80 1-Hexanol 56 55 43 41 102
4.82 Benzene,1,3-dimethyl- [m-xylene] 91 106 105 77 106
4.83 p-Xylene 91 106 105 77 106
4.88 4-Heptanone 71 43 114 41 114
5.09 3-Heptanone 57 85 72 41 114
5.16 2-Heptanone 43 58 71 59 114
5.23 Cyclohexanone 55 42 98 69 98
5.24 Nonane 43 57 71 41 128
5.30 Heptanal 70 44 41 55 114
6.23 Benzaldehyde 106 105 77 51 106
6.35 1-Heptanol 70 56 55 43 116
6.51 1-Octen-3-ol 57 43 72 41 128
6.55 Phenol 94 66 65 55 94
6.66 6-Methyl-hepten-2-one 43 42 126 69 126
6.67 1-Decene 56 55 41 70 140
6.69 2-Pentylfuran 81 82 138 53 138
7.29 D-Limonene 68 93 67 79 136
7.39 BenzylAlcohol 79 77 108 107 108
7.39 1,2-Dichlorobenzene 146 148 111 113 146
7.89 Acetophenone 105 77 120 51 120
7.99 1-Octanol 55 41 69 70 130
8.36 Undecane 57 43 71 41 156
8.43 Nonanal 57 41 56 55 142
8.65 1,2,4,5-Tetramethylbenzene 119 134 91 134
9.52 Menthol 71 81 95 41 156
9.69 Naphthalene 128 127 129 102 128
9.73 1-Dodecene 55 43 41 69 168
9.76 2-Decanone 58 43 71 59 156
9.85 Dodecane 57 43 71 41 170
9.94 Decanal 57 43 41 55 156
11.26 Tridecane 57 43 71 85 184
11.51 1-Methylnaphthalene 142 141 115 143 142
12.49 1-Tetradecene 41 55 83 69 196
12.59 Tetradecane 57 43 71 85 198
12.72 Dodecanal 57 41 43 67 184
13.06 (Z)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
13.29 (E)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
13.53 1-Dodecanol 55 69 83 168 186
15.04 Hexadecane 57 71 43 85 226
16.17 Heptadecane 57 71 43 85 240
16.58 2,6-Diisopropylnaphthalene 197 212 155 198 212
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B5  Table 77. Target ion and qualifying ions for frequently occurring urine 
VOCs for identification and quantitation 
 
  
RT (min) Compound Name Target Q1 Q2 Q3 MW (g/mol)
Toluene 91 92 65 92
2-Pentanone 43 86 41 58 86
Pyrrole 67 39 41 28 67
4-Nonylphenol 107 220 108 220
7.08 4-Heptanone 71 43 114 41 114
7.38 3-Heptanone 57 85 72 41 114
7.46 2-Heptanone 43 58 71 59 114
8.68 Benzaldehyde 106 105 77 51 106
8.80 Dimethyltrisulfide 126 79 45 64 126
9.15 1-Decene 41 55 56 70 140
9.77 1,2-Dichlorobenzene 146 148 111 75 146
10.24 1-Octanol 56 55 41 69 130
10.30 4-Methylphenol 107 108 77 79 108
10.62 3,7-dimethyl-,6-Octadien-3-ol 93 71 41 43 154
10.65 Nonanal 57 41 56 98 142
11.29 (E)-2-Nonenal 41 55 70 43 140
11.47 Menthol 71 81 95 41 156
11.71 MethylSalicylate 120 98 152 121 152
11.77 Decanal 57 43 41 55 156
12.67 5-(2-propenyl)-1,3-Benzodioxole 162 131 104 103 162
13.94 (E)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
14.10 (Z)-6,10-dimethyl-5,9-Undecadien-2-one 43 69 41 151 194
14.64 ButylatedHydroxytoluene 205 220 206 57 220
14.99 Dodecanoicacid 73 60 200 43 200
15.26 Hexadecane 57 71 43 85 226
15.39 4-(1,1,3,3-Tetramethylbutyl)-phenol 135 107 206
15.55 Diphenylamine 169 168 167 170 169
15.63 Benzophenone 105 182 77 51 182
16.02 Heptadecane 57 43 71 85 240
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